id	sid	tid	token	lemma	pos
dpc-4852	1	1	dermatology	dermatology	NOUN
dpc-4852	1	2	:	:	PUNCT
dpc-4852	1	3	practical	practical	ADJ
dpc-4852	1	4	and	and	CCONJ
dpc-4852	1	5	conceptual	conceptual	ADJ
dpc-4852	1	6	original	original	ADJ
dpc-4852	1	7	article	article	NOUN
dpc-4852	1	8	|	|	ADV
dpc-4852	1	9	dermatol	dermatol	ADJ
dpc-4852	1	10	pract	pract	NOUN
dpc-4852	1	11	concept	concept	NOUN
dpc-4852	1	12	.	.	PUNCT
dpc-4852	2	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	2	2	1	1	NUM
dpc-4852	2	3	bullous	bullous	ADJ
dpc-4852	2	4	pemphigoid	pemphigoid	NOUN
dpc-4852	2	5	and	and	CCONJ
dpc-4852	2	6	epidemiological	epidemiological	ADJ
dpc-4852	2	7	patterns	pattern	NOUN
dpc-4852	2	8	in	in	ADP
dpc-4852	2	9	northern	northern	ADJ
dpc-4852	2	10	greece	greece	PROPN
dpc-4852	2	11	:	:	PUNCT
dpc-4852	2	12	insights	insight	NOUN
dpc-4852	2	13	from	from	ADP
dpc-4852	2	14	an	an	DET
dpc-4852	2	15	8	8	NUM
dpc-4852	2	16	-	-	PUNCT
dpc-4852	2	17	year	year	NOUN
dpc-4852	2	18	observational	observational	ADJ
dpc-4852	2	19	study	study	NOUN
dpc-4852	2	20	athina	athina	NOUN
dpc-4852	2	21	-	-	PUNCT
dpc-4852	2	22	ioanna	ioanna	PROPN
dpc-4852	2	23	daponte1	daponte1	PROPN
dpc-4852	2	24	,	,	PUNCT
dpc-4852	2	25	evangelia	evangelia	PROPN
dpc-4852	2	26	kalloniati1	kalloniati1	PROPN
dpc-4852	2	27	,	,	PUNCT
dpc-4852	2	28	parthena	parthena	PROPN
dpc-4852	2	29	meltzanidou1	meltzanidou1	PROPN
dpc-4852	2	30	,	,	PUNCT
dpc-4852	2	31	maria	maria	PROPN
dpc-4852	2	32	giannouli1	giannouli1	PROPN
dpc-4852	2	33	,	,	PUNCT
dpc-4852	2	34	anastasia	anastasia	PROPN
dpc-4852	2	35	tsitlakidou1	tsitlakidou1	PROPN
dpc-4852	2	36	,	,	PUNCT
dpc-4852	2	37	valentina	valentina	PROPN
dpc-4852	2	38	oflidou1	oflidou1	PROPN
dpc-4852	2	39	,	,	PUNCT
dpc-4852	2	40	maria	maria	PROPN
dpc-4852	2	41	boziou1	boziou1	PROPN
dpc-4852	2	42	,	,	PUNCT
dpc-4852	2	43	aikaterini	aikaterini	PROPN
dpc-4852	2	44	kyriakou1	kyriakou1	PROPN
dpc-4852	2	45	,	,	PUNCT
dpc-4852	2	46	stylianos	stylianos	VERB
dpc-4852	2	47	charalampidis1	charalampidis1	NOUN
dpc-4852	2	48	,	,	PUNCT
dpc-4852	2	49	christina	christina	PROPN
dpc-4852	2	50	fotiadou1	fotiadou1	PROPN
dpc-4852	2	51	,	,	PUNCT
dpc-4852	2	52	anastasia	anastasia	PROPN
dpc-4852	2	53	giannakou2	giannakou2	PROPN
dpc-4852	2	54	,	,	PUNCT
dpc-4852	2	55	αlexandros	αlexandros	PROPN
dpc-4852	2	56	lambropoulos3	lambropoulos3	PROPN
dpc-4852	2	57	,	,	PUNCT
dpc-4852	2	58	anastasia	anastasia	PROPN
dpc-4852	2	59	trigoni1	trigoni1	PROPN
dpc-4852	2	60	,	,	PUNCT
dpc-4852	2	61	myrto	myrto	PROPN
dpc-4852	2	62	-	-	PUNCT
dpc-4852	2	63	georgia	georgia	PROPN
dpc-4852	2	64	trakatelli1	trakatelli1	PROPN
dpc-4852	2	65	,	,	PUNCT
dpc-4852	2	66	zoe	zoe	PROPN
dpc-4852	2	67	apalla1	apalla1	PROPN
dpc-4852	2	68	,	,	PUNCT
dpc-4852	2	69	elizabeth	elizabeth	PROPN
dpc-4852	2	70	lazaridou1	lazaridou1	PROPN
dpc-4852	2	71	,	,	PUNCT
dpc-4852	2	72	aikaterini	aikaterini	PROPN
dpc-4852	2	73	patsatsi1	patsatsi1	PROPN
dpc-4852	2	74	1	1	NUM
dpc-4852	2	75	second	second	ADJ
dpc-4852	2	76	dermatology	dermatology	NOUN
dpc-4852	2	77	department	department	NOUN
dpc-4852	2	78	,	,	PUNCT
dpc-4852	2	79	aristotle	aristotle	PROPN
dpc-4852	2	80	university	university	PROPN
dpc-4852	2	81	of	of	ADP
dpc-4852	2	82	thessaloniki	thessaloniki	PROPN
dpc-4852	2	83	school	school	NOUN
dpc-4852	2	84	of	of	ADP
dpc-4852	2	85	medicine	medicine	NOUN
dpc-4852	2	86	,	,	PUNCT
dpc-4852	2	87	papageorgiou	papageorgiou	PROPN
dpc-4852	2	88	general	general	ADJ
dpc-4852	2	89	hospital	hospital	PROPN
dpc-4852	2	90	,	,	PUNCT
dpc-4852	2	91	thessaloniki	thessaloniki	PROPN
dpc-4852	2	92	,	,	PUNCT
dpc-4852	2	93	greece	greece	PROPN
dpc-4852	2	94	2	2	NUM
dpc-4852	2	95	laboratory	laboratory	NOUN
dpc-4852	2	96	of	of	ADP
dpc-4852	2	97	immunology	immunology	NOUN
dpc-4852	2	98	,	,	PUNCT
dpc-4852	2	99	papageorgiou	papageorgiou	PROPN
dpc-4852	2	100	general	general	ADJ
dpc-4852	2	101	hospital	hospital	PROPN
dpc-4852	2	102	,	,	PUNCT
dpc-4852	2	103	thessaloniki	thessaloniki	PROPN
dpc-4852	2	104	,	,	PUNCT
dpc-4852	2	105	greece	greece	PROPN
dpc-4852	2	106	3	3	NUM
dpc-4852	2	107	laboratory	laboratory	NOUN
dpc-4852	2	108	of	of	ADP
dpc-4852	2	109	medical	medical	ADJ
dpc-4852	2	110	biology	biology	NOUN
dpc-4852	2	111	-	-	PUNCT
dpc-4852	2	112	genetics	genetic	NOUN
dpc-4852	2	113	,	,	PUNCT
dpc-4852	2	114	medical	medical	ADJ
dpc-4852	2	115	school	school	NOUN
dpc-4852	2	116	,	,	PUNCT
dpc-4852	2	117	aristotle	aristotle	PROPN
dpc-4852	2	118	university	university	PROPN
dpc-4852	2	119	,	,	PUNCT
dpc-4852	2	120	thessaloniki	thessaloniki	PROPN
dpc-4852	2	121	,	,	PUNCT
dpc-4852	2	122	greece	greece	PROPN
dpc-4852	2	123	key	key	ADJ
dpc-4852	2	124	words	word	NOUN
dpc-4852	2	125	:	:	PUNCT
dpc-4852	2	126	bullous	bullous	ADJ
dpc-4852	2	127	pemphigoid	pemphigoid	NOUN
dpc-4852	2	128	,	,	PUNCT
dpc-4852	2	129	epidemiology	epidemiology	NOUN
dpc-4852	2	130	,	,	PUNCT
dpc-4852	2	131	northern	northern	PROPN
dpc-4852	2	132	greece	greece	PROPN
dpc-4852	2	133	,	,	PUNCT
dpc-4852	2	134	autoimmune	autoimmune	ADJ
dpc-4852	2	135	blistering	blister	VERB
dpc-4852	2	136	diseases	disease	NOUN
dpc-4852	2	137	,	,	PUNCT
dpc-4852	2	138	dpp-4	dpp-4	NUM
dpc-4852	2	139	inhibitors	inhibitor	NOUN
dpc-4852	2	140	citation	citation	NOUN
dpc-4852	2	141	:	:	PUNCT
dpc-4852	2	142	daponte	daponte	PROPN
dpc-4852	2	143	a	a	PROPN
dpc-4852	2	144	-	-	PUNCT
dpc-4852	2	145	i	i	PROPN
dpc-4852	2	146	,	,	PUNCT
dpc-4852	2	147	kalloniati	kalloniati	PROPN
dpc-4852	2	148	e	e	PROPN
dpc-4852	2	149	,	,	PUNCT
dpc-4852	2	150	meltzanidou	meltzanidou	NOUN
dpc-4852	2	151	p	p	NOUN
dpc-4852	2	152	,	,	PUNCT
dpc-4852	2	153	et	et	PROPN
dpc-4852	2	154	al	al	PROPN
dpc-4852	2	155	.	.	PUNCT
dpc-4852	3	1	bullous	bullous	ADJ
dpc-4852	3	2	pemphigoid	pemphigoid	NOUN
dpc-4852	3	3	and	and	CCONJ
dpc-4852	3	4	epidemiological	epidemiological	ADJ
dpc-4852	3	5	patterns	pattern	NOUN
dpc-4852	3	6	in	in	ADP
dpc-4852	3	7	northern	northern	ADJ
dpc-4852	3	8	greece	greece	PROPN
dpc-4852	3	9	:	:	PUNCT
dpc-4852	3	10	insights	insight	NOUN
dpc-4852	3	11	from	from	ADP
dpc-4852	3	12	an	an	DET
dpc-4852	3	13	8	8	NUM
dpc-4852	3	14	-	-	PUNCT
dpc-4852	3	15	year	year	NOUN
dpc-4852	3	16	observational	observational	ADJ
dpc-4852	3	17	study	study	NOUN
dpc-4852	3	18	.	.	PUNCT
dpc-4852	4	1	dermatol	dermatol	NOUN
dpc-4852	4	2	pract	pract	PROPN
dpc-4852	4	3	concept	concept	NOUN
dpc-4852	4	4	.	.	PUNCT
dpc-4852	5	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	5	2	.	.	PUNCT
dpc-4852	6	1	doi	doi	NOUN
dpc-4852	6	2	:	:	PUNCT
dpc-4852	6	3	https://doi.org/10.5826	https://doi.org/10.5826	ADJ
dpc-4852	6	4	/	/	SYM
dpc-4852	6	5	dpc.1502a4852	dpc.1502a4852	NOUN
dpc-4852	6	6	accepted	accept	VERB
dpc-4852	6	7	:	:	PUNCT
dpc-4852	6	8	december	december	PROPN
dpc-4852	6	9	20	20	NUM
dpc-4852	6	10	,	,	PUNCT
dpc-4852	6	11	2024	2024	NUM
dpc-4852	6	12	;	;	PUNCT
dpc-4852	6	13	published	publish	VERB
dpc-4852	6	14	:	:	PUNCT
dpc-4852	7	1	april	april	PROPN
dpc-4852	7	2	2025	2025	NUM
dpc-4852	7	3	copyright	copyright	NOUN
dpc-4852	7	4	:	:	PUNCT
dpc-4852	7	5	©	©	PROPN
dpc-4852	7	6	2025	2025	NUM
dpc-4852	7	7	daponte	daponte	NOUN
dpc-4852	7	8	et	et	PROPN
dpc-4852	7	9	al	al	PROPN
dpc-4852	7	10	.	.	PUNCT
dpc-4852	8	1	this	this	PRON
dpc-4852	8	2	is	be	AUX
dpc-4852	8	3	an	an	DET
dpc-4852	8	4	open	open	ADJ
dpc-4852	8	5	-	-	PUNCT
dpc-4852	8	6	access	access	NOUN
dpc-4852	8	7	article	article	NOUN
dpc-4852	8	8	distributed	distribute	VERB
dpc-4852	8	9	under	under	ADP
dpc-4852	8	10	the	the	DET
dpc-4852	8	11	terms	term	NOUN
dpc-4852	8	12	of	of	ADP
dpc-4852	8	13	the	the	DET
dpc-4852	8	14	creative	creative	ADJ
dpc-4852	8	15	commons	common	NOUN
dpc-4852	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4852	8	17	license	license	NOUN
dpc-4852	8	18	(	(	PUNCT
dpc-4852	8	19	by	by	ADP
dpc-4852	8	20	-	-	PUNCT
dpc-4852	8	21	nc-4.0	nc-4.0	NOUN
dpc-4852	8	22	)	)	PUNCT
dpc-4852	8	23	,	,	PUNCT
dpc-4852	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4852	8	25	,	,	PUNCT
dpc-4852	8	26	which	which	PRON
dpc-4852	8	27	permits	permit	VERB
dpc-4852	8	28	unrestricted	unrestricted	ADJ
dpc-4852	8	29	noncommercial	noncommercial	ADJ
dpc-4852	8	30	use	use	NOUN
dpc-4852	8	31	,	,	PUNCT
dpc-4852	8	32	distribution	distribution	NOUN
dpc-4852	8	33	,	,	PUNCT
dpc-4852	8	34	and	and	CCONJ
dpc-4852	8	35	reproduction	reproduction	NOUN
dpc-4852	8	36	in	in	ADP
dpc-4852	8	37	any	any	DET
dpc-4852	8	38	medium	medium	NOUN
dpc-4852	8	39	,	,	PUNCT
dpc-4852	8	40	provided	provide	VERB
dpc-4852	8	41	the	the	DET
dpc-4852	8	42	original	original	ADJ
dpc-4852	8	43	authors	author	NOUN
dpc-4852	8	44	and	and	CCONJ
dpc-4852	8	45	source	source	NOUN
dpc-4852	8	46	are	be	AUX
dpc-4852	8	47	credited	credit	VERB
dpc-4852	8	48	.	.	PUNCT
dpc-4852	9	1	funding	funding	NOUN
dpc-4852	9	2	:	:	PUNCT
dpc-4852	9	3	none	none	NOUN
dpc-4852	9	4	.	.	PUNCT
dpc-4852	10	1	competing	compete	VERB
dpc-4852	10	2	interests	interest	NOUN
dpc-4852	10	3	:	:	PUNCT
dpc-4852	10	4	none	none	NOUN
dpc-4852	10	5	.	.	PUNCT
dpc-4852	11	1	authorship	authorship	NOUN
dpc-4852	11	2	:	:	PUNCT
dpc-4852	11	3	all	all	DET
dpc-4852	11	4	authors	author	NOUN
dpc-4852	11	5	have	have	AUX
dpc-4852	11	6	contributed	contribute	VERB
dpc-4852	11	7	significantly	significantly	ADV
dpc-4852	11	8	to	to	ADP
dpc-4852	11	9	this	this	DET
dpc-4852	11	10	publication	publication	NOUN
dpc-4852	11	11	.	.	PUNCT
dpc-4852	12	1	corresponding	correspond	VERB
dpc-4852	12	2	author	author	NOUN
dpc-4852	12	3	:	:	PUNCT
dpc-4852	12	4	aikaterini	aikaterini	PROPN
dpc-4852	12	5	patsatsi	patsatsi	PROPN
dpc-4852	12	6	,	,	PUNCT
dpc-4852	12	7	a.p	a.p	PROPN
dpc-4852	12	8	.	.	PROPN
dpc-4852	12	9	professor	professor	PROPN
dpc-4852	12	10	,	,	PUNCT
dpc-4852	12	11	second	second	ADJ
dpc-4852	12	12	dermatology	dermatology	NOUN
dpc-4852	12	13	and	and	CCONJ
dpc-4852	12	14	venereology	venereology	NOUN
dpc-4852	12	15	department	department	PROPN
dpc-4852	12	16	,	,	PUNCT
dpc-4852	12	17	aristotle	aristotle	PROPN
dpc-4852	12	18	university	university	PROPN
dpc-4852	12	19	of	of	ADP
dpc-4852	12	20	thessaloniki	thessaloniki	PROPN
dpc-4852	12	21	school	school	NOUN
dpc-4852	12	22	of	of	ADP
dpc-4852	12	23	medicine	medicine	NOUN
dpc-4852	12	24	,	,	PUNCT
dpc-4852	12	25	papageorgiou	papageorgiou	PROPN
dpc-4852	12	26	general	general	ADJ
dpc-4852	12	27	hospital	hospital	PROPN
dpc-4852	12	28	,	,	PUNCT
dpc-4852	12	29	thessaloniki	thessaloniki	PROPN
dpc-4852	12	30	,	,	PUNCT
dpc-4852	12	31	greece	greece	PROPN
dpc-4852	12	32	;	;	PUNCT
dpc-4852	12	33	papageorgiou	papageorgiou	PROPN
dpc-4852	12	34	general	general	ADJ
dpc-4852	12	35	hospital	hospital	NOUN
dpc-4852	12	36	,	,	PUNCT
dpc-4852	12	37	municipality	municipality	NOUN
dpc-4852	12	38	of	of	ADP
dpc-4852	12	39	pavlos	pavlos	PROPN
dpc-4852	12	40	melas	melas	PROPN
dpc-4852	12	41	,	,	PUNCT
dpc-4852	12	42	56403	56403	NUM
dpc-4852	12	43	.	.	PUNCT
dpc-4852	13	1	orcid	orcid	NOUN
dpc-4852	14	1	i	i	PRON
dpc-4852	14	2	d	d	NOUN
dpc-4852	14	3	:	:	PUNCT
dpc-4852	14	4	0000	0000	NUM
dpc-4852	14	5	-	-	PUNCT
dpc-4852	14	6	0001	0001	NUM
dpc-4852	14	7	-	-	PUNCT
dpc-4852	14	8	9616	9616	NUM
dpc-4852	14	9	-	-	SYM
dpc-4852	14	10	2001	2001	NUM
dpc-4852	14	11	.	.	PUNCT
dpc-4852	15	1	e	e	X
dpc-4852	15	2	-mail	-mail	NOUN
dpc-4852	15	3	:	:	PUNCT
dpc-4852	15	4	katerinapatsatsi@gmail.com	katerinapatsatsi@gmail.com	X
dpc-4852	15	5	,	,	PUNCT
dpc-4852	15	6	apatsats@auth.gr	apatsats@auth.gr	PROPN
dpc-4852	15	7	introduction	introduction	NOUN
dpc-4852	15	8	:	:	PUNCT
dpc-4852	15	9	bullous	bullous	ADJ
dpc-4852	15	10	pemphigoid	pemphigoid	NOUN
dpc-4852	15	11	(	(	PUNCT
dpc-4852	15	12	bp	bp	PROPN
dpc-4852	15	13	)	)	PUNCT
dpc-4852	15	14	is	be	AUX
dpc-4852	15	15	an	an	DET
dpc-4852	15	16	autoimmune	autoimmune	ADJ
dpc-4852	15	17	disorder	disorder	NOUN
dpc-4852	15	18	causing	cause	VERB
dpc-4852	15	19	tense	tense	ADJ
dpc-4852	15	20	blisters	blister	NOUN
dpc-4852	15	21	on	on	ADP
dpc-4852	15	22	the	the	DET
dpc-4852	15	23	skin	skin	NOUN
dpc-4852	15	24	and	and	CCONJ
dpc-4852	15	25	sometimes	sometimes	ADV
dpc-4852	15	26	mucous	mucous	ADJ
dpc-4852	15	27	membranes	membrane	NOUN
dpc-4852	15	28	,	,	PUNCT
dpc-4852	15	29	primarily	primarily	ADV
dpc-4852	15	30	affecting	affect	VERB
dpc-4852	15	31	older	old	ADJ
dpc-4852	15	32	adults	adult	NOUN
dpc-4852	15	33	.	.	PUNCT
dpc-4852	16	1	it	it	PRON
dpc-4852	16	2	results	result	VERB
dpc-4852	16	3	from	from	ADP
dpc-4852	16	4	autoantibodies	autoantibody	NOUN
dpc-4852	16	5	attacking	attack	VERB
dpc-4852	16	6	the	the	DET
dpc-4852	16	7	epidermal	epidermal	ADJ
dpc-4852	16	8	basement	basement	NOUN
dpc-4852	16	9	membrane	membrane	NOUN
dpc-4852	16	10	.	.	PUNCT
dpc-4852	17	1	the	the	DET
dpc-4852	17	2	incidence	incidence	NOUN
dpc-4852	17	3	of	of	ADP
dpc-4852	17	4	bp	bp	PROPN
dpc-4852	17	5	is	be	AUX
dpc-4852	17	6	rising	rise	VERB
dpc-4852	17	7	globally	globally	ADV
dpc-4852	17	8	,	,	PUNCT
dpc-4852	17	9	particularly	particularly	ADV
dpc-4852	17	10	due	due	ADJ
dpc-4852	17	11	to	to	ADP
dpc-4852	17	12	drug	drug	NOUN
dpc-4852	17	13	-	-	PUNCT
dpc-4852	17	14	induced	induce	VERB
dpc-4852	17	15	cases	case	NOUN
dpc-4852	17	16	.	.	PUNCT
dpc-4852	18	1	objectives	objective	NOUN
dpc-4852	18	2	:	:	PUNCT
dpc-4852	18	3	this	this	DET
dpc-4852	18	4	study	study	NOUN
dpc-4852	18	5	aimed	aim	VERB
dpc-4852	18	6	to	to	PART
dpc-4852	18	7	present	present	VERB
dpc-4852	18	8	epidemiological	epidemiological	ADJ
dpc-4852	18	9	data	datum	NOUN
dpc-4852	18	10	on	on	ADP
dpc-4852	18	11	bp	bp	PROPN
dpc-4852	18	12	patients	patient	NOUN
dpc-4852	18	13	,	,	PUNCT
dpc-4852	18	14	response	response	NOUN
dpc-4852	18	15	to	to	ADP
dpc-4852	18	16	systemic	systemic	ADJ
dpc-4852	18	17	corticosteroid	corticosteroid	ADJ
dpc-4852	18	18	therapy	therapy	NOUN
dpc-4852	18	19	,	,	PUNCT
dpc-4852	18	20	relapse	relapse	NOUN
dpc-4852	18	21	rates	rate	NOUN
dpc-4852	18	22	,	,	PUNCT
dpc-4852	18	23	need	need	VERB
dpc-4852	18	24	for	for	ADP
dpc-4852	18	25	additional	additional	ADJ
dpc-4852	18	26	therapy	therapy	NOUN
dpc-4852	18	27	,	,	PUNCT
dpc-4852	18	28	and	and	CCONJ
dpc-4852	18	29	overall	overall	ADJ
dpc-4852	18	30	prognosis	prognosis	NOUN
dpc-4852	18	31	.	.	PUNCT
dpc-4852	19	1	methods	method	NOUN
dpc-4852	19	2	:	:	PUNCT
dpc-4852	19	3	this	this	DET
dpc-4852	19	4	retrospective	retrospective	ADJ
dpc-4852	19	5	study	study	NOUN
dpc-4852	19	6	included	include	VERB
dpc-4852	19	7	patients	patient	NOUN
dpc-4852	19	8	diagnosed	diagnose	VERB
dpc-4852	19	9	with	with	ADP
dpc-4852	19	10	bp	bp	PROPN
dpc-4852	19	11	and	and	CCONJ
dpc-4852	19	12	admitted	admit	VERB
dpc-4852	19	13	to	to	ADP
dpc-4852	19	14	the	the	DET
dpc-4852	19	15	dermatology	dermatology	NOUN
dpc-4852	19	16	department	department	NOUN
dpc-4852	19	17	of	of	ADP
dpc-4852	19	18	a	a	DET
dpc-4852	19	19	referral	referral	ADJ
dpc-4852	19	20	center	center	NOUN
dpc-4852	19	21	in	in	ADP
dpc-4852	19	22	northern	northern	PROPN
dpc-4852	19	23	greece	greece	PROPN
dpc-4852	19	24	from	from	ADP
dpc-4852	19	25	2014	2014	NUM
dpc-4852	19	26	to	to	ADP
dpc-4852	19	27	2022	2022	NUM
dpc-4852	19	28	.	.	PUNCT
dpc-4852	20	1	the	the	DET
dpc-4852	20	2	registry	registry	NOUN
dpc-4852	20	3	included	include	VERB
dpc-4852	20	4	parameters	parameter	NOUN
dpc-4852	20	5	such	such	ADJ
dpc-4852	20	6	as	as	ADP
dpc-4852	20	7	sex	sex	NOUN
dpc-4852	20	8	,	,	PUNCT
dpc-4852	20	9	age	age	NOUN
dpc-4852	20	10	at	at	ADP
dpc-4852	20	11	onset	onset	NOUN
dpc-4852	20	12	,	,	PUNCT
dpc-4852	20	13	comorbidities	comorbiditie	NOUN
dpc-4852	20	14	,	,	PUNCT
dpc-4852	20	15	drug	drug	NOUN
dpc-4852	20	16	associations	association	NOUN
dpc-4852	20	17	,	,	PUNCT
dpc-4852	20	18	hospitalization	hospitalization	NOUN
dpc-4852	20	19	,	,	PUNCT
dpc-4852	20	20	additional	additional	ADJ
dpc-4852	20	21	immunosuppressive	immunosuppressive	ADJ
dpc-4852	20	22	therapy	therapy	NOUN
dpc-4852	20	23	or	or	CCONJ
dpc-4852	20	24	doxycycline	doxycycline	NOUN
dpc-4852	20	25	use	use	NOUN
dpc-4852	20	26	,	,	PUNCT
dpc-4852	20	27	time	time	NOUN
dpc-4852	20	28	to	to	ADP
dpc-4852	20	29	tapering	tapering	NOUN
dpc-4852	20	30	,	,	PUNCT
dpc-4852	20	31	and	and	CCONJ
dpc-4852	20	32	number	number	NOUN
dpc-4852	20	33	of	of	ADP
dpc-4852	20	34	relapses	relapse	NOUN
dpc-4852	20	35	.	.	PUNCT
dpc-4852	21	1	abstract	abstract	ADJ
dpc-4852	21	2	2	2	NUM
dpc-4852	21	3	original	original	ADJ
dpc-4852	21	4	article	article	NOUN
dpc-4852	21	5	|	|	ADV
dpc-4852	21	6	dermatol	dermatol	ADJ
dpc-4852	21	7	pract	pract	NOUN
dpc-4852	21	8	concept	concept	NOUN
dpc-4852	21	9	.	.	PUNCT
dpc-4852	22	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	22	2	introduction	introduction	NOUN
dpc-4852	22	3	definition	definition	NOUN
dpc-4852	22	4	and	and	CCONJ
dpc-4852	22	5	epidemiology	epidemiology	NOUN
dpc-4852	22	6	bp	bp	PROPN
dpc-4852	22	7	is	be	AUX
dpc-4852	22	8	a	a	DET
dpc-4852	22	9	prevalent	prevalent	ADJ
dpc-4852	22	10	autoimmune	autoimmune	ADJ
dpc-4852	22	11	disorder	disorder	NOUN
dpc-4852	22	12	characterized	characterize	VERB
dpc-4852	22	13	by	by	ADP
dpc-4852	22	14	the	the	DET
dpc-4852	22	15	formation	formation	NOUN
dpc-4852	22	16	of	of	ADP
dpc-4852	22	17	tense	tense	ADJ
dpc-4852	22	18	blisters	blister	NOUN
dpc-4852	22	19	or	or	CCONJ
dpc-4852	22	20	bullae	bullae	NOUN
dpc-4852	22	21	,	,	PUNCT
dpc-4852	22	22	primarily	primarily	ADV
dpc-4852	22	23	on	on	ADP
dpc-4852	22	24	the	the	DET
dpc-4852	22	25	skin	skin	NOUN
dpc-4852	22	26	but	but	CCONJ
dpc-4852	22	27	occasionally	occasionally	ADV
dpc-4852	22	28	that	that	PRON
dpc-4852	22	29	affect	affect	VERB
dpc-4852	22	30	mucous	mucous	ADJ
dpc-4852	22	31	membranes	membrane	NOUN
dpc-4852	22	32	such	such	ADJ
dpc-4852	22	33	as	as	ADP
dpc-4852	22	34	the	the	DET
dpc-4852	22	35	oral	oral	ADJ
dpc-4852	22	36	cavity	cavity	NOUN
dpc-4852	22	37	,	,	PUNCT
dpc-4852	22	38	pharynx	pharynx	NOUN
dpc-4852	22	39	,	,	PUNCT
dpc-4852	22	40	esophagus	esophagus	NOUN
dpc-4852	22	41	,	,	PUNCT
dpc-4852	22	42	and	and	CCONJ
dpc-4852	22	43	genitalia	genitalia	NOUN
dpc-4852	23	1	[	[	X
dpc-4852	23	2	1	1	NUM
dpc-4852	23	3	]	]	PUNCT
dpc-4852	23	4	.	.	PUNCT
dpc-4852	24	1	it	it	PRON
dpc-4852	24	2	was	be	AUX
dpc-4852	24	3	first	first	ADV
dpc-4852	24	4	identified	identify	VERB
dpc-4852	24	5	as	as	ADP
dpc-4852	24	6	a	a	DET
dpc-4852	24	7	distinct	distinct	ADJ
dpc-4852	24	8	clinical	clinical	ADJ
dpc-4852	24	9	entity	entity	NOUN
dpc-4852	24	10	in	in	ADP
dpc-4852	24	11	1953	1953	NUM
dpc-4852	24	12	by	by	ADP
dpc-4852	24	13	lever	lever	NOUN
dpc-4852	25	1	[	[	X
dpc-4852	25	2	2	2	NUM
dpc-4852	25	3	]	]	PUNCT
dpc-4852	25	4	.	.	PUNCT
dpc-4852	26	1	the	the	DET
dpc-4852	26	2	pathogenesis	pathogenesis	NOUN
dpc-4852	26	3	of	of	ADP
dpc-4852	26	4	bp	bp	PROPN
dpc-4852	26	5	involves	involve	VERB
dpc-4852	26	6	a	a	DET
dpc-4852	26	7	complex	complex	ADJ
dpc-4852	26	8	interplay	interplay	NOUN
dpc-4852	26	9	between	between	ADP
dpc-4852	26	10	genetic	genetic	ADJ
dpc-4852	26	11	and	and	CCONJ
dpc-4852	26	12	environmental	environmental	ADJ
dpc-4852	26	13	factors	factor	NOUN
dpc-4852	26	14	which	which	PRON
dpc-4852	26	15	trigger	trigger	VERB
dpc-4852	26	16	an	an	DET
dpc-4852	26	17	aberrant	aberrant	ADJ
dpc-4852	26	18	immune	immune	ADJ
dpc-4852	26	19	response	response	NOUN
dpc-4852	26	20	.	.	PUNCT
dpc-4852	27	1	autoantibodies	autoantibody	NOUN
dpc-4852	27	2	play	play	VERB
dpc-4852	27	3	a	a	DET
dpc-4852	27	4	critical	critical	ADJ
dpc-4852	27	5	role	role	NOUN
dpc-4852	27	6	,	,	PUNCT
dpc-4852	27	7	targeting	target	VERB
dpc-4852	27	8	hemidesmosomal	hemidesmosomal	ADJ
dpc-4852	27	9	proteins	protein	NOUN
dpc-4852	27	10	bp180	bp180	PROPN
dpc-4852	27	11	and	and	CCONJ
dpc-4852	27	12	bp230	bp230	VERB
dpc-4852	27	13	in	in	ADP
dpc-4852	27	14	the	the	DET
dpc-4852	27	15	epidermal	epidermal	ADJ
dpc-4852	27	16	basement	basement	NOUN
dpc-4852	27	17	membrane	membrane	NOUN
dpc-4852	27	18	,	,	PUNCT
dpc-4852	27	19	leading	lead	VERB
dpc-4852	27	20	to	to	ADP
dpc-4852	27	21	complement	complement	NOUN
dpc-4852	27	22	activation	activation	NOUN
dpc-4852	27	23	,	,	PUNCT
dpc-4852	27	24	leukocyte	leukocyte	NOUN
dpc-4852	27	25	recruitment	recruitment	NOUN
dpc-4852	27	26	,	,	PUNCT
dpc-4852	27	27	and	and	CCONJ
dpc-4852	27	28	subsequent	subsequent	ADJ
dpc-4852	27	29	tissue	tissue	NOUN
dpc-4852	27	30	damage	damage	NOUN
dpc-4852	27	31	[	[	X
dpc-4852	27	32	3	3	NUM
dpc-4852	27	33	]	]	PUNCT
dpc-4852	27	34	.	.	PUNCT
dpc-4852	28	1	recent	recent	ADJ
dpc-4852	28	2	evidence	evidence	NOUN
dpc-4852	28	3	indicates	indicate	VERB
dpc-4852	28	4	a	a	DET
dpc-4852	28	5	noteworthy	noteworthy	ADJ
dpc-4852	28	6	increase	increase	NOUN
dpc-4852	28	7	in	in	ADP
dpc-4852	28	8	the	the	DET
dpc-4852	28	9	occurrence	occurrence	NOUN
dpc-4852	28	10	of	of	ADP
dpc-4852	28	11	bp	bp	PROPN
dpc-4852	28	12	,	,	PUNCT
dpc-4852	28	13	with	with	ADP
dpc-4852	28	14	reported	report	VERB
dpc-4852	28	15	rises	rise	NOUN
dpc-4852	28	16	of	of	ADP
dpc-4852	28	17	1.9	1.9	NUM
dpc-4852	28	18	to	to	PART
dpc-4852	28	19	4.3	4.3	NUM
dpc-4852	28	20	-	-	ADJ
dpc-4852	28	21	fold	fold	VERB
dpc-4852	28	22	over	over	ADP
dpc-4852	28	23	the	the	DET
dpc-4852	28	24	past	past	ADJ
dpc-4852	28	25	two	two	NUM
dpc-4852	28	26	decades	decade	NOUN
dpc-4852	28	27	[	[	X
dpc-4852	28	28	4	4	NUM
dpc-4852	28	29	-	-	SYM
dpc-4852	28	30	6	6	NUM
dpc-4852	28	31	]	]	PUNCT
dpc-4852	28	32	.	.	PUNCT
dpc-4852	29	1	although	although	SCONJ
dpc-4852	29	2	the	the	DET
dpc-4852	29	3	incidence	incidence	NOUN
dpc-4852	29	4	exhibits	exhibit	VERB
dpc-4852	29	5	geographic	geographic	ADJ
dpc-4852	29	6	variation	variation	NOUN
dpc-4852	29	7	and	and	CCONJ
dpc-4852	29	8	is	be	AUX
dpc-4852	29	9	considered	consider	VERB
dpc-4852	29	10	low	low	ADJ
dpc-4852	29	11	,	,	PUNCT
dpc-4852	29	12	there	there	PRON
dpc-4852	29	13	is	be	VERB
dpc-4852	29	14	an	an	DET
dpc-4852	29	15	upward	upward	ADJ
dpc-4852	29	16	trend	trend	NOUN
dpc-4852	29	17	[	[	X
dpc-4852	29	18	6	6	NUM
dpc-4852	29	19	]	]	PUNCT
dpc-4852	29	20	.	.	PUNCT
dpc-4852	30	1	this	this	DET
dpc-4852	30	2	increase	increase	NOUN
dpc-4852	30	3	is	be	AUX
dpc-4852	30	4	partially	partially	ADV
dpc-4852	30	5	attributed	attribute	VERB
dpc-4852	30	6	to	to	ADP
dpc-4852	30	7	drug	drug	NOUN
dpc-4852	30	8	-	-	PUNCT
dpc-4852	30	9	induced	induce	VERB
dpc-4852	30	10	cases	case	NOUN
dpc-4852	30	11	,	,	PUNCT
dpc-4852	30	12	with	with	ADP
dpc-4852	30	13	dipeptidyl	dipeptidyl	NOUN
dpc-4852	30	14	peptidase-4	peptidase-4	NOUN
dpc-4852	30	15	(	(	PUNCT
dpc-4852	30	16	dpp-4	dpp-4	X
dpc-4852	30	17	)	)	PUNCT
dpc-4852	30	18	inhibitors	inhibitor	NOUN
dpc-4852	30	19	(	(	PUNCT
dpc-4852	30	20	gliptins	gliptin	NOUN
dpc-4852	30	21	)	)	PUNCT
dpc-4852	30	22	playing	play	VERB
dpc-4852	30	23	a	a	DET
dpc-4852	30	24	significant	significant	ADJ
dpc-4852	30	25	role	role	NOUN
dpc-4852	30	26	.	.	PUNCT
dpc-4852	31	1	ddp-4	ddp-4	SYM
dpc-4852	31	2	inhibitors	inhibitor	NOUN
dpc-4852	31	3	may	may	AUX
dpc-4852	31	4	disrupt	disrupt	VERB
dpc-4852	31	5	the	the	DET
dpc-4852	31	6	plasmin	plasmin	ADJ
dpc-4852	31	7	formation	formation	NOUN
dpc-4852	31	8	,	,	PUNCT
dpc-4852	31	9	leading	lead	VERB
dpc-4852	31	10	to	to	ADP
dpc-4852	31	11	improper	improper	ADJ
dpc-4852	31	12	cleavage	cleavage	NOUN
dpc-4852	31	13	of	of	ADP
dpc-4852	31	14	bp180	bp180	PROPN
dpc-4852	31	15	,	,	PUNCT
dpc-4852	31	16	thus	thus	ADV
dpc-4852	31	17	inducing	induce	VERB
dpc-4852	31	18	bp	bp	PROPN
dpc-4852	31	19	.	.	PUNCT
dpc-4852	32	1	other	other	ADJ
dpc-4852	32	2	drugs	drug	NOUN
dpc-4852	32	3	implicated	implicate	VERB
dpc-4852	32	4	include	include	VERB
dpc-4852	32	5	loop	loop	NOUN
dpc-4852	32	6	diuretics	diuretic	NOUN
dpc-4852	32	7	,	,	PUNCT
dpc-4852	32	8	aldosterone	aldosterone	NOUN
dpc-4852	32	9	antagonists	antagonist	NOUN
dpc-4852	32	10	,	,	PUNCT
dpc-4852	32	11	penicillin	penicillin	NOUN
dpc-4852	32	12	and	and	CCONJ
dpc-4852	32	13	cephalosporins	cephalosporin	NOUN
dpc-4852	32	14	,	,	PUNCT
dpc-4852	32	15	further	far	ADV
dpc-4852	32	16	emphasizing	emphasize	VERB
dpc-4852	32	17	the	the	DET
dpc-4852	32	18	need	need	NOUN
dpc-4852	32	19	for	for	ADP
dpc-4852	32	20	careful	careful	ADJ
dpc-4852	32	21	monitoring	monitoring	NOUN
dpc-4852	32	22	of	of	ADP
dpc-4852	32	23	medication	medication	NOUN
dpc-4852	32	24	-	-	PUNCT
dpc-4852	32	25	related	relate	VERB
dpc-4852	32	26	risks	risk	NOUN
dpc-4852	32	27	in	in	ADP
dpc-4852	32	28	susceptible	susceptible	ADJ
dpc-4852	32	29	populations	population	NOUN
dpc-4852	32	30	[	[	X
dpc-4852	32	31	7	7	NUM
dpc-4852	32	32	]	]	PUNCT
dpc-4852	32	33	.	.	PUNCT
dpc-4852	33	1	the	the	DET
dpc-4852	33	2	true	true	ADJ
dpc-4852	33	3	disease	disease	NOUN
dpc-4852	33	4	burden	burden	NOUN
dpc-4852	33	5	may	may	AUX
dpc-4852	33	6	be	be	AUX
dpc-4852	33	7	underestimated	underestimate	VERB
dpc-4852	33	8	,	,	PUNCT
dpc-4852	33	9	emphasizing	emphasize	VERB
dpc-4852	33	10	the	the	DET
dpc-4852	33	11	necessity	necessity	NOUN
dpc-4852	33	12	for	for	ADP
dpc-4852	33	13	more	more	ADJ
dpc-4852	33	14	epidemiological	epidemiological	ADJ
dpc-4852	33	15	studies	study	NOUN
dpc-4852	33	16	on	on	ADP
dpc-4852	33	17	this	this	DET
dpc-4852	33	18	autoimmune	autoimmune	ADJ
dpc-4852	33	19	condition[8,9	condition[8,9	PROPN
dpc-4852	33	20	]	]	PUNCT
dpc-4852	33	21	.	.	PUNCT
dpc-4852	34	1	bp	bp	PROPN
dpc-4852	34	2	is	be	AUX
dpc-4852	34	3	recognized	recognize	VERB
dpc-4852	34	4	as	as	ADP
dpc-4852	34	5	a	a	DET
dpc-4852	34	6	condition	condition	NOUN
dpc-4852	34	7	affecting	affect	VERB
dpc-4852	34	8	the	the	DET
dpc-4852	34	9	elderly	elderly	ADJ
dpc-4852	34	10	,	,	PUNCT
dpc-4852	34	11	with	with	ADP
dpc-4852	34	12	the	the	DET
dpc-4852	34	13	typical	typical	ADJ
dpc-4852	34	14	age	age	NOUN
dpc-4852	34	15	at	at	ADP
dpc-4852	34	16	onset	onset	NOUN
dpc-4852	34	17	ranging	range	VERB
dpc-4852	34	18	from	from	ADP
dpc-4852	34	19	66	66	NUM
dpc-4852	34	20	to	to	PART
dpc-4852	34	21	83	83	NUM
dpc-4852	34	22	years	year	NOUN
dpc-4852	34	23	in	in	ADP
dpc-4852	34	24	various	various	ADJ
dpc-4852	34	25	global	global	ADJ
dpc-4852	34	26	cohorts	cohort	NOUN
dpc-4852	34	27	.	.	PUNCT
dpc-4852	35	1	the	the	DET
dpc-4852	35	2	incidence	incidence	NOUN
dpc-4852	35	3	escalates	escalate	VERB
dpc-4852	35	4	significantly	significantly	ADV
dpc-4852	35	5	with	with	ADP
dpc-4852	35	6	advancing	advance	VERB
dpc-4852	35	7	age	age	NOUN
dpc-4852	35	8	,	,	PUNCT
dpc-4852	35	9	peaking	peak	VERB
dpc-4852	35	10	at	at	ADP
dpc-4852	35	11	190	190	NUM
dpc-4852	35	12	to	to	PART
dpc-4852	35	13	312	312	NUM
dpc-4852	35	14	cases	case	NOUN
dpc-4852	35	15	per	per	ADP
dpc-4852	35	16	million	million	NUM
dpc-4852	35	17	per	per	ADP
dpc-4852	35	18	year	year	NOUN
dpc-4852	35	19	in	in	ADP
dpc-4852	35	20	individuals	individual	NOUN
dpc-4852	35	21	aged	age	VERB
dpc-4852	35	22	80	80	NUM
dpc-4852	35	23	years	year	NOUN
dpc-4852	35	24	and	and	CCONJ
dpc-4852	35	25	above	above	ADP
dpc-4852	35	26	[	[	X
dpc-4852	35	27	9	9	NUM
dpc-4852	35	28	,	,	PUNCT
dpc-4852	35	29	10	10	NUM
dpc-4852	35	30	]	]	PUNCT
dpc-4852	35	31	.	.	PUNCT
dpc-4852	36	1	there	there	PRON
dpc-4852	36	2	is	be	VERB
dpc-4852	36	3	evidence	evidence	NOUN
dpc-4852	36	4	suggesting	suggest	VERB
dpc-4852	36	5	a	a	DET
dpc-4852	36	6	genetic	genetic	ADJ
dpc-4852	36	7	predisposition	predisposition	NOUN
dpc-4852	36	8	to	to	ADP
dpc-4852	36	9	bp	bp	PROPN
dpc-4852	36	10	,	,	PUNCT
dpc-4852	36	11	with	with	ADP
dpc-4852	36	12	certain	certain	ADJ
dpc-4852	36	13	human	human	ADJ
dpc-4852	36	14	leukocyte	leukocyte	NOUN
dpc-4852	36	15	antigen	antigen	NOUN
dpc-4852	36	16	(	(	PUNCT
dpc-4852	36	17	hla	hla	NOUN
dpc-4852	36	18	)	)	PUNCT
dpc-4852	36	19	alleles	allele	NOUN
dpc-4852	36	20	,	,	PUNCT
dpc-4852	36	21	such	such	ADJ
dpc-4852	36	22	as	as	ADP
dpc-4852	36	23	hla	hla	NOUN
dpc-4852	36	24	-	-	PUNCT
dpc-4852	36	25	dqb10301	dqb10301	NOUN
dpc-4852	36	26	,	,	PUNCT
dpc-4852	36	27	hladrb10401	hladrb10401	PROPN
dpc-4852	36	28	,	,	PUNCT
dpc-4852	36	29	and	and	CCONJ
dpc-4852	36	30	hla	hla	NOUN
dpc-4852	36	31	-	-	PUNCT
dpc-4852	36	32	dqb1	dqb1	PROPN
dpc-4852	36	33	*	*	NOUN
dpc-4852	36	34	0503	0503	NUM
dpc-4852	36	35	,	,	PUNCT
dpc-4852	36	36	identified	identify	VERB
dpc-4852	36	37	as	as	ADP
dpc-4852	36	38	potential	potential	ADJ
dpc-4852	36	39	risk	risk	NOUN
dpc-4852	36	40	factors	factor	NOUN
dpc-4852	36	41	.	.	PUNCT
dpc-4852	37	1	however	however	ADV
dpc-4852	37	2	,	,	PUNCT
dpc-4852	37	3	the	the	DET
dpc-4852	37	4	association	association	NOUN
dpc-4852	37	5	between	between	ADP
dpc-4852	37	6	hla	hla	PROPN
dpc-4852	37	7	alleles	allele	NOUN
dpc-4852	37	8	and	and	CCONJ
dpc-4852	37	9	bp	bp	PROPN
dpc-4852	37	10	varies	vary	VERB
dpc-4852	37	11	across	across	ADP
dpc-4852	37	12	different	different	ADJ
dpc-4852	37	13	ethnic	ethnic	ADJ
dpc-4852	37	14	groups	group	NOUN
dpc-4852	37	15	[	[	X
dpc-4852	37	16	11	11	NUM
dpc-4852	37	17	]	]	PUNCT
dpc-4852	37	18	.	.	PUNCT
dpc-4852	38	1	clinical	clinical	ADJ
dpc-4852	38	2	presentation	presentation	NOUN
dpc-4852	38	3	the	the	DET
dpc-4852	38	4	characteristic	characteristic	ADJ
dpc-4852	38	5	clinical	clinical	ADJ
dpc-4852	38	6	presentation	presentation	NOUN
dpc-4852	38	7	involves	involve	VERB
dpc-4852	38	8	the	the	DET
dpc-4852	38	9	development	development	NOUN
dpc-4852	38	10	of	of	ADP
dpc-4852	38	11	tense	tense	ADJ
dpc-4852	38	12	blisters	blister	NOUN
dpc-4852	38	13	,	,	PUNCT
dpc-4852	38	14	which	which	PRON
dpc-4852	38	15	may	may	AUX
dpc-4852	38	16	develop	develop	VERB
dpc-4852	38	17	on	on	ADP
dpc-4852	38	18	skin	skin	NOUN
dpc-4852	38	19	with	with	ADP
dpc-4852	38	20	normal	normal	ADJ
dpc-4852	38	21	appearance	appearance	NOUN
dpc-4852	38	22	or	or	CCONJ
dpc-4852	38	23	on	on	ADP
dpc-4852	38	24	inflamed	inflame	VERB
dpc-4852	38	25	skin	skin	NOUN
dpc-4852	38	26	[	[	X
dpc-4852	38	27	12	12	NUM
dpc-4852	38	28	]	]	PUNCT
dpc-4852	38	29	.	.	PUNCT
dpc-4852	39	1	before	before	ADP
dpc-4852	39	2	this	this	PRON
dpc-4852	39	3	,	,	PUNCT
dpc-4852	39	4	an	an	DET
dpc-4852	39	5	urticarial	urticarial	ADJ
dpc-4852	39	6	or	or	CCONJ
dpc-4852	39	7	eczematous	eczematous	ADJ
dpc-4852	39	8	rash	rash	NOUN
dpc-4852	39	9	may	may	AUX
dpc-4852	39	10	occur	occur	VERB
dpc-4852	39	11	.	.	PUNCT
dpc-4852	40	1	the	the	DET
dpc-4852	40	2	level	level	NOUN
dpc-4852	40	3	of	of	ADP
dpc-4852	40	4	itchiness	itchiness	NOUN
dpc-4852	40	5	can	can	AUX
dpc-4852	40	6	vary	vary	VERB
dpc-4852	40	7	from	from	ADP
dpc-4852	40	8	none	none	NOUN
dpc-4852	40	9	to	to	ADP
dpc-4852	40	10	intense	intense	ADJ
dpc-4852	40	11	,	,	PUNCT
dpc-4852	40	12	and	and	CCONJ
dpc-4852	40	13	it	it	PRON
dpc-4852	40	14	might	might	AUX
dpc-4852	40	15	precede	precede	VERB
dpc-4852	40	16	the	the	DET
dpc-4852	40	17	development	development	NOUN
dpc-4852	40	18	of	of	ADP
dpc-4852	40	19	blisters	blister	NOUN
dpc-4852	40	20	that	that	PRON
dpc-4852	40	21	contain	contain	VERB
dpc-4852	40	22	either	either	CCONJ
dpc-4852	40	23	clear	clear	ADJ
dpc-4852	40	24	or	or	CCONJ
dpc-4852	40	25	bloodstained	bloodstained	ADJ
dpc-4852	40	26	fluid	fluid	NOUN
dpc-4852	40	27	.	.	PUNCT
dpc-4852	41	1	these	these	DET
dpc-4852	41	2	blisters	blister	NOUN
dpc-4852	41	3	typically	typically	ADV
dpc-4852	41	4	manifest	manifest	VERB
dpc-4852	41	5	across	across	ADP
dpc-4852	41	6	the	the	DET
dpc-4852	41	7	whole	whole	ADJ
dpc-4852	41	8	body	body	NOUN
dpc-4852	41	9	and	and	CCONJ
dpc-4852	41	10	are	be	AUX
dpc-4852	41	11	more	more	ADV
dpc-4852	41	12	likely	likely	ADJ
dpc-4852	41	13	to	to	PART
dpc-4852	41	14	appear	appear	VERB
dpc-4852	41	15	on	on	ADP
dpc-4852	41	16	the	the	DET
dpc-4852	41	17	limbs	limb	NOUN
dpc-4852	41	18	.	.	PUNCT
dpc-4852	42	1	there	there	PRON
dpc-4852	42	2	are	be	VERB
dpc-4852	42	3	also	also	ADV
dpc-4852	42	4	localized	localized	ADJ
dpc-4852	42	5	forms	form	NOUN
dpc-4852	42	6	of	of	ADP
dpc-4852	42	7	the	the	DET
dpc-4852	42	8	condition	condition	NOUN
dpc-4852	42	9	.	.	PUNCT
dpc-4852	43	1	bp	bp	PROPN
dpc-4852	43	2	can	can	AUX
dpc-4852	43	3	extend	extend	VERB
dpc-4852	43	4	to	to	PART
dpc-4852	43	5	affect	affect	VERB
dpc-4852	43	6	mucosal	mucosal	NOUN
dpc-4852	43	7	surfaces	surface	NOUN
dpc-4852	43	8	,	,	PUNCT
dpc-4852	43	9	such	such	ADJ
dpc-4852	43	10	as	as	ADP
dpc-4852	43	11	the	the	DET
dpc-4852	43	12	mouth	mouth	NOUN
dpc-4852	43	13	,	,	PUNCT
dpc-4852	43	14	and	and	CCONJ
dpc-4852	43	15	is	be	AUX
dpc-4852	43	16	generally	generally	ADV
dpc-4852	43	17	not	not	PART
dpc-4852	43	18	associated	associate	VERB
dpc-4852	43	19	with	with	ADP
dpc-4852	43	20	scarring	scar	VERB
dpc-4852	43	21	[	[	PUNCT
dpc-4852	43	22	13	13	NUM
dpc-4852	43	23	]	]	PUNCT
dpc-4852	43	24	.	.	PUNCT
dpc-4852	44	1	diagnosis	diagnosis	NOUN
dpc-4852	44	2	and	and	CCONJ
dpc-4852	44	3	therapeutic	therapeutic	ADJ
dpc-4852	44	4	strategies	strategy	NOUN
dpc-4852	44	5	the	the	DET
dpc-4852	44	6	most	most	ADV
dpc-4852	44	7	reliable	reliable	ADJ
dpc-4852	44	8	diagnostic	diagnostic	ADJ
dpc-4852	44	9	method	method	NOUN
dpc-4852	44	10	for	for	ADP
dpc-4852	44	11	bp	bp	PROPN
dpc-4852	44	12	involves	involve	VERB
dpc-4852	44	13	a	a	DET
dpc-4852	44	14	perilesional	perilesional	ADJ
dpc-4852	44	15	skin	skin	NOUN
dpc-4852	44	16	biopsy	biopsy	NOUN
dpc-4852	44	17	for	for	ADP
dpc-4852	44	18	immunopathological	immunopathological	ADJ
dpc-4852	44	19	analysis	analysis	NOUN
dpc-4852	44	20	.	.	PUNCT
dpc-4852	45	1	a	a	DET
dpc-4852	45	2	direct	direct	ADJ
dpc-4852	45	3	immunofluorescence	immunofluorescence	NOUN
dpc-4852	45	4	technique	technique	NOUN
dpc-4852	45	5	conducted	conduct	VERB
dpc-4852	45	6	on	on	ADP
dpc-4852	45	7	the	the	DET
dpc-4852	45	8	individual	individual	NOUN
dpc-4852	45	9	’s	’s	PART
dpc-4852	45	10	skin	skin	NOUN
dpc-4852	45	11	reveals	reveal	VERB
dpc-4852	45	12	deposits	deposit	NOUN
dpc-4852	45	13	of	of	ADP
dpc-4852	45	14	immunoglobulin	immunoglobulin	NOUN
dpc-4852	45	15	g	g	PROPN
dpc-4852	45	16	(	(	PUNCT
dpc-4852	45	17	igg	igg	PROPN
dpc-4852	45	18	)	)	PUNCT
dpc-4852	45	19	autoantibodies	autoantibody	NOUN
dpc-4852	45	20	and	and	CCONJ
dpc-4852	45	21	complement	complement	NOUN
dpc-4852	45	22	component	component	NOUN
dpc-4852	45	23	3	3	NUM
dpc-4852	45	24	(	(	PUNCT
dpc-4852	45	25	c3	c3	PROPN
dpc-4852	45	26	)	)	PUNCT
dpc-4852	45	27	at	at	ADP
dpc-4852	45	28	the	the	DET
dpc-4852	45	29	dermoepidermal	dermoepidermal	ADJ
dpc-4852	45	30	junction	junction	NOUN
dpc-4852	45	31	,	,	PUNCT
dpc-4852	45	32	binding	bind	VERB
dpc-4852	45	33	to	to	ADP
dpc-4852	45	34	bp230	bp230	PROPN
dpc-4852	45	35	and	and	CCONJ
dpc-4852	45	36	bp180	bp180	PROPN
dpc-4852	45	37	autoantigens	autoantigen	NOUN
dpc-4852	45	38	.	.	PUNCT
dpc-4852	46	1	enzyme	enzyme	NOUN
dpc-4852	46	2	-	-	PUNCT
dpc-4852	46	3	linked	link	VERB
dpc-4852	46	4	immunosorbent	immunosorbent	NOUN
dpc-4852	46	5	assay	assay	PROPN
dpc-4852	46	6	(	(	PUNCT
dpc-4852	46	7	elisa	elisa	NOUN
dpc-4852	46	8	)	)	PUNCT
dpc-4852	46	9	and	and	CCONJ
dpc-4852	46	10	indirect	indirect	ADJ
dpc-4852	46	11	immunofluorescence	immunofluorescence	NOUN
dpc-4852	46	12	utilizing	utilize	VERB
dpc-4852	46	13	serum	serum	NOUN
dpc-4852	46	14	can	can	AUX
dpc-4852	46	15	demonstrate	demonstrate	VERB
dpc-4852	46	16	circulating	circulate	VERB
dpc-4852	46	17	autoantibodies	autoantibody	NOUN
dpc-4852	46	18	directed	direct	VERB
dpc-4852	46	19	against	against	ADP
dpc-4852	46	20	basement	basement	NOUN
dpc-4852	46	21	membrane	membrane	NOUN
dpc-4852	46	22	proteins	protein	NOUN
dpc-4852	46	23	and	and	CCONJ
dpc-4852	46	24	especially	especially	ADV
dpc-4852	46	25	the	the	DET
dpc-4852	46	26	nc16a	nc16a	NOUN
dpc-4852	46	27	portion	portion	NOUN
dpc-4852	46	28	of	of	ADP
dpc-4852	46	29	bp180	bp180	ADJ
dpc-4852	46	30	antigen	antigen	NOUN
dpc-4852	47	1	[	[	X
dpc-4852	47	2	14	14	NUM
dpc-4852	47	3	,	,	PUNCT
dpc-4852	47	4	15	15	NUM
dpc-4852	47	5	]	]	PUNCT
dpc-4852	47	6	.	.	PUNCT
dpc-4852	48	1	direct	direct	ADJ
dpc-4852	48	2	immunofluorescence	immunofluorescence	NOUN
dpc-4852	48	3	(	(	PUNCT
dpc-4852	48	4	dif	dif	X
dpc-4852	48	5	)	)	PUNCT
dpc-4852	48	6	is	be	AUX
dpc-4852	48	7	the	the	DET
dpc-4852	48	8	standard	standard	ADJ
dpc-4852	48	9	diagnostic	diagnostic	ADJ
dpc-4852	48	10	method	method	NOUN
dpc-4852	48	11	for	for	ADP
dpc-4852	48	12	immunobullous	immunobullous	ADJ
dpc-4852	48	13	diseases	disease	NOUN
dpc-4852	48	14	.	.	PUNCT
dpc-4852	49	1	dif	dif	X
dpc-4852	49	2	in	in	ADP
dpc-4852	49	3	pemphigoid	pemphigoid	ADJ
dpc-4852	49	4	diseases	disease	NOUN
dpc-4852	49	5	allows	allow	VERB
dpc-4852	49	6	for	for	ADP
dpc-4852	49	7	the	the	DET
dpc-4852	49	8	identification	identification	NOUN
dpc-4852	49	9	of	of	ADP
dpc-4852	49	10	two	two	NUM
dpc-4852	49	11	antibody	antibody	NOUN
dpc-4852	49	12	deposition	deposition	NOUN
dpc-4852	49	13	patterns	pattern	NOUN
dpc-4852	49	14	at	at	ADP
dpc-4852	49	15	the	the	DET
dpc-4852	49	16	dermal	dermal	NOUN
dpc-4852	49	17	-	-	PUNCT
dpc-4852	49	18	epidermal	epidermal	ADJ
dpc-4852	49	19	junction	junction	NOUN
dpc-4852	49	20	:	:	PUNCT
dpc-4852	49	21	u	u	NOUN
dpc-4852	49	22	-	-	VERB
dpc-4852	49	23	serrated	serrate	VERB
dpc-4852	49	24	and	and	CCONJ
dpc-4852	49	25	n	n	CCONJ
dpc-4852	49	26	-	-	PUNCT
dpc-4852	49	27	serrated	serrate	VERB
dpc-4852	49	28	.	.	PUNCT
dpc-4852	50	1	the	the	DET
dpc-4852	50	2	u	u	NOUN
dpc-4852	50	3	-	-	ADJ
dpc-4852	50	4	serrated	serrate	VERB
dpc-4852	50	5	pattern	pattern	NOUN
dpc-4852	50	6	is	be	AUX
dpc-4852	50	7	associated	associate	VERB
dpc-4852	50	8	with	with	ADP
dpc-4852	50	9	epidermolysis	epidermolysis	NOUN
dpc-4852	50	10	bullosa	bullosa	PROPN
dpc-4852	50	11	acquisita	acquisita	PROPN
dpc-4852	50	12	,	,	PUNCT
dpc-4852	50	13	while	while	SCONJ
dpc-4852	50	14	the	the	DET
dpc-4852	50	15	n	n	CCONJ
dpc-4852	50	16	-	-	PUNCT
dpc-4852	50	17	serrated	serrate	VERB
dpc-4852	50	18	pattern	pattern	NOUN
dpc-4852	50	19	is	be	AUX
dpc-4852	50	20	present	present	ADJ
dpc-4852	50	21	in	in	ADP
dpc-4852	50	22	all	all	DET
dpc-4852	50	23	other	other	ADJ
dpc-4852	50	24	pemphigoid	pemphigoid	ADJ
dpc-4852	50	25	diseases	disease	NOUN
dpc-4852	51	1	[	[	X
dpc-4852	51	2	16	16	NUM
dpc-4852	51	3	]	]	PUNCT
dpc-4852	51	4	.	.	PUNCT
dpc-4852	52	1	however	however	ADV
dpc-4852	52	2	,	,	PUNCT
dpc-4852	52	3	it	it	PRON
dpc-4852	52	4	is	be	AUX
dpc-4852	52	5	not	not	PART
dpc-4852	52	6	consistently	consistently	ADV
dpc-4852	52	7	effective	effective	ADJ
dpc-4852	52	8	in	in	ADP
dpc-4852	52	9	distinguishing	distinguish	VERB
dpc-4852	52	10	between	between	ADP
dpc-4852	52	11	different	different	ADJ
dpc-4852	52	12	subtypes	subtype	NOUN
dpc-4852	52	13	of	of	ADP
dpc-4852	52	14	subepidermal	subepidermal	ADJ
dpc-4852	52	15	immunobullous	immunobullous	ADJ
dpc-4852	52	16	diseases	disease	NOUN
dpc-4852	52	17	.	.	PUNCT
dpc-4852	53	1	immunofluorescence	immunofluorescence	NOUN
dpc-4852	53	2	techniques	technique	NOUN
dpc-4852	53	3	on	on	ADP
dpc-4852	53	4	split	split	ADJ
dpc-4852	53	5	skin	skin	NOUN
dpc-4852	53	6	,	,	PUNCT
dpc-4852	53	7	results	result	VERB
dpc-4852	53	8	:	:	PUNCT
dpc-4852	53	9	among	among	ADP
dpc-4852	53	10	the	the	DET
dpc-4852	53	11	188	188	NUM
dpc-4852	53	12	patients	patient	NOUN
dpc-4852	53	13	(	(	PUNCT
dpc-4852	53	14	88	88	NUM
dpc-4852	53	15	females	female	NOUN
dpc-4852	53	16	,	,	PUNCT
dpc-4852	53	17	100	100	NUM
dpc-4852	53	18	males	male	NOUN
dpc-4852	53	19	;	;	PUNCT
dpc-4852	53	20	mean	mean	VERB
dpc-4852	53	21	age	age	NOUN
dpc-4852	53	22	76	76	NUM
dpc-4852	53	23	years	year	NOUN
dpc-4852	53	24	)	)	PUNCT
dpc-4852	53	25	,	,	PUNCT
dpc-4852	53	26	97	97	NUM
dpc-4852	53	27	%	%	NOUN
dpc-4852	53	28	received	receive	VERB
dpc-4852	53	29	systemic	systemic	ADJ
dpc-4852	53	30	corticosteroid	corticosteroid	ADJ
dpc-4852	53	31	therapy	therapy	NOUN
dpc-4852	53	32	,	,	PUNCT
dpc-4852	53	33	while	while	SCONJ
dpc-4852	53	34	1.6	1.6	NUM
dpc-4852	53	35	%	%	NOUN
dpc-4852	53	36	were	be	AUX
dpc-4852	53	37	treated	treat	VERB
dpc-4852	53	38	with	with	ADP
dpc-4852	53	39	potent	potent	ADJ
dpc-4852	53	40	topical	topical	ADJ
dpc-4852	53	41	steroids	steroid	NOUN
dpc-4852	53	42	alone	alone	ADV
dpc-4852	53	43	.	.	PUNCT
dpc-4852	54	1	doxycycline	doxycycline	PROPN
dpc-4852	54	2	was	be	AUX
dpc-4852	54	3	administered	administer	VERB
dpc-4852	54	4	to	to	ADP
dpc-4852	54	5	8	8	NUM
dpc-4852	54	6	%	%	NOUN
dpc-4852	54	7	of	of	ADP
dpc-4852	54	8	patients	patient	NOUN
dpc-4852	54	9	,	,	PUNCT
dpc-4852	54	10	and	and	CCONJ
dpc-4852	54	11	11.7	11.7	NUM
dpc-4852	54	12	%	%	NOUN
dpc-4852	54	13	received	receive	VERB
dpc-4852	54	14	additional	additional	ADJ
dpc-4852	54	15	immunosuppressive	immunosuppressive	ADJ
dpc-4852	54	16	agents	agent	NOUN
dpc-4852	54	17	.	.	PUNCT
dpc-4852	55	1	the	the	DET
dpc-4852	55	2	most	most	ADV
dpc-4852	55	3	common	common	ADJ
dpc-4852	55	4	comorbidity	comorbidity	NOUN
dpc-4852	55	5	was	be	AUX
dpc-4852	55	6	diabetes	diabetes	NOUN
dpc-4852	55	7	mellitus	mellitus	NOUN
dpc-4852	55	8	(	(	PUNCT
dpc-4852	55	9	60.6	60.6	NUM
dpc-4852	55	10	%	%	NOUN
dpc-4852	55	11	)	)	PUNCT
dpc-4852	55	12	.	.	PUNCT
dpc-4852	56	1	bp	bp	PROPN
dpc-4852	56	2	was	be	AUX
dpc-4852	56	3	associated	associate	VERB
dpc-4852	56	4	with	with	ADP
dpc-4852	56	5	gliptin	gliptin	PROPN
dpc-4852	56	6	intake	intake	NOUN
dpc-4852	56	7	in	in	ADP
dpc-4852	56	8	36	36	NUM
dpc-4852	56	9	%	%	NOUN
dpc-4852	56	10	of	of	ADP
dpc-4852	56	11	cases	case	NOUN
dpc-4852	56	12	.	.	PUNCT
dpc-4852	57	1	hospitalization	hospitalization	NOUN
dpc-4852	57	2	was	be	AUX
dpc-4852	57	3	required	require	VERB
dpc-4852	57	4	for	for	ADP
dpc-4852	57	5	79	79	NUM
dpc-4852	57	6	%	%	NOUN
dpc-4852	57	7	of	of	ADP
dpc-4852	57	8	patients	patient	NOUN
dpc-4852	57	9	with	with	ADP
dpc-4852	57	10	corticosteroid	corticosteroid	ADJ
dpc-4852	57	11	tapering	tapering	NOUN
dpc-4852	57	12	initiated	initiate	VERB
dpc-4852	57	13	on	on	ADP
dpc-4852	57	14	average	average	ADJ
dpc-4852	57	15	by	by	ADP
dpc-4852	57	16	day	day	NOUN
dpc-4852	57	17	twenty	twenty	NUM
dpc-4852	57	18	-	-	PUNCT
dpc-4852	57	19	three	three	NUM
dpc-4852	57	20	.	.	PUNCT
dpc-4852	58	1	disease	disease	NOUN
dpc-4852	58	2	recurrence	recurrence	NOUN
dpc-4852	58	3	occurred	occur	VERB
dpc-4852	58	4	in	in	ADP
dpc-4852	58	5	34	34	NUM
dpc-4852	58	6	%	%	NOUN
dpc-4852	58	7	of	of	ADP
dpc-4852	58	8	cases	case	NOUN
dpc-4852	58	9	.	.	PUNCT
dpc-4852	59	1	conclusion	conclusion	NOUN
dpc-4852	59	2	:	:	PUNCT
dpc-4852	59	3	the	the	DET
dpc-4852	59	4	high	high	ADJ
dpc-4852	59	5	incidence	incidence	NOUN
dpc-4852	59	6	rates	rate	NOUN
dpc-4852	59	7	in	in	ADP
dpc-4852	59	8	older	old	ADJ
dpc-4852	59	9	adults	adult	NOUN
dpc-4852	59	10	and	and	CCONJ
dpc-4852	59	11	dpp-4	dpp-4	ADJ
dpc-4852	59	12	inhibitor	inhibitor	NOUN
dpc-4852	59	13	users	user	NOUN
dpc-4852	59	14	underscore	underscore	VERB
dpc-4852	59	15	the	the	DET
dpc-4852	59	16	need	need	NOUN
dpc-4852	59	17	for	for	ADP
dpc-4852	59	18	continued	continue	VERB
dpc-4852	59	19	vigilance	vigilance	NOUN
dpc-4852	59	20	and	and	CCONJ
dpc-4852	59	21	research	research	NOUN
dpc-4852	59	22	.	.	PUNCT
dpc-4852	60	1	systemic	systemic	ADJ
dpc-4852	60	2	corticosteroids	corticosteroid	NOUN
dpc-4852	60	3	remain	remain	VERB
dpc-4852	60	4	the	the	DET
dpc-4852	60	5	primary	primary	ADJ
dpc-4852	60	6	treatment	treatment	NOUN
dpc-4852	60	7	at	at	ADP
dpc-4852	60	8	our	our	PRON
dpc-4852	60	9	center	center	NOUN
dpc-4852	60	10	.	.	PUNCT
dpc-4852	61	1	continuous	continuous	ADJ
dpc-4852	61	2	monitoring	monitoring	NOUN
dpc-4852	61	3	and	and	CCONJ
dpc-4852	61	4	refinement	refinement	NOUN
dpc-4852	61	5	of	of	ADP
dpc-4852	61	6	prevention	prevention	NOUN
dpc-4852	61	7	and	and	CCONJ
dpc-4852	61	8	management	management	NOUN
dpc-4852	61	9	strategies	strategy	NOUN
dpc-4852	61	10	are	be	AUX
dpc-4852	61	11	crucial	crucial	ADJ
dpc-4852	61	12	for	for	ADP
dpc-4852	61	13	effectively	effectively	ADV
dpc-4852	61	14	addressing	address	VERB
dpc-4852	61	15	bp	bp	PROPN
dpc-4852	61	16	.	.	PUNCT
dpc-4852	62	1	original	original	ADJ
dpc-4852	62	2	article	article	NOUN
dpc-4852	62	3	|	|	ADV
dpc-4852	62	4	dermatol	dermatol	ADJ
dpc-4852	62	5	pract	pract	NOUN
dpc-4852	62	6	concept	concept	NOUN
dpc-4852	62	7	.	.	PUNCT
dpc-4852	63	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	63	2	3	3	NUM
dpc-4852	63	3	introduced	introduce	VERB
dpc-4852	63	4	in	in	ADP
dpc-4852	63	5	the	the	DET
dpc-4852	63	6	late	late	ADJ
dpc-4852	63	7	1980s	1980s	NUM
dpc-4852	63	8	,	,	PUNCT
dpc-4852	63	9	enable	enable	VERB
dpc-4852	63	10	a	a	DET
dpc-4852	63	11	more	more	ADV
dpc-4852	63	12	precise	precise	ADJ
dpc-4852	63	13	localization	localization	NOUN
dpc-4852	63	14	of	of	ADP
dpc-4852	63	15	the	the	DET
dpc-4852	63	16	antigen	antigen	NOUN
dpc-4852	63	17	-	-	PUNCT
dpc-4852	63	18	antibody	antibody	NOUN
dpc-4852	63	19	-	-	PUNCT
dpc-4852	63	20	binding	bind	VERB
dpc-4852	63	21	site	site	NOUN
dpc-4852	63	22	.	.	PUNCT
dpc-4852	64	1	the	the	DET
dpc-4852	64	2	procedure	procedure	NOUN
dpc-4852	64	3	involves	involve	VERB
dpc-4852	64	4	incubating	incubate	VERB
dpc-4852	64	5	punch	punch	NOUN
dpc-4852	64	6	biopsy	biopsy	NOUN
dpc-4852	64	7	specimens	specimen	NOUN
dpc-4852	64	8	in	in	ADP
dpc-4852	64	9	5	5	NUM
dpc-4852	64	10	ml	ml	NOUN
dpc-4852	64	11	of	of	ADP
dpc-4852	64	12	1	1	NUM
dpc-4852	64	13	mol	mol	ADP
dpc-4852	64	14	/	/	SYM
dpc-4852	64	15	l	l	NOUN
dpc-4852	64	16	nacl	nacl	NOUN
dpc-4852	64	17	at	at	ADP
dpc-4852	64	18	4	4	NUM
dpc-4852	64	19	°	°	ADP
dpc-4852	64	20	c	c	NOUN
dpc-4852	64	21	for	for	ADP
dpc-4852	64	22	24	24	NUM
dpc-4852	64	23	hours	hour	NOUN
dpc-4852	64	24	,	,	PUNCT
dpc-4852	64	25	after	after	ADP
dpc-4852	64	26	which	which	PRON
dpc-4852	64	27	the	the	DET
dpc-4852	64	28	epidermis	epidermis	NOUN
dpc-4852	64	29	is	be	AUX
dpc-4852	64	30	separated	separate	VERB
dpc-4852	64	31	from	from	ADP
dpc-4852	64	32	the	the	DET
dpc-4852	64	33	dermis	dermis	NOUN
dpc-4852	64	34	using	use	VERB
dpc-4852	64	35	fine	fine	ADJ
dpc-4852	64	36	forceps	forceps	NOUN
dpc-4852	64	37	[	[	X
dpc-4852	64	38	17	17	NUM
dpc-4852	64	39	]	]	PUNCT
dpc-4852	64	40	.	.	PUNCT
dpc-4852	65	1	incubation	incubation	NOUN
dpc-4852	65	2	of	of	ADP
dpc-4852	65	3	skin	skin	NOUN
dpc-4852	65	4	tissue	tissue	NOUN
dpc-4852	65	5	in	in	ADP
dpc-4852	65	6	one	one	NUM
dpc-4852	65	7	molar	molar	ADJ
dpc-4852	65	8	sodium	sodium	NOUN
dpc-4852	65	9	chloride	chloride	NOUN
dpc-4852	65	10	results	result	NOUN
dpc-4852	65	11	in	in	ADP
dpc-4852	65	12	the	the	DET
dpc-4852	65	13	separation	separation	NOUN
dpc-4852	65	14	of	of	ADP
dpc-4852	65	15	the	the	DET
dpc-4852	65	16	dermis	dermis	NOUN
dpc-4852	65	17	from	from	ADP
dpc-4852	65	18	the	the	DET
dpc-4852	65	19	epidermis	epidermis	NOUN
dpc-4852	65	20	within	within	ADP
dpc-4852	65	21	the	the	DET
dpc-4852	65	22	lamina	lamina	ADJ
dpc-4852	65	23	lucida	lucida	PROPN
dpc-4852	65	24	level	level	NOUN
dpc-4852	65	25	of	of	ADP
dpc-4852	65	26	the	the	DET
dpc-4852	65	27	basement	basement	NOUN
dpc-4852	65	28	membrane	membrane	NOUN
dpc-4852	65	29	,	,	PUNCT
dpc-4852	65	30	visible	visible	ADJ
dpc-4852	65	31	under	under	ADP
dpc-4852	65	32	electron	electron	NOUN
dpc-4852	65	33	microscopic	microscopic	ADJ
dpc-4852	65	34	examination	examination	NOUN
dpc-4852	65	35	[	[	X
dpc-4852	65	36	18	18	NUM
dpc-4852	65	37	]	]	PUNCT
dpc-4852	65	38	.	.	PUNCT
dpc-4852	66	1	this	this	DET
dpc-4852	66	2	differentiation	differentiation	NOUN
dpc-4852	66	3	is	be	AUX
dpc-4852	66	4	essential	essential	ADJ
dpc-4852	66	5	to	to	PART
dpc-4852	66	6	distinguish	distinguish	VERB
dpc-4852	66	7	bp	bp	PROPN
dpc-4852	66	8	from	from	ADP
dpc-4852	66	9	other	other	ADJ
dpc-4852	66	10	autoimmune	autoimmune	ADJ
dpc-4852	66	11	bullous	bullous	ADJ
dpc-4852	66	12	diseases	disease	NOUN
dpc-4852	66	13	,	,	PUNCT
dpc-4852	66	14	such	such	ADJ
dpc-4852	66	15	as	as	ADP
dpc-4852	66	16	epidermolysis	epidermolysis	NOUN
dpc-4852	66	17	bullosa	bullosa	PROPN
dpc-4852	66	18	acquisita	acquisita	NOUN
dpc-4852	66	19	and	and	CCONJ
dpc-4852	66	20	bullous	bullous	ADJ
dpc-4852	66	21	systemic	systemic	ADJ
dpc-4852	66	22	lupus	lupus	PROPN
dpc-4852	66	23	erythematosus	erythematosus	PROPN
dpc-4852	66	24	.	.	PUNCT
dpc-4852	67	1	in	in	ADP
dpc-4852	67	2	bp	bp	PROPN
dpc-4852	67	3	,	,	PUNCT
dpc-4852	67	4	fluorescence	fluorescence	NOUN
dpc-4852	67	5	is	be	AUX
dpc-4852	67	6	typically	typically	ADV
dpc-4852	67	7	at	at	ADP
dpc-4852	67	8	the	the	DET
dpc-4852	67	9	roof	roof	NOUN
dpc-4852	67	10	(	(	PUNCT
dpc-4852	67	11	epidermal	epidermal	ADJ
dpc-4852	67	12	binding	binding	NOUN
dpc-4852	67	13	)	)	PUNCT
dpc-4852	67	14	,	,	PUNCT
dpc-4852	67	15	whereas	whereas	SCONJ
dpc-4852	67	16	in	in	ADP
dpc-4852	67	17	other	other	ADJ
dpc-4852	67	18	diseases	disease	NOUN
dpc-4852	67	19	,	,	PUNCT
dpc-4852	67	20	it	it	PRON
dpc-4852	67	21	is	be	AUX
dpc-4852	67	22	often	often	ADV
dpc-4852	67	23	at	at	ADP
dpc-4852	67	24	the	the	DET
dpc-4852	67	25	floor	floor	NOUN
dpc-4852	67	26	of	of	ADP
dpc-4852	67	27	the	the	DET
dpc-4852	67	28	blister	blister	NOUN
dpc-4852	67	29	(	(	PUNCT
dpc-4852	67	30	dermal	dermal	ADJ
dpc-4852	67	31	binding	binding	NOUN
dpc-4852	67	32	)	)	PUNCT
dpc-4852	68	1	[	[	X
dpc-4852	68	2	19	19	NUM
dpc-4852	68	3	]	]	PUNCT
dpc-4852	68	4	.	.	PUNCT
dpc-4852	69	1	immunoelectron	immunoelectron	ADJ
dpc-4852	69	2	microscopy	microscopy	NOUN
dpc-4852	69	3	and	and	CCONJ
dpc-4852	69	4	immunoblotting	immunoblotting	NOUN
dpc-4852	69	5	offer	offer	VERB
dpc-4852	69	6	greater	great	ADJ
dpc-4852	69	7	specificity	specificity	NOUN
dpc-4852	69	8	in	in	ADP
dpc-4852	69	9	investigations	investigation	NOUN
dpc-4852	69	10	and	and	CCONJ
dpc-4852	69	11	may	may	AUX
dpc-4852	69	12	even	even	ADV
dpc-4852	69	13	lead	lead	VERB
dpc-4852	69	14	to	to	ADP
dpc-4852	69	15	a	a	DET
dpc-4852	69	16	change	change	NOUN
dpc-4852	69	17	in	in	ADP
dpc-4852	69	18	diagnosis	diagnosis	NOUN
dpc-4852	69	19	in	in	ADP
dpc-4852	69	20	some	some	DET
dpc-4852	69	21	cases	case	NOUN
dpc-4852	69	22	[	[	X
dpc-4852	69	23	20	20	NUM
dpc-4852	69	24	]	]	PUNCT
dpc-4852	69	25	.	.	PUNCT
dpc-4852	70	1	however	however	ADV
dpc-4852	70	2	,	,	PUNCT
dpc-4852	70	3	these	these	DET
dpc-4852	70	4	advanced	advanced	ADJ
dpc-4852	70	5	investigations	investigation	NOUN
dpc-4852	70	6	are	be	AUX
dpc-4852	70	7	primarily	primarily	ADV
dpc-4852	70	8	limited	limit	VERB
dpc-4852	70	9	to	to	ADP
dpc-4852	70	10	research	research	NOUN
dpc-4852	70	11	centers	center	NOUN
dpc-4852	70	12	,	,	PUNCT
dpc-4852	70	13	while	while	SCONJ
dpc-4852	70	14	elisas	elisa	NOUN
dpc-4852	70	15	for	for	ADP
dpc-4852	70	16	detecting	detect	VERB
dpc-4852	70	17	circulating	circulate	VERB
dpc-4852	70	18	igg	igg	NOUN
dpc-4852	70	19	autoantibodies	autoantibody	NOUN
dpc-4852	70	20	to	to	ADP
dpc-4852	70	21	bp180	bp180	PROPN
dpc-4852	70	22	and	and	CCONJ
dpc-4852	70	23	bp230	bp230	VERB
dpc-4852	70	24	antigens	antigen	NOUN
dpc-4852	70	25	are	be	AUX
dpc-4852	70	26	now	now	ADV
dpc-4852	70	27	widely	widely	ADV
dpc-4852	70	28	available	available	ADJ
dpc-4852	70	29	.	.	PUNCT
dpc-4852	71	1	one	one	NUM
dpc-4852	71	2	limitation	limitation	NOUN
dpc-4852	71	3	of	of	ADP
dpc-4852	71	4	elisas	elisas	PROPN
dpc-4852	71	5	is	be	AUX
dpc-4852	71	6	that	that	SCONJ
dpc-4852	71	7	they	they	PRON
dpc-4852	71	8	only	only	ADV
dpc-4852	71	9	detect	detect	VERB
dpc-4852	71	10	autoantibody	autoantibody	ADJ
dpc-4852	71	11	binding	bind	VERB
dpc-4852	71	12	to	to	ADP
dpc-4852	71	13	bp180	bp180	PROPN
dpc-4852	71	14	and	and	CCONJ
dpc-4852	71	15	bp230	bp230	PROPN
dpc-4852	71	16	autoantigens	autoantigen	NOUN
dpc-4852	71	17	,	,	PUNCT
dpc-4852	71	18	leaving	leave	VERB
dpc-4852	71	19	other	other	ADJ
dpc-4852	71	20	autoantigens	autoantigen	NOUN
dpc-4852	71	21	undetected	undetecte	VERB
dpc-4852	71	22	by	by	ADP
dpc-4852	71	23	this	this	DET
dpc-4852	71	24	method	method	NOUN
dpc-4852	71	25	[	[	X
dpc-4852	71	26	21	21	NUM
dpc-4852	71	27	]	]	PUNCT
dpc-4852	71	28	.	.	PUNCT
dpc-4852	72	1	bp	bp	PROPN
dpc-4852	72	2	runs	run	VERB
dpc-4852	72	3	a	a	DET
dpc-4852	72	4	chronic	chronic	ADJ
dpc-4852	72	5	course	course	NOUN
dpc-4852	72	6	and	and	CCONJ
dpc-4852	72	7	thus	thus	ADV
dpc-4852	72	8	requires	require	VERB
dpc-4852	72	9	long	long	ADJ
dpc-4852	72	10	-	-	PUNCT
dpc-4852	72	11	term	term	NOUN
dpc-4852	72	12	treatment	treatment	NOUN
dpc-4852	72	13	.	.	PUNCT
dpc-4852	73	1	current	current	ADJ
dpc-4852	73	2	therapeutic	therapeutic	ADJ
dpc-4852	73	3	options	option	NOUN
dpc-4852	73	4	involve	involve	VERB
dpc-4852	73	5	topical	topical	ADJ
dpc-4852	73	6	and	and	CCONJ
dpc-4852	73	7	oral	oral	ADJ
dpc-4852	73	8	steroids	steroid	NOUN
dpc-4852	73	9	as	as	ADV
dpc-4852	73	10	well	well	ADV
dpc-4852	73	11	as	as	ADP
dpc-4852	73	12	immunosuppressants	immunosuppressant	NOUN
dpc-4852	73	13	.	.	PUNCT
dpc-4852	74	1	for	for	ADP
dpc-4852	74	2	severe	severe	ADJ
dpc-4852	74	3	cases	case	NOUN
dpc-4852	74	4	,	,	PUNCT
dpc-4852	74	5	plasma	plasma	NOUN
dpc-4852	74	6	exchange	exchange	NOUN
dpc-4852	74	7	,	,	PUNCT
dpc-4852	74	8	anti	anti	ADJ
dpc-4852	74	9	-	-	ADJ
dpc-4852	74	10	inflammatory	inflammatory	ADJ
dpc-4852	74	11	antibiotics	antibiotic	NOUN
dpc-4852	74	12	,	,	PUNCT
dpc-4852	74	13	nicotinamide	nicotinamide	NOUN
dpc-4852	74	14	,	,	PUNCT
dpc-4852	74	15	biologics	biologic	NOUN
dpc-4852	74	16	like	like	ADP
dpc-4852	74	17	rituximab	rituximab	NOUN
dpc-4852	74	18	,	,	PUNCT
dpc-4852	74	19	and	and	CCONJ
dpc-4852	74	20	intravenous	intravenous	ADJ
dpc-4852	74	21	immunoglobulins	immunoglobulin	NOUN
dpc-4852	74	22	are	be	AUX
dpc-4852	74	23	considered	consider	VERB
dpc-4852	74	24	[	[	PUNCT
dpc-4852	74	25	22	22	NUM
dpc-4852	74	26	-	-	SYM
dpc-4852	74	27	25	25	NUM
dpc-4852	74	28	]	]	PUNCT
dpc-4852	74	29	.	.	PUNCT
dpc-4852	75	1	however	however	ADV
dpc-4852	75	2	,	,	PUNCT
dpc-4852	75	3	these	these	DET
dpc-4852	75	4	treatments	treatment	NOUN
dpc-4852	75	5	pose	pose	VERB
dpc-4852	75	6	risks	risk	NOUN
dpc-4852	75	7	of	of	ADP
dpc-4852	75	8	severe	severe	ADJ
dpc-4852	75	9	adverse	adverse	ADJ
dpc-4852	75	10	effects	effect	NOUN
dpc-4852	75	11	and	and	CCONJ
dpc-4852	75	12	financial	financial	ADJ
dpc-4852	75	13	burden	burden	NOUN
dpc-4852	75	14	.	.	PUNCT
dpc-4852	76	1	historically	historically	ADV
dpc-4852	76	2	,	,	PUNCT
dpc-4852	76	3	oral	oral	ADJ
dpc-4852	76	4	corticosteroids	corticosteroid	NOUN
dpc-4852	76	5	were	be	AUX
dpc-4852	76	6	standard	standard	ADJ
dpc-4852	76	7	,	,	PUNCT
dpc-4852	76	8	but	but	CCONJ
dpc-4852	76	9	recent	recent	ADJ
dpc-4852	76	10	evidence	evidence	NOUN
dpc-4852	76	11	suggests	suggest	VERB
dpc-4852	76	12	high	high	ADJ
dpc-4852	76	13	-	-	PUNCT
dpc-4852	76	14	potency	potency	NOUN
dpc-4852	76	15	topical	topical	ADJ
dpc-4852	76	16	steroids	steroid	NOUN
dpc-4852	76	17	,	,	PUNCT
dpc-4852	76	18	like	like	ADP
dpc-4852	76	19	clobetasol	clobetasol	NOUN
dpc-4852	76	20	propionate	propionate	NOUN
dpc-4852	76	21	cream	cream	NOUN
dpc-4852	76	22	,	,	PUNCT
dpc-4852	76	23	may	may	AUX
dpc-4852	76	24	be	be	AUX
dpc-4852	76	25	equally	equally	ADV
dpc-4852	76	26	effective	effective	ADJ
dpc-4852	76	27	[	[	X
dpc-4852	76	28	26	26	NUM
dpc-4852	76	29	]	]	PUNCT
dpc-4852	76	30	,	,	PUNCT
dpc-4852	76	31	while	while	SCONJ
dpc-4852	76	32	some	some	DET
dpc-4852	76	33	studies	study	NOUN
dpc-4852	76	34	state	state	VERB
dpc-4852	76	35	that	that	SCONJ
dpc-4852	76	36	topical	topical	ADJ
dpc-4852	76	37	treatment	treatment	NOUN
dpc-4852	76	38	is	be	AUX
dpc-4852	76	39	superior	superior	ADJ
dpc-4852	76	40	to	to	PART
dpc-4852	76	41	oral	oral	ADJ
dpc-4852	76	42	corticosteroid	corticosteroid	ADJ
dpc-4852	76	43	treatment	treatment	NOUN
dpc-4852	77	1	[	[	X
dpc-4852	77	2	9	9	NUM
dpc-4852	77	3	]	]	PUNCT
dpc-4852	77	4	.	.	PUNCT
dpc-4852	78	1	antibiotics	antibiotic	NOUN
dpc-4852	78	2	with	with	ADP
dpc-4852	78	3	anti	anti	ADJ
dpc-4852	78	4	-	-	ADJ
dpc-4852	78	5	inflammatory	inflammatory	ADJ
dpc-4852	78	6	properties	property	NOUN
dpc-4852	78	7	,	,	PUNCT
dpc-4852	78	8	notably	notably	ADV
dpc-4852	78	9	in	in	ADP
dpc-4852	78	10	an	an	DET
dpc-4852	78	11	aging	age	VERB
dpc-4852	78	12	population	population	NOUN
dpc-4852	78	13	,	,	PUNCT
dpc-4852	78	14	have	have	AUX
dpc-4852	78	15	demonstrated	demonstrate	VERB
dpc-4852	78	16	efficacy	efficacy	NOUN
dpc-4852	78	17	and	and	CCONJ
dpc-4852	78	18	safety	safety	NOUN
dpc-4852	78	19	[	[	X
dpc-4852	78	20	27	27	NUM
dpc-4852	78	21	]	]	PUNCT
dpc-4852	78	22	.	.	PUNCT
dpc-4852	79	1	biological	biological	ADJ
dpc-4852	79	2	therapies	therapy	NOUN
dpc-4852	79	3	,	,	PUNCT
dpc-4852	79	4	including	include	VERB
dpc-4852	79	5	anti	anti	ADJ
dpc-4852	79	6	-	-	ADJ
dpc-4852	79	7	cd20	cd20	ADJ
dpc-4852	79	8	monoclonal	monoclonal	NOUN
dpc-4852	79	9	antibodies	antibody	NOUN
dpc-4852	79	10	(	(	PUNCT
dpc-4852	79	11	rituximab	rituximab	NOUN
dpc-4852	79	12	)	)	PUNCT
dpc-4852	79	13	,	,	PUNCT
dpc-4852	79	14	omalizumab	omalizumab	NOUN
dpc-4852	79	15	,	,	PUNCT
dpc-4852	79	16	and	and	CCONJ
dpc-4852	79	17	dupilumab	dupilumab	NOUN
dpc-4852	79	18	,	,	PUNCT
dpc-4852	79	19	are	be	AUX
dpc-4852	79	20	emerging	emerge	VERB
dpc-4852	79	21	as	as	ADP
dpc-4852	79	22	treatment	treatment	NOUN
dpc-4852	79	23	options	option	NOUN
dpc-4852	79	24	[	[	X
dpc-4852	79	25	28	28	NUM
dpc-4852	79	26	,	,	PUNCT
dpc-4852	79	27	29	29	NUM
dpc-4852	79	28	]	]	PUNCT
dpc-4852	79	29	.	.	PUNCT
dpc-4852	80	1	additionally	additionally	ADV
dpc-4852	80	2	,	,	PUNCT
dpc-4852	80	3	plasma	plasma	NOUN
dpc-4852	80	4	exchange	exchange	NOUN
dpc-4852	80	5	and	and	CCONJ
dpc-4852	80	6	intravenously	intravenously	ADV
dpc-4852	80	7	applied	apply	VERB
dpc-4852	80	8	pooled	pool	VERB
dpc-4852	80	9	immunoglobulins	immunoglobulin	NOUN
dpc-4852	80	10	are	be	AUX
dpc-4852	80	11	considered	consider	VERB
dpc-4852	80	12	for	for	ADP
dpc-4852	80	13	selected	select	VERB
dpc-4852	80	14	cases	case	NOUN
dpc-4852	80	15	[	[	X
dpc-4852	80	16	30	30	NUM
dpc-4852	80	17	]	]	PUNCT
dpc-4852	80	18	.	.	PUNCT
dpc-4852	81	1	continuous	continuous	ADJ
dpc-4852	81	2	exploration	exploration	NOUN
dpc-4852	81	3	of	of	ADP
dpc-4852	81	4	new	new	ADJ
dpc-4852	81	5	treatment	treatment	NOUN
dpc-4852	81	6	options	option	NOUN
dpc-4852	81	7	aiming	aim	VERB
dpc-4852	81	8	to	to	PART
dpc-4852	81	9	improve	improve	VERB
dpc-4852	81	10	healing	healing	NOUN
dpc-4852	81	11	and	and	CCONJ
dpc-4852	81	12	minimize	minimize	VERB
dpc-4852	81	13	adverse	adverse	ADJ
dpc-4852	81	14	effects	effect	NOUN
dpc-4852	81	15	is	be	AUX
dpc-4852	81	16	ongoing	ongoing	ADJ
dpc-4852	81	17	,	,	PUNCT
dpc-4852	81	18	although	although	SCONJ
dpc-4852	81	19	the	the	DET
dpc-4852	81	20	clinical	clinical	ADJ
dpc-4852	81	21	efficacy	efficacy	NOUN
dpc-4852	81	22	of	of	ADP
dpc-4852	81	23	these	these	DET
dpc-4852	81	24	options	option	NOUN
dpc-4852	81	25	requires	require	VERB
dpc-4852	81	26	further	further	ADJ
dpc-4852	81	27	establishment	establishment	NOUN
dpc-4852	81	28	.	.	PUNCT
dpc-4852	82	1	objectives	objective	VERB
dpc-4852	82	2	this	this	DET
dpc-4852	82	3	study	study	NOUN
dpc-4852	82	4	aimed	aim	VERB
dpc-4852	82	5	to	to	PART
dpc-4852	82	6	share	share	VERB
dpc-4852	82	7	recent	recent	ADJ
dpc-4852	82	8	epidemiological	epidemiological	ADJ
dpc-4852	82	9	data	datum	NOUN
dpc-4852	82	10	from	from	ADP
dpc-4852	82	11	bp	bp	PROPN
dpc-4852	82	12	patients	patient	NOUN
dpc-4852	82	13	in	in	ADP
dpc-4852	82	14	a	a	DET
dpc-4852	82	15	northern	northern	ADJ
dpc-4852	82	16	greece	greece	PROPN
dpc-4852	82	17	tertiary	tertiary	ADJ
dpc-4852	82	18	hospital	hospital	NOUN
dpc-4852	82	19	and	and	CCONJ
dpc-4852	82	20	the	the	DET
dpc-4852	82	21	treatment	treatment	NOUN
dpc-4852	82	22	protocol	protocol	NOUN
dpc-4852	82	23	we	we	PRON
dpc-4852	82	24	have	have	AUX
dpc-4852	82	25	been	be	AUX
dpc-4852	82	26	following	follow	VERB
dpc-4852	82	27	for	for	ADP
dpc-4852	82	28	the	the	DET
dpc-4852	82	29	past	past	ADJ
dpc-4852	82	30	eight	eight	NUM
dpc-4852	82	31	years	year	NOUN
dpc-4852	82	32	.	.	PUNCT
dpc-4852	83	1	focusing	focus	VERB
dpc-4852	83	2	on	on	ADP
dpc-4852	83	3	this	this	DET
dpc-4852	83	4	specific	specific	ADJ
dpc-4852	83	5	region	region	NOUN
dpc-4852	83	6	provides	provide	VERB
dpc-4852	83	7	insights	insight	NOUN
dpc-4852	83	8	into	into	ADP
dpc-4852	83	9	local	local	ADJ
dpc-4852	83	10	prevalence	prevalence	NOUN
dpc-4852	83	11	and	and	CCONJ
dpc-4852	83	12	trends	trend	NOUN
dpc-4852	83	13	.	.	PUNCT
dpc-4852	84	1	additionally	additionally	ADV
dpc-4852	84	2	,	,	PUNCT
dpc-4852	84	3	the	the	DET
dpc-4852	84	4	study	study	NOUN
dpc-4852	84	5	explored	explore	VERB
dpc-4852	84	6	the	the	DET
dpc-4852	84	7	recurrence	recurrence	NOUN
dpc-4852	84	8	rate	rate	NOUN
dpc-4852	84	9	of	of	ADP
dpc-4852	84	10	bp	bp	PROPN
dpc-4852	84	11	and	and	CCONJ
dpc-4852	84	12	evaluated	evaluate	VERB
dpc-4852	84	13	the	the	DET
dpc-4852	84	14	effectiveness	effectiveness	NOUN
dpc-4852	84	15	of	of	ADP
dpc-4852	84	16	current	current	ADJ
dpc-4852	84	17	treatments	treatment	NOUN
dpc-4852	84	18	.	.	PUNCT
dpc-4852	85	1	by	by	ADP
dpc-4852	85	2	doing	do	VERB
dpc-4852	85	3	so	so	ADV
dpc-4852	85	4	,	,	PUNCT
dpc-4852	85	5	the	the	DET
dpc-4852	85	6	research	research	NOUN
dpc-4852	85	7	contributes	contribute	VERB
dpc-4852	85	8	practical	practical	ADJ
dpc-4852	85	9	knowledge	knowledge	NOUN
dpc-4852	85	10	to	to	PART
dpc-4852	85	11	improve	improve	VERB
dpc-4852	85	12	the	the	DET
dpc-4852	85	13	care	care	NOUN
dpc-4852	85	14	of	of	ADP
dpc-4852	85	15	individuals	individual	NOUN
dpc-4852	85	16	with	with	ADP
dpc-4852	85	17	bp	bp	PROPN
dpc-4852	85	18	.	.	PUNCT
dpc-4852	86	1	methods	method	NOUN
dpc-4852	86	2	this	this	DET
dpc-4852	86	3	observational	observational	ADJ
dpc-4852	86	4	retrospective	retrospective	ADJ
dpc-4852	86	5	cross	cross	ADJ
dpc-4852	86	6	-	-	ADJ
dpc-4852	86	7	sectional	sectional	ADJ
dpc-4852	86	8	study	study	NOUN
dpc-4852	86	9	was	be	AUX
dpc-4852	86	10	designed	design	VERB
dpc-4852	86	11	to	to	PART
dpc-4852	86	12	follow	follow	VERB
dpc-4852	86	13	the	the	DET
dpc-4852	86	14	strobe	strobe	NOUN
dpc-4852	86	15	statement	statement	NOUN
dpc-4852	87	1	[	[	X
dpc-4852	87	2	31	31	NUM
dpc-4852	87	3	]	]	PUNCT
dpc-4852	87	4	.	.	PUNCT
dpc-4852	88	1	patients	patient	NOUN
dpc-4852	88	2	diagnosed	diagnose	VERB
dpc-4852	88	3	with	with	ADP
dpc-4852	88	4	bp	bp	PROPN
dpc-4852	88	5	and	and	CCONJ
dpc-4852	88	6	admitted	admit	VERB
dpc-4852	88	7	to	to	ADP
dpc-4852	88	8	the	the	DET
dpc-4852	88	9	dermatology	dermatology	NOUN
dpc-4852	88	10	department	department	NOUN
dpc-4852	88	11	of	of	ADP
dpc-4852	88	12	our	our	PRON
dpc-4852	88	13	hospital	hospital	NOUN
dpc-4852	88	14	during	during	ADP
dpc-4852	88	15	the	the	DET
dpc-4852	88	16	study	study	NOUN
dpc-4852	88	17	period	period	NOUN
dpc-4852	88	18	from	from	ADP
dpc-4852	88	19	2014	2014	NUM
dpc-4852	88	20	until	until	SCONJ
dpc-4852	88	21	2022	2022	NUM
dpc-4852	88	22	were	be	AUX
dpc-4852	88	23	included	include	VERB
dpc-4852	88	24	in	in	ADP
dpc-4852	88	25	this	this	DET
dpc-4852	88	26	study	study	NOUN
dpc-4852	88	27	.	.	PUNCT
dpc-4852	89	1	the	the	DET
dpc-4852	89	2	sources	source	NOUN
dpc-4852	89	3	of	of	ADP
dpc-4852	89	4	the	the	DET
dpc-4852	89	5	present	present	ADJ
dpc-4852	89	6	data	datum	NOUN
dpc-4852	89	7	were	be	AUX
dpc-4852	89	8	patient	patient	ADJ
dpc-4852	89	9	report	report	NOUN
dpc-4852	89	10	files	file	NOUN
dpc-4852	89	11	,	,	PUNCT
dpc-4852	89	12	admission	admission	NOUN
dpc-4852	89	13	files	file	NOUN
dpc-4852	89	14	,	,	PUNCT
dpc-4852	89	15	and	and	CCONJ
dpc-4852	89	16	the	the	DET
dpc-4852	89	17	hospital	hospital	NOUN
dpc-4852	89	18	’s	’s	PART
dpc-4852	89	19	record	record	NOUN
dpc-4852	89	20	system	system	NOUN
dpc-4852	89	21	(	(	PUNCT
dpc-4852	89	22	sap	sap	PROPN
dpc-4852	89	23	)	)	PUNCT
dpc-4852	89	24	.	.	PUNCT
dpc-4852	90	1	the	the	DET
dpc-4852	90	2	parameters	parameter	NOUN
dpc-4852	90	3	of	of	ADP
dpc-4852	90	4	inclusion	inclusion	NOUN
dpc-4852	90	5	in	in	ADP
dpc-4852	90	6	the	the	DET
dpc-4852	90	7	study	study	NOUN
dpc-4852	90	8	were	be	AUX
dpc-4852	90	9	based	base	VERB
dpc-4852	90	10	on	on	ADP
dpc-4852	90	11	the	the	DET
dpc-4852	90	12	fulfilment	fulfilment	NOUN
dpc-4852	90	13	of	of	ADP
dpc-4852	90	14	clinical	clinical	ADJ
dpc-4852	90	15	,	,	PUNCT
dpc-4852	90	16	histological	histological	ADJ
dpc-4852	90	17	,	,	PUNCT
dpc-4852	90	18	and	and	CCONJ
dpc-4852	90	19	immunological	immunological	ADJ
dpc-4852	90	20	confirmations	confirmation	NOUN
dpc-4852	90	21	of	of	ADP
dpc-4852	90	22	bp	bp	PROPN
dpc-4852	90	23	.	.	PUNCT
dpc-4852	91	1	specifically	specifically	ADV
dpc-4852	91	2	,	,	PUNCT
dpc-4852	91	3	only	only	ADV
dpc-4852	91	4	patients	patient	NOUN
dpc-4852	91	5	who	who	PRON
dpc-4852	91	6	exhibited	exhibit	VERB
dpc-4852	91	7	clinical	clinical	ADJ
dpc-4852	91	8	(	(	PUNCT
dpc-4852	91	9	urticarial	urticarial	ADJ
dpc-4852	91	10	,	,	PUNCT
dpc-4852	91	11	eczematous	eczematous	ADJ
dpc-4852	91	12	,	,	PUNCT
dpc-4852	91	13	excoriated	excoriate	VERB
dpc-4852	91	14	,	,	PUNCT
dpc-4852	91	15	and/or	and/or	CCONJ
dpc-4852	91	16	bullous	bullous	ADJ
dpc-4852	91	17	lesions	lesion	NOUN
dpc-4852	91	18	accompanied	accompany	VERB
dpc-4852	91	19	by	by	ADP
dpc-4852	91	20	varying	vary	VERB
dpc-4852	91	21	degrees	degree	NOUN
dpc-4852	91	22	of	of	ADP
dpc-4852	91	23	pruritus	pruritus	NOUN
dpc-4852	91	24	)	)	PUNCT
dpc-4852	91	25	,	,	PUNCT
dpc-4852	91	26	histological	histological	ADJ
dpc-4852	91	27	(	(	PUNCT
dpc-4852	91	28	subepidermal	subepidermal	NOUN
dpc-4852	91	29	clefts	cleft	NOUN
dpc-4852	91	30	,	,	PUNCT
dpc-4852	91	31	eosinophilic	eosinophilic	ADJ
dpc-4852	91	32	spongiosis	spongiosis	NOUN
dpc-4852	91	33	,	,	PUNCT
dpc-4852	91	34	and/or	and/or	CCONJ
dpc-4852	91	35	dermal	dermal	ADJ
dpc-4852	91	36	infiltration	infiltration	NOUN
dpc-4852	91	37	of	of	ADP
dpc-4852	91	38	eosinophils	eosinophil	NOUN
dpc-4852	91	39	)	)	PUNCT
dpc-4852	91	40	,	,	PUNCT
dpc-4852	91	41	and	and	CCONJ
dpc-4852	91	42	immunological	immunological	ADJ
dpc-4852	91	43	(	(	PUNCT
dpc-4852	91	44	immunofluorescence	immunofluorescence	NOUN
dpc-4852	91	45	microscopy	microscopy	NOUN
dpc-4852	91	46	showing	show	VERB
dpc-4852	91	47	linear	linear	ADJ
dpc-4852	91	48	deposition	deposition	NOUN
dpc-4852	91	49	of	of	ADP
dpc-4852	91	50	igg	igg	PROPN
dpc-4852	91	51	and	and	CCONJ
dpc-4852	91	52	c3	c3	PROPN
dpc-4852	91	53	in	in	ADP
dpc-4852	91	54	a	a	DET
dpc-4852	91	55	linear	linear	ADJ
dpc-4852	91	56	band	band	NOUN
dpc-4852	91	57	at	at	ADP
dpc-4852	91	58	the	the	DET
dpc-4852	91	59	dermo	dermo	NOUN
dpc-4852	91	60	epidermal	epidermal	ADJ
dpc-4852	91	61	junction	junction	NOUN
dpc-4852	91	62	of	of	ADP
dpc-4852	91	63	perilesional	perilesional	ADJ
dpc-4852	91	64	skin	skin	NOUN
dpc-4852	91	65	)	)	PUNCT
dpc-4852	91	66	features	feature	NOUN
dpc-4852	91	67	were	be	AUX
dpc-4852	91	68	included	include	VERB
dpc-4852	91	69	.	.	PUNCT
dpc-4852	92	1	the	the	DET
dpc-4852	92	2	exclusion	exclusion	NOUN
dpc-4852	92	3	criteria	criterion	NOUN
dpc-4852	92	4	included	include	VERB
dpc-4852	92	5	inadequate	inadequate	ADJ
dpc-4852	92	6	documentation	documentation	NOUN
dpc-4852	92	7	to	to	PART
dpc-4852	92	8	confirm	confirm	VERB
dpc-4852	92	9	the	the	DET
dpc-4852	92	10	diagnosis	diagnosis	NOUN
dpc-4852	92	11	of	of	ADP
dpc-4852	92	12	bp	bp	PROPN
dpc-4852	92	13	and	and	CCONJ
dpc-4852	92	14	a	a	DET
dpc-4852	92	15	lack	lack	NOUN
dpc-4852	92	16	of	of	ADP
dpc-4852	92	17	follow	follow	NOUN
dpc-4852	92	18	-	-	PUNCT
dpc-4852	92	19	up	up	ADP
dpc-4852	92	20	information	information	NOUN
dpc-4852	92	21	.	.	PUNCT
dpc-4852	93	1	data	datum	NOUN
dpc-4852	93	2	on	on	ADP
dpc-4852	93	3	patient	patient	ADJ
dpc-4852	93	4	age	age	NOUN
dpc-4852	93	5	at	at	ADP
dpc-4852	93	6	the	the	DET
dpc-4852	93	7	time	time	NOUN
dpc-4852	93	8	of	of	ADP
dpc-4852	93	9	onset	onset	NOUN
dpc-4852	93	10	of	of	ADP
dpc-4852	93	11	the	the	DET
dpc-4852	93	12	disease	disease	NOUN
dpc-4852	93	13	,	,	PUNCT
dpc-4852	93	14	sex	sex	NOUN
dpc-4852	93	15	,	,	PUNCT
dpc-4852	93	16	concomitant	concomitant	ADJ
dpc-4852	93	17	medications	medication	NOUN
dpc-4852	93	18	,	,	PUNCT
dpc-4852	93	19	history	history	NOUN
dpc-4852	93	20	of	of	ADP
dpc-4852	93	21	hospitalization	hospitalization	NOUN
dpc-4852	93	22	,	,	PUNCT
dpc-4852	93	23	and	and	CCONJ
dpc-4852	93	24	length	length	NOUN
dpc-4852	93	25	of	of	ADP
dpc-4852	93	26	stay	stay	NOUN
dpc-4852	93	27	were	be	AUX
dpc-4852	93	28	included	include	VERB
dpc-4852	93	29	.	.	PUNCT
dpc-4852	94	1	in	in	ADP
dpc-4852	94	2	terms	term	NOUN
dpc-4852	94	3	of	of	ADP
dpc-4852	94	4	treatment	treatment	NOUN
dpc-4852	94	5	documentation	documentation	NOUN
dpc-4852	94	6	,	,	PUNCT
dpc-4852	94	7	the	the	DET
dpc-4852	94	8	following	follow	VERB
dpc-4852	94	9	parameters	parameter	NOUN
dpc-4852	94	10	were	be	AUX
dpc-4852	94	11	measured	measure	VERB
dpc-4852	94	12	:	:	PUNCT
dpc-4852	94	13	the	the	DET
dpc-4852	94	14	duration	duration	NOUN
dpc-4852	94	15	of	of	ADP
dpc-4852	94	16	systematic	systematic	ADJ
dpc-4852	94	17	corticosteroid	corticosteroid	ADJ
dpc-4852	94	18	therapy	therapy	NOUN
dpc-4852	94	19	,	,	PUNCT
dpc-4852	94	20	the	the	DET
dpc-4852	94	21	additional	additional	ADJ
dpc-4852	94	22	administration	administration	NOUN
dpc-4852	94	23	or	or	CCONJ
dpc-4852	94	24	not	not	PART
dpc-4852	94	25	of	of	ADP
dpc-4852	94	26	immunosuppressive	immunosuppressive	ADJ
dpc-4852	94	27	agents	agent	NOUN
dpc-4852	94	28	,	,	PUNCT
dpc-4852	94	29	the	the	DET
dpc-4852	94	30	initiation	initiation	NOUN
dpc-4852	94	31	of	of	ADP
dpc-4852	94	32	steroid	steroid	NOUN
dpc-4852	94	33	tapering	tapering	NOUN
dpc-4852	94	34	,	,	PUNCT
dpc-4852	94	35	the	the	DET
dpc-4852	94	36	duration	duration	NOUN
dpc-4852	94	37	of	of	ADP
dpc-4852	94	38	maintenance	maintenance	NOUN
dpc-4852	94	39	therapy	therapy	NOUN
dpc-4852	94	40	,	,	PUNCT
dpc-4852	94	41	and	and	CCONJ
dpc-4852	94	42	the	the	DET
dpc-4852	94	43	presence	presence	NOUN
dpc-4852	94	44	or	or	CCONJ
dpc-4852	94	45	absence	absence	NOUN
dpc-4852	94	46	of	of	ADP
dpc-4852	94	47	relapses	relapse	NOUN
dpc-4852	94	48	.	.	PUNCT
dpc-4852	95	1	results	result	NOUN
dpc-4852	95	2	in	in	ADP
dpc-4852	95	3	this	this	DET
dpc-4852	95	4	retrospective	retrospective	ADJ
dpc-4852	95	5	study	study	NOUN
dpc-4852	95	6	,	,	PUNCT
dpc-4852	95	7	a	a	DET
dpc-4852	95	8	total	total	NOUN
dpc-4852	95	9	of	of	ADP
dpc-4852	95	10	188	188	NUM
dpc-4852	95	11	patients	patient	NOUN
dpc-4852	95	12	were	be	AUX
dpc-4852	95	13	included	include	VERB
dpc-4852	95	14	.	.	PUNCT
dpc-4852	96	1	the	the	DET
dpc-4852	96	2	patients	patient	NOUN
dpc-4852	96	3	’	’	PART
dpc-4852	96	4	ages	age	NOUN
dpc-4852	96	5	ranged	range	VERB
dpc-4852	96	6	from	from	ADP
dpc-4852	96	7	43	43	NUM
dpc-4852	96	8	to	to	PART
dpc-4852	96	9	95	95	NUM
dpc-4852	96	10	years	year	NOUN
dpc-4852	96	11	,	,	PUNCT
dpc-4852	96	12	with	with	ADP
dpc-4852	96	13	an	an	DET
dpc-4852	96	14	average	average	ADJ
dpc-4852	96	15	age	age	NOUN
dpc-4852	96	16	of	of	ADP
dpc-4852	96	17	76	76	NUM
dpc-4852	96	18	years	year	NOUN
dpc-4852	96	19	and	and	CCONJ
dpc-4852	96	20	a	a	DET
dpc-4852	96	21	male	male	NOUN
dpc-4852	96	22	/	/	SYM
dpc-4852	96	23	female	female	ADJ
dpc-4852	96	24	(	(	PUNCT
dpc-4852	96	25	m	m	NOUN
dpc-4852	96	26	/	/	SYM
dpc-4852	96	27	f	f	X
dpc-4852	96	28	)	)	PUNCT
dpc-4852	96	29	ratio	ratio	NOUN
dpc-4852	96	30	of	of	ADP
dpc-4852	96	31	1.13:1	1.13:1	NUM
dpc-4852	96	32	.	.	PUNCT
dpc-4852	97	1	out	out	ADP
dpc-4852	97	2	of	of	ADP
dpc-4852	97	3	188	188	NUM
dpc-4852	97	4	patients	patient	NOUN
dpc-4852	97	5	,	,	PUNCT
dpc-4852	97	6	148	148	NUM
dpc-4852	97	7	(	(	PUNCT
dpc-4852	97	8	79.0	79.0	NUM
dpc-4852	97	9	%	%	NOUN
dpc-4852	97	10	)	)	PUNCT
dpc-4852	97	11	bp	bp	PROPN
dpc-4852	97	12	patients	patient	NOUN
dpc-4852	97	13	needed	need	VERB
dpc-4852	97	14	hospitalization	hospitalization	NOUN
dpc-4852	97	15	,	,	PUNCT
dpc-4852	97	16	and	and	CCONJ
dpc-4852	97	17	92	92	NUM
dpc-4852	97	18	(	(	PUNCT
dpc-4852	97	19	48.9	48.9	NUM
dpc-4852	97	20	%	%	NOUN
dpc-4852	97	21	)	)	PUNCT
dpc-4852	97	22	were	be	AUX
dpc-4852	97	23	hospitalized	hospitalize	VERB
dpc-4852	97	24	at	at	ADP
dpc-4852	97	25	first	first	ADJ
dpc-4852	97	26	diagnosis	diagnosis	NOUN
dpc-4852	97	27	.	.	PUNCT
dpc-4852	98	1	the	the	DET
dpc-4852	98	2	average	average	ADJ
dpc-4852	98	3	duration	duration	NOUN
dpc-4852	98	4	of	of	ADP
dpc-4852	98	5	hospitalization	hospitalization	NOUN
dpc-4852	98	6	was	be	AUX
dpc-4852	98	7	11.78	11.78	NUM
dpc-4852	98	8	days	day	NOUN
dpc-4852	98	9	.	.	PUNCT
dpc-4852	99	1	out	out	ADP
dpc-4852	99	2	of	of	ADP
dpc-4852	99	3	92	92	NUM
dpc-4852	99	4	women	woman	NOUN
dpc-4852	99	5	,	,	PUNCT
dpc-4852	99	6	79	79	NUM
dpc-4852	99	7	were	be	AUX
dpc-4852	99	8	hospitalized	hospitalize	VERB
dpc-4852	99	9	,	,	PUNCT
dpc-4852	99	10	and	and	CCONJ
dpc-4852	99	11	out	out	ADP
dpc-4852	99	12	of	of	ADP
dpc-4852	99	13	98	98	NUM
dpc-4852	99	14	men	man	NOUN
dpc-4852	99	15	,	,	PUNCT
dpc-4852	99	16	76	76	NUM
dpc-4852	99	17	were	be	AUX
dpc-4852	99	18	hospitalized	hospitalize	VERB
dpc-4852	99	19	.	.	PUNCT
dpc-4852	100	1	in	in	ADP
dpc-4852	100	2	182	182	NUM
dpc-4852	100	3	(	(	PUNCT
dpc-4852	100	4	96.8	96.8	NUM
dpc-4852	100	5	%	%	NOUN
dpc-4852	100	6	)	)	PUNCT
dpc-4852	100	7	patients	patient	NOUN
dpc-4852	100	8	,	,	PUNCT
dpc-4852	100	9	systemic	systemic	ADJ
dpc-4852	100	10	corticosteroid	corticosteroid	NOUN
dpc-4852	100	11	therapy	therapy	NOUN
dpc-4852	100	12	was	be	AUX
dpc-4852	100	13	administered	administer	VERB
dpc-4852	100	14	as	as	ADP
dpc-4852	100	15	the	the	DET
dpc-4852	100	16	main	main	ADJ
dpc-4852	100	17	treatment	treatment	NOUN
dpc-4852	100	18	,	,	PUNCT
dpc-4852	100	19	while	while	SCONJ
dpc-4852	100	20	in	in	ADP
dpc-4852	100	21	only	only	ADV
dpc-4852	100	22	three	three	NUM
dpc-4852	100	23	(	(	PUNCT
dpc-4852	100	24	1.6	1.6	NUM
dpc-4852	100	25	%	%	NOUN
dpc-4852	100	26	)	)	PUNCT
dpc-4852	100	27	patients	patient	NOUN
dpc-4852	100	28	,	,	PUNCT
dpc-4852	100	29	the	the	DET
dpc-4852	100	30	disease	disease	NOUN
dpc-4852	100	31	was	be	AUX
dpc-4852	100	32	controlled	control	VERB
dpc-4852	100	33	exclusively	exclusively	ADV
dpc-4852	100	34	with	with	ADP
dpc-4852	100	35	potent	potent	ADJ
dpc-4852	100	36	topical	topical	ADJ
dpc-4852	100	37	steroids	steroid	NOUN
dpc-4852	100	38	(	(	PUNCT
dpc-4852	100	39	clobetasol	clobetasol	NOUN
dpc-4852	100	40	propionate	propionate	NOUN
dpc-4852	100	41	)	)	PUNCT
dpc-4852	100	42	.	.	PUNCT
dpc-4852	101	1	in	in	ADP
dpc-4852	101	2	conjunction	conjunction	NOUN
dpc-4852	101	3	with	with	ADP
dpc-4852	101	4	topical	topical	ADJ
dpc-4852	101	5	steroids	steroid	NOUN
dpc-4852	101	6	,	,	PUNCT
dpc-4852	101	7	15	15	NUM
dpc-4852	101	8	(	(	PUNCT
dpc-4852	101	9	8	8	NUM
dpc-4852	101	10	%	%	NOUN
dpc-4852	101	11	)	)	PUNCT
dpc-4852	101	12	patients	patient	NOUN
dpc-4852	101	13	received	receive	VERB
dpc-4852	101	14	therapy	therapy	NOUN
dpc-4852	101	15	with	with	ADP
dpc-4852	101	16	doxycycline	doxycycline	NOUN
dpc-4852	101	17	,	,	PUNCT
dpc-4852	101	18	and	and	CCONJ
dpc-4852	101	19	in	in	ADP
dpc-4852	101	20	4	4	NUM
dpc-4852	101	21	original	original	ADJ
dpc-4852	101	22	article	article	NOUN
dpc-4852	101	23	|	|	ADV
dpc-4852	101	24	dermatol	dermatol	ADJ
dpc-4852	101	25	pract	pract	NOUN
dpc-4852	101	26	concept	concept	NOUN
dpc-4852	101	27	.	.	PUNCT
dpc-4852	102	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	102	2	comorbidities	comorbiditie	NOUN
dpc-4852	102	3	the	the	DET
dpc-4852	102	4	most	most	ADV
dpc-4852	102	5	common	common	ADJ
dpc-4852	102	6	type	type	NOUN
dpc-4852	102	7	of	of	ADP
dpc-4852	102	8	comorbidity	comorbidity	NOUN
dpc-4852	102	9	found	find	VERB
dpc-4852	102	10	in	in	ADP
dpc-4852	102	11	our	our	PRON
dpc-4852	102	12	study	study	NOUN
dpc-4852	102	13	was	be	AUX
dpc-4852	102	14	diabetes	diabetes	NOUN
dpc-4852	102	15	mellitus	mellitus	NOUN
dpc-4852	102	16	,	,	PUNCT
dpc-4852	102	17	which	which	PRON
dpc-4852	102	18	affected	affect	VERB
dpc-4852	102	19	60.6	60.6	NUM
dpc-4852	102	20	%	%	NOUN
dpc-4852	102	21	(	(	PUNCT
dpc-4852	102	22	n=114	n=114	X
dpc-4852	102	23	)	)	PUNCT
dpc-4852	102	24	of	of	ADP
dpc-4852	102	25	the	the	DET
dpc-4852	102	26	patients	patient	NOUN
dpc-4852	102	27	.	.	PUNCT
dpc-4852	103	1	bp	bp	PROPN
dpc-4852	103	2	was	be	AUX
dpc-4852	103	3	also	also	ADV
dpc-4852	103	4	associated	associate	VERB
dpc-4852	103	5	with	with	ADP
dpc-4852	103	6	the	the	DET
dpc-4852	103	7	following	follow	VERB
dpc-4852	103	8	comorbidities	comorbiditie	NOUN
dpc-4852	103	9	:	:	PUNCT
dpc-4852	103	10	hypertension	hypertension	NOUN
dpc-4852	103	11	(	(	PUNCT
dpc-4852	103	12	45.2	45.2	NUM
dpc-4852	103	13	%	%	NOUN
dpc-4852	103	14	,	,	PUNCT
dpc-4852	103	15	n=	n=	ADJ
dpc-4852	103	16	85	85	NUM
dpc-4852	103	17	)	)	PUNCT
dpc-4852	103	18	,	,	PUNCT
dpc-4852	103	19	chronic	chronic	ADJ
dpc-4852	103	20	kidney	kidney	NOUN
dpc-4852	103	21	disease	disease	NOUN
dpc-4852	103	22	(	(	PUNCT
dpc-4852	103	23	8	8	NUM
dpc-4852	103	24	%	%	NOUN
dpc-4852	103	25	,	,	PUNCT
dpc-4852	103	26	n=15	n=15	NUM
dpc-4852	103	27	)	)	PUNCT
dpc-4852	103	28	,	,	PUNCT
dpc-4852	103	29	cardiac	cardiac	ADJ
dpc-4852	103	30	disease	disease	NOUN
dpc-4852	103	31	(	(	PUNCT
dpc-4852	103	32	10	10	NUM
dpc-4852	103	33	%	%	NOUN
dpc-4852	103	34	,	,	PUNCT
dpc-4852	103	35	n=19	n=19	PROPN
dpc-4852	103	36	)	)	PUNCT
dpc-4852	103	37	,	,	PUNCT
dpc-4852	103	38	and	and	CCONJ
dpc-4852	103	39	neurological	neurological	ADJ
dpc-4852	103	40	disease	disease	NOUN
dpc-4852	103	41	(	(	PUNCT
dpc-4852	103	42	11.8	11.8	NUM
dpc-4852	103	43	%	%	NOUN
dpc-4852	103	44	,	,	PUNCT
dpc-4852	103	45	n=22	n=22	PROPN
dpc-4852	103	46	)	)	PUNCT
dpc-4852	103	47	.	.	PUNCT
dpc-4852	104	1	the	the	DET
dpc-4852	104	2	number	number	NOUN
dpc-4852	104	3	of	of	ADP
dpc-4852	104	4	patients	patient	NOUN
dpc-4852	104	5	that	that	PRON
dpc-4852	104	6	had	have	AUX
dpc-4852	104	7	been	be	AUX
dpc-4852	104	8	diagnosed	diagnose	VERB
dpc-4852	104	9	with	with	ADP
dpc-4852	104	10	any	any	DET
dpc-4852	104	11	type	type	NOUN
dpc-4852	104	12	of	of	ADP
dpc-4852	104	13	cancer	cancer	NOUN
dpc-4852	104	14	/	/	SYM
dpc-4852	104	15	malignancy	malignancy	NOUN
dpc-4852	104	16	five	five	NUM
dpc-4852	104	17	years	year	NOUN
dpc-4852	104	18	before	before	ADP
dpc-4852	104	19	or	or	CCONJ
dpc-4852	104	20	five	five	NUM
dpc-4852	104	21	years	year	NOUN
dpc-4852	104	22	after	after	SCONJ
dpc-4852	104	23	the	the	DET
dpc-4852	104	24	diagnosis	diagnosis	NOUN
dpc-4852	104	25	of	of	ADP
dpc-4852	104	26	bp	bp	PROPN
dpc-4852	104	27	was	be	AUX
dpc-4852	104	28	also	also	ADV
dpc-4852	104	29	calculated	calculate	VERB
dpc-4852	104	30	(	(	PUNCT
dpc-4852	104	31	4.25	4.25	NUM
dpc-4852	104	32	%	%	NOUN
dpc-4852	104	33	)	)	PUNCT
dpc-4852	104	34	.	.	PUNCT
dpc-4852	105	1	it	it	PRON
dpc-4852	105	2	should	should	AUX
dpc-4852	105	3	be	be	AUX
dpc-4852	105	4	taken	take	VERB
dpc-4852	105	5	into	into	ADP
dpc-4852	105	6	consideration	consideration	NOUN
dpc-4852	105	7	that	that	SCONJ
dpc-4852	105	8	those	those	DET
dpc-4852	105	9	patients	patient	NOUN
dpc-4852	105	10	’	’	PART
dpc-4852	105	11	ages	age	NOUN
dpc-4852	105	12	was	be	AUX
dpc-4852	105	13	an	an	DET
dpc-4852	105	14	average	average	NOUN
dpc-4852	105	15	of	of	ADP
dpc-4852	105	16	82.125	82.125	NUM
dpc-4852	105	17	years	year	NOUN
dpc-4852	105	18	at	at	ADP
dpc-4852	105	19	the	the	DET
dpc-4852	105	20	time	time	NOUN
dpc-4852	105	21	of	of	ADP
dpc-4852	105	22	the	the	DET
dpc-4852	105	23	bp	bp	PROPN
dpc-4852	105	24	diagnosis	diagnosis	NOUN
dpc-4852	105	25	the	the	DET
dpc-4852	105	26	onset	onset	NOUN
dpc-4852	105	27	of	of	ADP
dpc-4852	105	28	bp	bp	PROPN
dpc-4852	105	29	was	be	AUX
dpc-4852	105	30	correlated	correlate	VERB
dpc-4852	105	31	with	with	ADP
dpc-4852	105	32	a	a	DET
dpc-4852	105	33	previous	previous	ADJ
dpc-4852	105	34	intake	intake	NOUN
dpc-4852	105	35	of	of	ADP
dpc-4852	105	36	dpp-4	dpp-4	ADJ
dpc-4852	105	37	inhibitor	inhibitor	NOUN
dpc-4852	105	38	in	in	ADP
dpc-4852	105	39	36	36	NUM
dpc-4852	105	40	%	%	NOUN
dpc-4852	105	41	(	(	PUNCT
dpc-4852	105	42	68	68	NUM
dpc-4852	105	43	cases	case	NOUN
dpc-4852	105	44	)	)	PUNCT
dpc-4852	105	45	,	,	PUNCT
dpc-4852	105	46	while	while	SCONJ
dpc-4852	105	47	vildagliptin	vildagliptin	NOUN
dpc-4852	105	48	was	be	AUX
dpc-4852	105	49	the	the	DET
dpc-4852	105	50	most	most	ADV
dpc-4852	105	51	common	common	ADJ
dpc-4852	105	52	inducible	inducible	ADJ
dpc-4852	105	53	dpp-4	dpp-4	ADJ
dpc-4852	105	54	inhibitor	inhibitor	NOUN
dpc-4852	105	55	(	(	PUNCT
dpc-4852	105	56	figures	figure	NOUN
dpc-4852	105	57	3	3	NUM
dpc-4852	105	58	and	and	CCONJ
dpc-4852	105	59	4	4	NUM
dpc-4852	105	60	)	)	PUNCT
dpc-4852	105	61	.	.	PUNCT
dpc-4852	106	1	scheduled	schedule	VERB
dpc-4852	106	2	follow	follow	NOUN
dpc-4852	106	3	-	-	PUNCT
dpc-4852	106	4	up	up	ADP
dpc-4852	106	5	visits	visit	NOUN
dpc-4852	106	6	were	be	AUX
dpc-4852	106	7	organized	organize	VERB
dpc-4852	106	8	on	on	ADP
dpc-4852	106	9	days	day	NOUN
dpc-4852	106	10	7	7	NUM
dpc-4852	106	11	,	,	PUNCT
dpc-4852	106	12	14	14	NUM
dpc-4852	106	13	,	,	PUNCT
dpc-4852	106	14	21	21	NUM
dpc-4852	106	15	,	,	PUNCT
dpc-4852	106	16	30	30	NUM
dpc-4852	106	17	,	,	PUNCT
dpc-4852	106	18	90	90	NUM
dpc-4852	106	19	,	,	PUNCT
dpc-4852	106	20	180	180	NUM
dpc-4852	106	21	,	,	PUNCT
dpc-4852	106	22	and	and	CCONJ
dpc-4852	106	23	360	360	NUM
dpc-4852	106	24	.	.	PUNCT
dpc-4852	107	1	during	during	ADP
dpc-4852	107	2	these	these	DET
dpc-4852	107	3	visits	visit	NOUN
dpc-4852	107	4	,	,	PUNCT
dpc-4852	107	5	meticulous	meticulous	ADJ
dpc-4852	107	6	records	record	NOUN
dpc-4852	107	7	were	be	AUX
dpc-4852	107	8	kept	keep	VERB
dpc-4852	107	9	,	,	PUNCT
dpc-4852	107	10	noting	note	VERB
dpc-4852	107	11	the	the	DET
dpc-4852	107	12	occurrence	occurrence	NOUN
dpc-4852	107	13	and	and	CCONJ
dpc-4852	107	14	date	date	NOUN
dpc-4852	107	15	of	of	ADP
dpc-4852	107	16	any	any	DET
dpc-4852	107	17	relapse	relapse	NOUN
dpc-4852	107	18	.	.	PUNCT
dpc-4852	108	1	recognizing	recognize	VERB
dpc-4852	108	2	the	the	DET
dpc-4852	108	3	heightened	heighten	VERB
dpc-4852	108	4	one	one	NUM
dpc-4852	108	5	-	-	PUNCT
dpc-4852	108	6	year	year	NOUN
dpc-4852	108	7	mortality	mortality	NOUN
dpc-4852	108	8	rate	rate	NOUN
dpc-4852	108	9	documented	document	VERB
dpc-4852	108	10	in	in	ADP
dpc-4852	108	11	recent	recent	ADJ
dpc-4852	108	12	series	series	NOUN
dpc-4852	108	13	,	,	PUNCT
dpc-4852	108	14	the	the	DET
dpc-4852	108	15	follow	follow	VERB
dpc-4852	108	16	-	-	PUNCT
dpc-4852	108	17	up	up	ADP
dpc-4852	108	18	protocol	protocol	NOUN
dpc-4852	108	19	was	be	AUX
dpc-4852	108	20	designed	design	VERB
dpc-4852	108	21	to	to	PART
dpc-4852	108	22	span	span	VERB
dpc-4852	108	23	12	12	NUM
dpc-4852	108	24	months	month	NOUN
dpc-4852	108	25	exclusively	exclusively	ADV
dpc-4852	108	26	.	.	PUNCT
dpc-4852	109	1	over	over	ADP
dpc-4852	109	2	the	the	DET
dpc-4852	109	3	course	course	NOUN
dpc-4852	109	4	of	of	ADP
dpc-4852	109	5	the	the	DET
dpc-4852	109	6	one	one	NUM
dpc-4852	109	7	-	-	PUNCT
dpc-4852	109	8	year	year	NOUN
dpc-4852	109	9	follow	follow	NOUN
dpc-4852	109	10	-	-	PUNCT
dpc-4852	109	11	up	up	NOUN
dpc-4852	109	12	,	,	PUNCT
dpc-4852	109	13	26	26	NUM
dpc-4852	109	14	patients	patient	NOUN
dpc-4852	109	15	(	(	PUNCT
dpc-4852	109	16	13.8	13.8	NUM
dpc-4852	109	17	%	%	NOUN
dpc-4852	109	18	)	)	PUNCT
dpc-4852	109	19	died	die	VERB
dpc-4852	109	20	.	.	PUNCT
dpc-4852	110	1	the	the	DET
dpc-4852	110	2	primary	primary	ADJ
dpc-4852	110	3	cause	cause	NOUN
dpc-4852	110	4	of	of	ADP
dpc-4852	110	5	death	death	NOUN
dpc-4852	110	6	was	be	AUX
dpc-4852	110	7	identified	identify	VERB
dpc-4852	110	8	in	in	ADP
dpc-4852	110	9	19	19	NUM
dpc-4852	110	10	cases	case	NOUN
dpc-4852	110	11	(	(	PUNCT
dpc-4852	110	12	figure	figure	NOUN
dpc-4852	110	13	5	5	NUM
dpc-4852	110	14	)	)	PUNCT
dpc-4852	110	15	,	,	PUNCT
dpc-4852	110	16	with	with	ADP
dpc-4852	110	17	predominant	predominant	ADJ
dpc-4852	110	18	factors	factor	NOUN
dpc-4852	110	19	including	include	VERB
dpc-4852	110	20	22	22	NUM
dpc-4852	110	21	patients	patient	NOUN
dpc-4852	110	22	(	(	PUNCT
dpc-4852	110	23	11.7	11.7	NUM
dpc-4852	110	24	%	%	NOUN
dpc-4852	110	25	)	)	PUNCT
dpc-4852	110	26	,	,	PUNCT
dpc-4852	110	27	additional	additional	ADJ
dpc-4852	110	28	treatment	treatment	NOUN
dpc-4852	110	29	with	with	ADP
dpc-4852	110	30	immunosuppressive	immunosuppressive	ADJ
dpc-4852	110	31	agents	agent	NOUN
dpc-4852	110	32	such	such	ADJ
dpc-4852	110	33	as	as	ADP
dpc-4852	110	34	azathioprine	azathioprine	NOUN
dpc-4852	110	35	(	(	PUNCT
dpc-4852	110	36	4.25	4.25	NUM
dpc-4852	110	37	%	%	NOUN
dpc-4852	110	38	)	)	PUNCT
dpc-4852	110	39	and	and	CCONJ
dpc-4852	110	40	dapsone	dapsone	NOUN
dpc-4852	110	41	(	(	PUNCT
dpc-4852	110	42	7.97	7.97	NUM
dpc-4852	110	43	%	%	NOUN
dpc-4852	110	44	)	)	PUNCT
dpc-4852	110	45	was	be	AUX
dpc-4852	110	46	prescribed	prescribe	VERB
dpc-4852	110	47	(	(	PUNCT
dpc-4852	110	48	table	table	NOUN
dpc-4852	110	49	1	1	NUM
dpc-4852	110	50	)	)	PUNCT
dpc-4852	110	51	.	.	PUNCT
dpc-4852	111	1	prednisone	prednisone	PROPN
dpc-4852	111	2	was	be	AUX
dpc-4852	111	3	given	give	VERB
dpc-4852	111	4	once	once	ADV
dpc-4852	111	5	daily	daily	ADV
dpc-4852	111	6	,	,	PUNCT
dpc-4852	111	7	with	with	ADP
dpc-4852	111	8	a	a	DET
dpc-4852	111	9	dosage	dosage	NOUN
dpc-4852	111	10	of	of	ADP
dpc-4852	111	11	0.5	0.5	NUM
dpc-4852	111	12	mg	mg	NOUN
dpc-4852	111	13	/	/	SYM
dpc-4852	111	14	kg	kg	PROPN
dpc-4852	111	15	of	of	ADP
dpc-4852	111	16	body	body	NOUN
dpc-4852	111	17	weight	weight	NOUN
dpc-4852	111	18	per	per	ADP
dpc-4852	111	19	day	day	NOUN
dpc-4852	111	20	for	for	ADP
dpc-4852	111	21	patients	patient	NOUN
dpc-4852	111	22	with	with	ADP
dpc-4852	111	23	moderate	moderate	ADJ
dpc-4852	111	24	disease	disease	NOUN
dpc-4852	111	25	and	and	CCONJ
dpc-4852	111	26	1	1	NUM
dpc-4852	111	27	mg/	mg/	NOUN
dpc-4852	111	28	kg	kg	NOUN
dpc-4852	111	29	per	per	ADP
dpc-4852	111	30	day	day	NOUN
dpc-4852	111	31	for	for	ADP
dpc-4852	111	32	those	those	PRON
dpc-4852	111	33	with	with	ADP
dpc-4852	111	34	extensive	extensive	ADJ
dpc-4852	111	35	disease	disease	NOUN
dpc-4852	111	36	.	.	PUNCT
dpc-4852	112	1	extensive	extensive	ADJ
dpc-4852	112	2	disease	disease	NOUN
dpc-4852	112	3	involved	involve	VERB
dpc-4852	112	4	widespread	widespread	ADJ
dpc-4852	112	5	blistering	blistering	ADJ
dpc-4852	112	6	,	,	PUNCT
dpc-4852	112	7	significant	significant	ADJ
dpc-4852	112	8	skin	skin	NOUN
dpc-4852	112	9	involvement	involvement	NOUN
dpc-4852	112	10	,	,	PUNCT
dpc-4852	112	11	and/or	and/or	CCONJ
dpc-4852	112	12	systemic	systemic	ADJ
dpc-4852	112	13	symptoms	symptom	NOUN
dpc-4852	112	14	,	,	PUNCT
dpc-4852	112	15	often	often	ADV
dpc-4852	112	16	causing	cause	VERB
dpc-4852	112	17	substantial	substantial	ADJ
dpc-4852	112	18	impact	impact	NOUN
dpc-4852	112	19	on	on	ADP
dpc-4852	112	20	the	the	DET
dpc-4852	112	21	patient	patient	NOUN
dpc-4852	112	22	’s	’s	PART
dpc-4852	112	23	quality	quality	NOUN
dpc-4852	112	24	of	of	ADP
dpc-4852	112	25	life	life	NOUN
dpc-4852	112	26	or	or	CCONJ
dpc-4852	112	27	requiring	require	VERB
dpc-4852	112	28	more	more	ADV
dpc-4852	112	29	aggressive	aggressive	ADJ
dpc-4852	112	30	management	management	NOUN
dpc-4852	112	31	(	(	PUNCT
dpc-4852	112	32	bullous	bullous	ADJ
dpc-4852	112	33	pemphigoid	pemphigoid	ADJ
dpc-4852	112	34	disease	disease	PROPN
dpc-4852	112	35	area	area	NOUN
dpc-4852	112	36	index	index	NOUN
dpc-4852	112	37	(	(	PUNCT
dpc-4852	112	38	bpdai	bpdai	PROPN
dpc-4852	112	39	)	)	PUNCT
dpc-4852	112	40	˃57	˃57	PUNCT
dpc-4852	113	1	[	[	X
dpc-4852	113	2	32	32	NUM
dpc-4852	113	3	]	]	PUNCT
dpc-4852	113	4	)	)	PUNCT
dpc-4852	113	5	,	,	PUNCT
dpc-4852	113	6	while	while	SCONJ
dpc-4852	113	7	moderate	moderate	ADJ
dpc-4852	113	8	disease	disease	NOUN
dpc-4852	113	9	was	be	AUX
dpc-4852	113	10	characterized	characterize	VERB
dpc-4852	113	11	by	by	ADP
dpc-4852	113	12	a	a	DET
dpc-4852	113	13	limited	limited	ADJ
dpc-4852	113	14	number	number	NOUN
dpc-4852	113	15	of	of	ADP
dpc-4852	113	16	blisters	blister	NOUN
dpc-4852	113	17	and	and	CCONJ
dpc-4852	113	18	less	less	ADV
dpc-4852	113	19	extensive	extensive	ADJ
dpc-4852	113	20	skin	skin	NOUN
dpc-4852	113	21	involvement	involvement	NOUN
dpc-4852	113	22	,	,	PUNCT
dpc-4852	113	23	with	with	ADP
dpc-4852	113	24	no	no	DET
dpc-4852	113	25	significant	significant	ADJ
dpc-4852	113	26	impairment	impairment	NOUN
dpc-4852	113	27	in	in	ADP
dpc-4852	113	28	daily	daily	ADJ
dpc-4852	113	29	activities	activity	NOUN
dpc-4852	113	30	or	or	CCONJ
dpc-4852	113	31	systemic	systemic	ADJ
dpc-4852	113	32	symptoms(bpdai	symptoms(bpdai	NOUN
dpc-4852	114	1	20–56	20–56	NUM
dpc-4852	115	1	[	[	X
dpc-4852	115	2	33]).the	33]).the	DET
dpc-4852	115	3	initial	initial	ADJ
dpc-4852	115	4	dose	dose	NOUN
dpc-4852	115	5	was	be	AUX
dpc-4852	115	6	maintained	maintain	VERB
dpc-4852	115	7	for	for	ADP
dpc-4852	115	8	15	15	NUM
dpc-4852	115	9	days	day	NOUN
dpc-4852	115	10	after	after	ADP
dpc-4852	115	11	achieving	achieve	VERB
dpc-4852	115	12	disease	disease	NOUN
dpc-4852	115	13	control	control	NOUN
dpc-4852	115	14	,	,	PUNCT
dpc-4852	115	15	followed	follow	VERB
dpc-4852	115	16	by	by	ADP
dpc-4852	115	17	a	a	DET
dpc-4852	115	18	gradual	gradual	ADJ
dpc-4852	115	19	reduction	reduction	NOUN
dpc-4852	115	20	of	of	ADP
dpc-4852	115	21	15	15	NUM
dpc-4852	115	22	%	%	NOUN
dpc-4852	115	23	every	every	DET
dpc-4852	115	24	three	three	NUM
dpc-4852	115	25	weeks	week	NOUN
dpc-4852	115	26	.	.	PUNCT
dpc-4852	116	1	the	the	DET
dpc-4852	116	2	treatment	treatment	NOUN
dpc-4852	116	3	was	be	AUX
dpc-4852	116	4	concluded	conclude	VERB
dpc-4852	116	5	after	after	ADP
dpc-4852	116	6	a	a	DET
dpc-4852	116	7	duration	duration	NOUN
dpc-4852	116	8	of	of	ADP
dpc-4852	116	9	12	12	NUM
dpc-4852	116	10	months	month	NOUN
dpc-4852	116	11	.	.	PUNCT
dpc-4852	117	1	tapering	taper	VERB
dpc-4852	117	2	of	of	ADP
dpc-4852	117	3	the	the	DET
dpc-4852	117	4	oral	oral	ADJ
dpc-4852	117	5	corticosteroid	corticosteroid	ADJ
dpc-4852	117	6	treatment	treatment	NOUN
dpc-4852	117	7	was	be	AUX
dpc-4852	117	8	initiated	initiate	VERB
dpc-4852	117	9	on	on	ADP
dpc-4852	117	10	average	average	ADJ
dpc-4852	117	11	on	on	ADP
dpc-4852	117	12	the	the	DET
dpc-4852	117	13	23rd	23rd	ADJ
dpc-4852	117	14	day	day	NOUN
dpc-4852	117	15	.	.	PUNCT
dpc-4852	118	1	patients	patient	NOUN
dpc-4852	118	2	on	on	ADP
dpc-4852	118	3	topical	topical	ADJ
dpc-4852	118	4	corticosteroids	corticosteroid	NOUN
dpc-4852	118	5	were	be	AUX
dpc-4852	118	6	prescribed	prescribe	VERB
dpc-4852	118	7	a	a	DET
dpc-4852	118	8	daily	daily	ADJ
dpc-4852	118	9	dose	dose	NOUN
dpc-4852	118	10	of	of	ADP
dpc-4852	118	11	40	40	NUM
dpc-4852	118	12	g	g	NOUN
dpc-4852	118	13	of	of	ADP
dpc-4852	118	14	clobetasol	clobetasol	NOUN
dpc-4852	118	15	propionate	propionate	NOUN
dpc-4852	118	16	applied	apply	VERB
dpc-4852	118	17	twice	twice	ADV
dpc-4852	118	18	daily	daily	ADV
dpc-4852	118	19	over	over	ADP
dpc-4852	118	20	the	the	DET
dpc-4852	118	21	entire	entire	ADJ
dpc-4852	118	22	body	body	NOUN
dpc-4852	118	23	surface	surface	NOUN
dpc-4852	118	24	until	until	ADP
dpc-4852	118	25	15	15	NUM
dpc-4852	118	26	days	day	NOUN
dpc-4852	118	27	after	after	ADP
dpc-4852	118	28	disease	disease	NOUN
dpc-4852	118	29	control	control	NOUN
dpc-4852	118	30	.	.	PUNCT
dpc-4852	119	1	following	follow	VERB
dpc-4852	119	2	this	this	PRON
dpc-4852	119	3	,	,	PUNCT
dpc-4852	119	4	a	a	DET
dpc-4852	119	5	gradual	gradual	ADJ
dpc-4852	119	6	reduction	reduction	NOUN
dpc-4852	119	7	plan	plan	NOUN
dpc-4852	119	8	was	be	AUX
dpc-4852	119	9	implemented	implement	VERB
dpc-4852	119	10	:	:	PUNCT
dpc-4852	119	11	decreasing	decrease	VERB
dpc-4852	119	12	to	to	ADP
dpc-4852	119	13	20	20	NUM
dpc-4852	119	14	g	g	NOUN
dpc-4852	119	15	daily	daily	ADV
dpc-4852	119	16	for	for	ADP
dpc-4852	119	17	one	one	NUM
dpc-4852	119	18	month	month	NOUN
dpc-4852	119	19	,	,	PUNCT
dpc-4852	119	20	10	10	NUM
dpc-4852	119	21	g	g	NOUN
dpc-4852	119	22	daily	daily	ADV
dpc-4852	119	23	for	for	ADP
dpc-4852	119	24	two	two	NUM
dpc-4852	119	25	months	month	NOUN
dpc-4852	119	26	,	,	PUNCT
dpc-4852	119	27	10	10	NUM
dpc-4852	119	28	g	g	NOUN
dpc-4852	119	29	every	every	DET
dpc-4852	119	30	other	other	ADJ
dpc-4852	119	31	day	day	NOUN
dpc-4852	119	32	for	for	ADP
dpc-4852	119	33	four	four	NUM
dpc-4852	119	34	months	month	NOUN
dpc-4852	119	35	,	,	PUNCT
dpc-4852	119	36	and	and	CCONJ
dpc-4852	119	37	eventually	eventually	ADV
dpc-4852	119	38	settling	settle	VERB
dpc-4852	119	39	at	at	ADP
dpc-4852	119	40	10	10	NUM
dpc-4852	119	41	g	g	NOUN
dpc-4852	119	42	twice	twice	DET
dpc-4852	119	43	a	a	DET
dpc-4852	119	44	week	week	NOUN
dpc-4852	119	45	for	for	ADP
dpc-4852	119	46	the	the	DET
dpc-4852	119	47	subsequent	subsequent	ADJ
dpc-4852	119	48	four	four	NUM
dpc-4852	119	49	months	month	NOUN
dpc-4852	119	50	(	(	PUNCT
dpc-4852	119	51	figure	figure	NOUN
dpc-4852	119	52	1	1	NUM
dpc-4852	119	53	)	)	PUNCT
dpc-4852	119	54	.	.	PUNCT
dpc-4852	120	1	a	a	DET
dpc-4852	120	2	relapse	relapse	NOUN
dpc-4852	120	3	was	be	AUX
dpc-4852	120	4	characterized	characterize	VERB
dpc-4852	120	5	by	by	ADP
dpc-4852	120	6	the	the	DET
dpc-4852	120	7	presence	presence	NOUN
dpc-4852	120	8	of	of	ADP
dpc-4852	120	9	a	a	DET
dpc-4852	120	10	minimum	minimum	NOUN
dpc-4852	120	11	of	of	ADP
dpc-4852	120	12	three	three	NUM
dpc-4852	120	13	bullae	bullae	PROPN
dpc-4852	120	14	daily	daily	ADV
dpc-4852	120	15	for	for	ADP
dpc-4852	120	16	three	three	NUM
dpc-4852	120	17	consecutive	consecutive	ADJ
dpc-4852	120	18	days	day	NOUN
dpc-4852	120	19	while	while	SCONJ
dpc-4852	120	20	undergoing	undergo	VERB
dpc-4852	120	21	treatment	treatment	NOUN
dpc-4852	120	22	.	.	PUNCT
dpc-4852	121	1	for	for	ADP
dpc-4852	121	2	patients	patient	NOUN
dpc-4852	121	3	experiencing	experience	VERB
dpc-4852	121	4	a	a	DET
dpc-4852	121	5	relapse	relapse	NOUN
dpc-4852	121	6	during	during	ADP
dpc-4852	121	7	the	the	DET
dpc-4852	121	8	phase	phase	NOUN
dpc-4852	121	9	of	of	ADP
dpc-4852	121	10	dose	dose	NOUN
dpc-4852	121	11	reduction	reduction	NOUN
dpc-4852	121	12	,	,	PUNCT
dpc-4852	121	13	the	the	DET
dpc-4852	121	14	dosage	dosage	NOUN
dpc-4852	121	15	was	be	AUX
dpc-4852	121	16	escalated	escalate	VERB
dpc-4852	121	17	to	to	ADP
dpc-4852	121	18	the	the	DET
dpc-4852	121	19	prior	prior	ADJ
dpc-4852	121	20	level	level	NOUN
dpc-4852	121	21	that	that	PRON
dpc-4852	121	22	had	have	AUX
dpc-4852	121	23	effectively	effectively	ADV
dpc-4852	121	24	maintained	maintain	VERB
dpc-4852	121	25	disease	disease	NOUN
dpc-4852	121	26	control	control	NOUN
dpc-4852	121	27	.	.	PUNCT
dpc-4852	122	1	in	in	ADP
dpc-4852	122	2	total	total	ADJ
dpc-4852	122	3	,	,	PUNCT
dpc-4852	122	4	34	34	NUM
dpc-4852	122	5	%	%	NOUN
dpc-4852	122	6	of	of	ADP
dpc-4852	122	7	cases	case	NOUN
dpc-4852	122	8	exhibited	exhibit	VERB
dpc-4852	122	9	disease	disease	NOUN
dpc-4852	122	10	recurrence	recurrence	NOUN
dpc-4852	122	11	,	,	PUNCT
dpc-4852	122	12	whereas	whereas	SCONJ
dpc-4852	122	13	the	the	DET
dpc-4852	122	14	number	number	NOUN
dpc-4852	122	15	of	of	ADP
dpc-4852	122	16	relapses	relapse	NOUN
dpc-4852	122	17	was	be	AUX
dpc-4852	122	18	on	on	ADP
dpc-4852	122	19	average	average	ADJ
dpc-4852	122	20	0.70	0.70	NUM
dpc-4852	122	21	.	.	PUNCT
dpc-4852	123	1	specifically	specifically	ADV
dpc-4852	123	2	,	,	PUNCT
dpc-4852	123	3	123	123	NUM
dpc-4852	123	4	of	of	ADP
dpc-4852	123	5	the	the	DET
dpc-4852	123	6	patients	patient	NOUN
dpc-4852	123	7	had	have	VERB
dpc-4852	123	8	no	no	DET
dpc-4852	123	9	relapses	relapse	NOUN
dpc-4852	123	10	,	,	PUNCT
dpc-4852	123	11	38	38	NUM
dpc-4852	123	12	had	have	VERB
dpc-4852	123	13	one	one	NUM
dpc-4852	123	14	relapse	relapse	NOUN
dpc-4852	123	15	,	,	PUNCT
dpc-4852	123	16	one	one	NUM
dpc-4852	123	17	had	have	VERB
dpc-4852	123	18	four	four	NUM
dpc-4852	123	19	relapses	relapse	NOUN
dpc-4852	123	20	,	,	PUNCT
dpc-4852	123	21	four	four	NUM
dpc-4852	123	22	had	have	VERB
dpc-4852	123	23	five	five	NUM
dpc-4852	123	24	relapses	relapse	NOUN
dpc-4852	123	25	and	and	CCONJ
dpc-4852	123	26	two	two	NUM
dpc-4852	123	27	had	have	VERB
dpc-4852	123	28	six	six	NUM
dpc-4852	123	29	relapses	relapse	NOUN
dpc-4852	123	30	(	(	PUNCT
dpc-4852	123	31	figure	figure	NOUN
dpc-4852	123	32	2	2	NUM
dpc-4852	123	33	)	)	PUNCT
dpc-4852	123	34	.	.	PUNCT
dpc-4852	124	1	total	total	ADJ
dpc-4852	124	2	duration	duration	NOUN
dpc-4852	124	3	of	of	ADP
dpc-4852	124	4	systematic	systematic	ADJ
dpc-4852	124	5	steroid	steroid	NOUN
dpc-4852	124	6	therapy	therapy	NOUN
dpc-4852	124	7	was	be	AUX
dpc-4852	124	8	on	on	ADP
dpc-4852	124	9	average	average	ADJ
dpc-4852	124	10	16	16	NUM
dpc-4852	124	11	months	month	NOUN
dpc-4852	124	12	,	,	PUNCT
dpc-4852	124	13	and	and	CCONJ
dpc-4852	124	14	duration	duration	NOUN
dpc-4852	124	15	of	of	ADP
dpc-4852	124	16	maintenance	maintenance	NOUN
dpc-4852	124	17	treatment	treatment	NOUN
dpc-4852	124	18	was	be	AUX
dpc-4852	124	19	approximately	approximately	ADV
dpc-4852	124	20	13.8	13.8	NUM
dpc-4852	124	21	months	month	NOUN
dpc-4852	124	22	.	.	PUNCT
dpc-4852	125	1	figure	figure	NOUN
dpc-4852	125	2	1	1	NUM
dpc-4852	125	3	.	.	PUNCT
dpc-4852	125	4	corticosteroid	corticosteroid	ADJ
dpc-4852	125	5	treatment	treatment	NOUN
dpc-4852	125	6	tapering	tapering	NOUN
dpc-4852	125	7	period	period	NOUN
dpc-4852	125	8	measured	measure	VERB
dpc-4852	125	9	in	in	ADP
dpc-4852	125	10	days	day	NOUN
dpc-4852	125	11	.	.	PUNCT
dpc-4852	126	1	0.00	0.00	NUM
dpc-4852	126	2	%	%	NOUN
dpc-4852	126	3	10.00	10.00	NUM
dpc-4852	126	4	%	%	NOUN
dpc-4852	126	5	20.00	20.00	NUM
dpc-4852	126	6	%	%	NOUN
dpc-4852	126	7	30.00	30.00	NUM
dpc-4852	126	8	%	%	NOUN
dpc-4852	126	9	40.00	40.00	NUM
dpc-4852	126	10	%	%	NOUN
dpc-4852	126	11	50.00	50.00	NUM
dpc-4852	126	12	%	%	NOUN
dpc-4852	126	13	60.00	60.00	NUM
dpc-4852	126	14	%	%	NOUN
dpc-4852	126	15	70.00	70.00	NUM
dpc-4852	126	16	%	%	NOUN
dpc-4852	126	17	123/188	123/188	PROPN
dpc-4852	126	18	38/188	38/188	NUM
dpc-4852	126	19	1/188	1/188	NUM
dpc-4852	126	20	4/188	4/188	NUM
dpc-4852	126	21	2/188	2/188	NUM
dpc-4852	126	22	no	no	DET
dpc-4852	126	23	one	one	NUM
dpc-4852	126	24	four	four	NUM
dpc-4852	126	25	five	five	NUM
dpc-4852	126	26	six	six	NUM
dpc-4852	126	27	figure	figure	NOUN
dpc-4852	126	28	2	2	NUM
dpc-4852	126	29	.	.	NOUN
dpc-4852	126	30	frequency	frequency	NOUN
dpc-4852	126	31	of	of	ADP
dpc-4852	126	32	relapses	relapse	NOUN
dpc-4852	126	33	.	.	PUNCT
dpc-4852	127	1	table	table	NOUN
dpc-4852	127	2	1	1	NUM
dpc-4852	127	3	.	.	PUNCT
dpc-4852	127	4	treatment	treatment	NOUN
dpc-4852	127	5	modalities	modality	NOUN
dpc-4852	127	6	.	.	PUNCT
dpc-4852	128	1	treatment	treatment	NOUN
dpc-4852	128	2	number	number	NOUN
dpc-4852	128	3	of	of	ADP
dpc-4852	128	4	patients	patient	NOUN
dpc-4852	128	5	percentage	percentage	NOUN
dpc-4852	128	6	%	%	NOUN
dpc-4852	128	7	systemic	systemic	ADJ
dpc-4852	128	8	corticosteroids	corticosteroid	NOUN
dpc-4852	128	9	182	182	NUM
dpc-4852	128	10	96.8	96.8	NUM
dpc-4852	128	11	potent	potent	ADJ
dpc-4852	128	12	topical	topical	ADJ
dpc-4852	128	13	steroids	steroid	NOUN
dpc-4852	128	14	3	3	NUM
dpc-4852	128	15	1.6	1.6	NUM
dpc-4852	128	16	doxycycline	doxycycline	NOUN
dpc-4852	128	17	and	and	CCONJ
dpc-4852	128	18	topical	topical	ADJ
dpc-4852	128	19	steroids	steroid	NOUN
dpc-4852	128	20	15	15	NUM
dpc-4852	128	21	8.0	8.0	NUM
dpc-4852	128	22	immunosuppressive	immunosuppressive	ADJ
dpc-4852	128	23	agents	agent	NOUN
dpc-4852	128	24	and	and	CCONJ
dpc-4852	128	25	topical	topical	ADJ
dpc-4852	128	26	steroids	steroid	NOUN
dpc-4852	128	27	22	22	NUM
dpc-4852	128	28	11.7	11.7	NUM
dpc-4852	128	29	-azathioprine	-azathioprine	NOUN
dpc-4852	128	30	8	8	NUM
dpc-4852	128	31	4.25	4.25	NUM
dpc-4852	128	32	-dapsone	-dapsone	NUM
dpc-4852	128	33	15	15	NUM
dpc-4852	128	34	7.97	7.97	NUM
dpc-4852	128	35	original	original	ADJ
dpc-4852	128	36	article	article	NOUN
dpc-4852	128	37	|	|	ADV
dpc-4852	128	38	dermatol	dermatol	ADJ
dpc-4852	128	39	pract	pract	NOUN
dpc-4852	128	40	concept	concept	NOUN
dpc-4852	128	41	.	.	PUNCT
dpc-4852	129	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	129	2	5	5	NUM
dpc-4852	129	3	among	among	ADP
dpc-4852	129	4	different	different	ADJ
dpc-4852	129	5	populations	population	NOUN
dpc-4852	129	6	worldwide	worldwide	ADV
dpc-4852	129	7	ranges	range	VERB
dpc-4852	129	8	from	from	ADP
dpc-4852	129	9	12	12	NUM
dpc-4852	129	10	to	to	PART
dpc-4852	129	11	66	66	NUM
dpc-4852	129	12	cases	case	NOUN
dpc-4852	129	13	per	per	ADP
dpc-4852	129	14	1	1	NUM
dpc-4852	129	15	million	million	NUM
dpc-4852	129	16	people	people	NOUN
dpc-4852	129	17	[	[	X
dpc-4852	129	18	34	34	NUM
dpc-4852	129	19	]	]	PUNCT
dpc-4852	129	20	.	.	PUNCT
dpc-4852	130	1	in	in	ADP
dpc-4852	130	2	this	this	DET
dpc-4852	130	3	study	study	NOUN
dpc-4852	130	4	,	,	PUNCT
dpc-4852	130	5	the	the	DET
dpc-4852	130	6	average	average	ADJ
dpc-4852	130	7	age	age	NOUN
dpc-4852	130	8	at	at	ADP
dpc-4852	130	9	onset	onset	NOUN
dpc-4852	130	10	was	be	AUX
dpc-4852	130	11	76	76	NUM
dpc-4852	130	12	years	year	NOUN
dpc-4852	130	13	,	,	PUNCT
dpc-4852	130	14	aligning	align	VERB
dpc-4852	130	15	with	with	ADP
dpc-4852	130	16	recent	recent	ADJ
dpc-4852	130	17	reviews	review	NOUN
dpc-4852	130	18	.	.	PUNCT
dpc-4852	131	1	the	the	DET
dpc-4852	131	2	maleto	maleto	ADJ
dpc-4852	131	3	-	-	PUNCT
dpc-4852	131	4	female	female	ADJ
dpc-4852	131	5	(	(	PUNCT
dpc-4852	131	6	m	m	NOUN
dpc-4852	131	7	/	/	SYM
dpc-4852	131	8	f	f	X
dpc-4852	131	9	)	)	PUNCT
dpc-4852	131	10	ratio	ratio	NOUN
dpc-4852	131	11	of	of	ADP
dpc-4852	131	12	1.13:1	1.13:1	NUM
dpc-4852	131	13	observed	observe	VERB
dpc-4852	131	14	in	in	ADP
dpc-4852	131	15	our	our	PRON
dpc-4852	131	16	study	study	NOUN
dpc-4852	131	17	,	,	PUNCT
dpc-4852	131	18	while	while	SCONJ
dpc-4852	131	19	indicating	indicate	VERB
dpc-4852	131	20	a	a	DET
dpc-4852	131	21	slightly	slightly	ADV
dpc-4852	131	22	higher	high	ADJ
dpc-4852	131	23	prevalence	prevalence	NOUN
dpc-4852	131	24	in	in	ADP
dpc-4852	131	25	males	male	NOUN
dpc-4852	131	26	,	,	PUNCT
dpc-4852	131	27	does	do	AUX
dpc-4852	131	28	not	not	PART
dpc-4852	131	29	represent	represent	VERB
dpc-4852	131	30	a	a	DET
dpc-4852	131	31	marked	mark	VERB
dpc-4852	131	32	divergence	divergence	NOUN
dpc-4852	131	33	from	from	ADP
dpc-4852	131	34	the	the	DET
dpc-4852	131	35	ratios	ratio	NOUN
dpc-4852	131	36	reported	report	VERB
dpc-4852	131	37	in	in	ADP
dpc-4852	131	38	other	other	ADJ
dpc-4852	131	39	studies	study	NOUN
dpc-4852	131	40	.	.	PUNCT
dpc-4852	132	1	this	this	DET
dpc-4852	132	2	finding	finding	NOUN
dpc-4852	132	3	aligns	align	VERB
dpc-4852	132	4	with	with	ADP
dpc-4852	132	5	some	some	DET
dpc-4852	132	6	larger	large	ADJ
dpc-4852	132	7	retrospective	retrospective	ADJ
dpc-4852	132	8	studies	study	NOUN
dpc-4852	132	9	but	but	CCONJ
dpc-4852	132	10	contrasts	contrast	VERB
dpc-4852	132	11	with	with	ADP
dpc-4852	132	12	the	the	DET
dpc-4852	132	13	reported	report	VERB
dpc-4852	132	14	female	female	ADJ
dpc-4852	132	15	preponderance	preponderance	NOUN
dpc-4852	132	16	in	in	ADP
dpc-4852	132	17	the	the	DET
dpc-4852	132	18	literature	literature	NOUN
dpc-4852	132	19	,	,	PUNCT
dpc-4852	132	20	which	which	PRON
dpc-4852	132	21	shows	show	VERB
dpc-4852	132	22	m	m	PROPN
dpc-4852	132	23	/	/	SYM
dpc-4852	132	24	f	f	PROPN
dpc-4852	132	25	ratios	ratio	NOUN
dpc-4852	132	26	ranging	range	VERB
dpc-4852	132	27	between	between	ADP
dpc-4852	132	28	1:1.04	1:1.04	NUM
dpc-4852	132	29	and	and	CCONJ
dpc-4852	132	30	1:5.1	1:5.1	NUM
dpc-4852	132	31	.	.	PUNCT
dpc-4852	133	1	it	it	PRON
dpc-4852	133	2	is	be	AUX
dpc-4852	133	3	worth	worth	ADJ
dpc-4852	133	4	considering	consider	VERB
dpc-4852	133	5	whether	whether	SCONJ
dpc-4852	133	6	this	this	DET
dpc-4852	133	7	difference	difference	NOUN
dpc-4852	133	8	was	be	AUX
dpc-4852	133	9	statistically	statistically	ADV
dpc-4852	133	10	significant	significant	ADJ
dpc-4852	133	11	or	or	CCONJ
dpc-4852	133	12	whether	whether	SCONJ
dpc-4852	133	13	it	it	PRON
dpc-4852	133	14	falls	fall	VERB
dpc-4852	133	15	within	within	ADP
dpc-4852	133	16	the	the	DET
dpc-4852	133	17	expected	expect	VERB
dpc-4852	133	18	variability	variability	NOUN
dpc-4852	133	19	seen	see	VERB
dpc-4852	133	20	across	across	ADP
dpc-4852	133	21	studies	study	NOUN
dpc-4852	133	22	.	.	PUNCT
dpc-4852	134	1	further	further	ADJ
dpc-4852	134	2	analysis	analysis	NOUN
dpc-4852	134	3	is	be	AUX
dpc-4852	134	4	needed	need	VERB
dpc-4852	134	5	to	to	PART
dpc-4852	134	6	determine	determine	VERB
dpc-4852	134	7	if	if	SCONJ
dpc-4852	134	8	this	this	PRON
dpc-4852	134	9	reflects	reflect	VERB
dpc-4852	134	10	a	a	DET
dpc-4852	134	11	true	true	ADJ
dpc-4852	134	12	population	population	NOUN
dpc-4852	134	13	specific	specific	ADJ
dpc-4852	134	14	trend	trend	NOUN
dpc-4852	134	15	or	or	CCONJ
dpc-4852	134	16	a	a	DET
dpc-4852	134	17	result	result	NOUN
dpc-4852	134	18	of	of	ADP
dpc-4852	134	19	sampling	sample	VERB
dpc-4852	134	20	differences	difference	NOUN
dpc-4852	134	21	[	[	X
dpc-4852	134	22	35	35	NUM
dpc-4852	134	23	-	-	SYM
dpc-4852	134	24	37	37	NUM
dpc-4852	134	25	]	]	PUNCT
dpc-4852	134	26	.	.	PUNCT
dpc-4852	135	1	a	a	DET
dpc-4852	135	2	series	series	NOUN
dpc-4852	135	3	of	of	ADP
dpc-4852	135	4	comorbidities	comorbiditie	NOUN
dpc-4852	135	5	have	have	AUX
dpc-4852	135	6	been	be	AUX
dpc-4852	135	7	reported	report	VERB
dpc-4852	135	8	in	in	ADP
dpc-4852	135	9	bp	bp	PROPN
dpc-4852	135	10	patients	patient	NOUN
dpc-4852	135	11	,	,	PUNCT
dpc-4852	135	12	including	include	VERB
dpc-4852	135	13	autoimmune	autoimmune	ADJ
dpc-4852	135	14	,	,	PUNCT
dpc-4852	135	15	neuropsychiatric	neuropsychiatric	ADJ
dpc-4852	135	16	,	,	PUNCT
dpc-4852	135	17	cardiovascular	cardiovascular	ADJ
dpc-4852	135	18	and	and	CCONJ
dpc-4852	135	19	renal	renal	ADJ
dpc-4852	135	20	disease	disease	NOUN
dpc-4852	135	21	,	,	PUNCT
dpc-4852	135	22	malignancy	malignancy	NOUN
dpc-4852	135	23	,	,	PUNCT
dpc-4852	135	24	hypertension	hypertension	NOUN
dpc-4852	135	25	,	,	PUNCT
dpc-4852	135	26	and	and	CCONJ
dpc-4852	135	27	diabetes	diabetes	NOUN
dpc-4852	135	28	mellitus	mellitus	NOUN
dpc-4852	135	29	[	[	X
dpc-4852	135	30	38	38	NUM
dpc-4852	135	31	]	]	PUNCT
dpc-4852	135	32	.	.	PUNCT
dpc-4852	136	1	in	in	ADP
dpc-4852	136	2	the	the	DET
dpc-4852	136	3	current	current	ADJ
dpc-4852	136	4	study	study	NOUN
dpc-4852	136	5	,	,	PUNCT
dpc-4852	136	6	the	the	DET
dpc-4852	136	7	most	most	ADV
dpc-4852	136	8	common	common	ADJ
dpc-4852	136	9	comorbidities	comorbiditie	NOUN
dpc-4852	136	10	found	find	VERB
dpc-4852	136	11	in	in	ADP
dpc-4852	136	12	bp	bp	PROPN
dpc-4852	136	13	patients	patient	NOUN
dpc-4852	136	14	were	be	AUX
dpc-4852	136	15	diabetes	diabetes	NOUN
dpc-4852	136	16	mellitus	mellitus	NOUN
dpc-4852	136	17	(	(	PUNCT
dpc-4852	136	18	60.6	60.6	NUM
dpc-4852	136	19	%	%	NOUN
dpc-4852	136	20	)	)	PUNCT
dpc-4852	136	21	,	,	PUNCT
dpc-4852	136	22	hypertension	hypertension	NOUN
dpc-4852	136	23	(	(	PUNCT
dpc-4852	136	24	45.2	45.2	NUM
dpc-4852	136	25	%	%	NOUN
dpc-4852	136	26	)	)	PUNCT
dpc-4852	136	27	,	,	PUNCT
dpc-4852	136	28	kidney	kidney	NOUN
dpc-4852	136	29	disease	disease	NOUN
dpc-4852	136	30	(	(	PUNCT
dpc-4852	136	31	8	8	NUM
dpc-4852	136	32	%	%	NOUN
dpc-4852	136	33	)	)	PUNCT
dpc-4852	136	34	,	,	PUNCT
dpc-4852	136	35	and	and	CCONJ
dpc-4852	136	36	cardiovascular	cardiovascular	ADJ
dpc-4852	136	37	(	(	PUNCT
dpc-4852	136	38	10	10	NUM
dpc-4852	136	39	%	%	NOUN
dpc-4852	136	40	)	)	PUNCT
dpc-4852	136	41	and	and	CCONJ
dpc-4852	136	42	neuropsychiatric	neuropsychiatric	ADJ
dpc-4852	136	43	diseases	disease	NOUN
dpc-4852	136	44	(	(	PUNCT
dpc-4852	136	45	11.8	11.8	NUM
dpc-4852	136	46	%	%	NOUN
dpc-4852	136	47	)	)	PUNCT
dpc-4852	136	48	.	.	PUNCT
dpc-4852	137	1	these	these	DET
dpc-4852	137	2	findings	finding	NOUN
dpc-4852	137	3	are	be	AUX
dpc-4852	137	4	in	in	ADP
dpc-4852	137	5	line	line	NOUN
dpc-4852	137	6	with	with	ADP
dpc-4852	137	7	the	the	DET
dpc-4852	137	8	current	current	ADJ
dpc-4852	137	9	literature	literature	NOUN
dpc-4852	137	10	[	[	X
dpc-4852	137	11	39	39	NUM
dpc-4852	137	12	]	]	PUNCT
dpc-4852	137	13	.	.	PUNCT
dpc-4852	138	1	it	it	PRON
dpc-4852	138	2	is	be	AUX
dpc-4852	138	3	significant	significant	ADJ
dpc-4852	138	4	to	to	PART
dpc-4852	138	5	consider	consider	VERB
dpc-4852	138	6	that	that	SCONJ
dpc-4852	138	7	the	the	DET
dpc-4852	138	8	intake	intake	NOUN
dpc-4852	138	9	of	of	ADP
dpc-4852	138	10	immunosuppressants	immunosuppressant	NOUN
dpc-4852	138	11	can	can	AUX
dpc-4852	138	12	lead	lead	VERB
dpc-4852	138	13	to	to	ADP
dpc-4852	138	14	the	the	DET
dpc-4852	138	15	worsening	worsening	NOUN
dpc-4852	138	16	of	of	ADP
dpc-4852	138	17	preexisting	preexist	VERB
dpc-4852	138	18	pathologies	pathology	NOUN
dpc-4852	138	19	in	in	ADP
dpc-4852	138	20	patients	patient	NOUN
dpc-4852	138	21	with	with	ADP
dpc-4852	138	22	bp	bp	PROPN
dpc-4852	138	23	.	.	PUNCT
dpc-4852	139	1	the	the	DET
dpc-4852	139	2	increased	increase	VERB
dpc-4852	139	3	relapse	relapse	NOUN
dpc-4852	139	4	rate	rate	NOUN
dpc-4852	139	5	prompts	prompt	NOUN
dpc-4852	139	6	exploration	exploration	NOUN
dpc-4852	139	7	of	of	ADP
dpc-4852	139	8	identifying	identify	VERB
dpc-4852	139	9	high	high	ADJ
dpc-4852	139	10	-	-	PUNCT
dpc-4852	139	11	risk	risk	NOUN
dpc-4852	139	12	patients	patient	NOUN
dpc-4852	139	13	and	and	CCONJ
dpc-4852	139	14	optimal	optimal	ADJ
dpc-4852	139	15	management	management	NOUN
dpc-4852	139	16	strategies	strategy	NOUN
dpc-4852	139	17	.	.	PUNCT
dpc-4852	140	1	administering	administer	VERB
dpc-4852	140	2	adjuvant	adjuvant	ADJ
dpc-4852	140	3	immunosuppressive	immunosuppressive	ADJ
dpc-4852	140	4	agents	agent	NOUN
dpc-4852	140	5	may	may	AUX
dpc-4852	140	6	result	result	VERB
dpc-4852	140	7	into	into	ADP
dpc-4852	140	8	potential	potential	ADJ
dpc-4852	140	9	severe	severe	ADJ
dpc-4852	140	10	side	side	NOUN
dpc-4852	140	11	effects	effect	NOUN
dpc-4852	140	12	,	,	PUNCT
dpc-4852	140	13	emphasizing	emphasize	VERB
dpc-4852	140	14	the	the	DET
dpc-4852	140	15	vulnerability	vulnerability	NOUN
dpc-4852	140	16	of	of	ADP
dpc-4852	140	17	the	the	DET
dpc-4852	140	18	elderly	elderly	ADJ
dpc-4852	140	19	population	population	NOUN
dpc-4852	140	20	commonly	commonly	ADV
dpc-4852	140	21	affected	affect	VERB
dpc-4852	140	22	by	by	ADP
dpc-4852	140	23	bp	bp	PROPN
dpc-4852	141	1	[	[	X
dpc-4852	141	2	40	40	NUM
dpc-4852	141	3	]	]	PUNCT
dpc-4852	141	4	.	.	PUNCT
dpc-4852	142	1	this	this	DET
dpc-4852	142	2	study	study	NOUN
dpc-4852	142	3	underscores	underscore	VERB
dpc-4852	142	4	the	the	DET
dpc-4852	142	5	impact	impact	NOUN
dpc-4852	142	6	of	of	ADP
dpc-4852	142	7	dpp-4	dpp-4	ADJ
dpc-4852	142	8	inhibitors	inhibitor	NOUN
dpc-4852	142	9	,	,	PUNCT
dpc-4852	142	10	such	such	ADJ
dpc-4852	142	11	as	as	ADP
dpc-4852	142	12	vildagliptin	vildagliptin	NOUN
dpc-4852	142	13	and	and	CCONJ
dpc-4852	142	14	linagliptin	linagliptin	ADJ
dpc-4852	142	15	,	,	PUNCT
dpc-4852	142	16	in	in	ADP
dpc-4852	142	17	increasing	increase	VERB
dpc-4852	142	18	bp	bp	PROPN
dpc-4852	142	19	risk	risk	NOUN
dpc-4852	142	20	.	.	PUNCT
dpc-4852	143	1	another	another	DET
dpc-4852	143	2	study	study	NOUN
dpc-4852	143	3	conducted	conduct	VERB
dpc-4852	143	4	in	in	ADP
dpc-4852	143	5	greece	greece	PROPN
dpc-4852	143	6	exhibited	exhibit	VERB
dpc-4852	143	7	similar	similar	ADJ
dpc-4852	143	8	results	result	NOUN
dpc-4852	143	9	[	[	X
dpc-4852	143	10	41	41	NUM
dpc-4852	143	11	]	]	PUNCT
dpc-4852	143	12	.	.	PUNCT
dpc-4852	144	1	in	in	ADP
dpc-4852	144	2	a	a	DET
dpc-4852	144	3	large	large	ADJ
dpc-4852	144	4	series	series	NOUN
dpc-4852	144	5	of	of	ADP
dpc-4852	144	6	case	case	NOUN
dpc-4852	144	7	reports	report	VERB
dpc-4852	144	8	,	,	PUNCT
dpc-4852	144	9	the	the	DET
dpc-4852	144	10	findings	finding	NOUN
dpc-4852	144	11	suggest	suggest	VERB
dpc-4852	144	12	that	that	SCONJ
dpc-4852	144	13	dpp-4	dpp-4	PUNCT
dpc-4852	144	14	inhibitors	inhibitor	NOUN
dpc-4852	144	15	such	such	ADJ
dpc-4852	144	16	as	as	ADP
dpc-4852	144	17	vildagliptin	vildagliptin	NOUN
dpc-4852	144	18	,	,	PUNCT
dpc-4852	144	19	sitagliptin	sitagliptin	NOUN
dpc-4852	144	20	,	,	PUNCT
dpc-4852	144	21	linagliptin	linagliptin	ADJ
dpc-4852	144	22	,	,	PUNCT
dpc-4852	144	23	anagliptin	anagliptin	NOUN
dpc-4852	144	24	,	,	PUNCT
dpc-4852	144	25	and	and	CCONJ
dpc-4852	144	26	alogliptin	alogliptin	NOUN
dpc-4852	144	27	were	be	AUX
dpc-4852	144	28	identified	identify	VERB
dpc-4852	144	29	as	as	ADP
dpc-4852	144	30	inducing	induce	VERB
dpc-4852	144	31	agents	agent	NOUN
dpc-4852	144	32	for	for	ADP
dpc-4852	144	33	bp	bp	PROPN
dpc-4852	144	34	.	.	PUNCT
dpc-4852	145	1	furthermore	furthermore	ADV
dpc-4852	145	2	,	,	PUNCT
dpc-4852	145	3	a	a	DET
dpc-4852	145	4	recent	recent	ADJ
dpc-4852	145	5	retrospective	retrospective	ADJ
dpc-4852	145	6	study	study	NOUN
dpc-4852	145	7	demonstrated	demonstrate	VERB
dpc-4852	145	8	that	that	SCONJ
dpc-4852	145	9	the	the	DET
dpc-4852	145	10	use	use	NOUN
dpc-4852	145	11	of	of	ADP
dpc-4852	145	12	this	this	DET
dpc-4852	145	13	class	class	NOUN
dpc-4852	145	14	of	of	ADP
dpc-4852	145	15	n=68	n=68	ADP
dpc-4852	145	16	n=41	n=41	PROPN
dpc-4852	145	17	0	0	NUM
dpc-4852	145	18	10	10	NUM
dpc-4852	145	19	20	20	NUM
dpc-4852	145	20	30	30	NUM
dpc-4852	145	21	40	40	NUM
dpc-4852	145	22	50	50	NUM
dpc-4852	145	23	60	60	NUM
dpc-4852	145	24	70	70	NUM
dpc-4852	145	25	80	80	NUM
dpc-4852	145	26	dpp4	dpp4	PROPN
dpc-4852	145	27	others	other	NOUN
dpc-4852	145	28	bp	bp	PROPN
dpc-4852	145	29	and	and	CCONJ
dpc-4852	145	30	an	an	DET
dpc-4852	145	31	�	�	PROPN
dpc-4852	145	32	diabe	diabe	PROPN
dpc-4852	145	33	�	�	PROPN
dpc-4852	145	34	cs	cs	ADJ
dpc-4852	145	35	figure	figure	NOUN
dpc-4852	145	36	3	3	NUM
dpc-4852	145	37	.	.	NOUN
dpc-4852	145	38	number	number	NOUN
dpc-4852	145	39	of	of	ADP
dpc-4852	145	40	patients	patient	NOUN
dpc-4852	145	41	with	with	ADP
dpc-4852	145	42	bullous	bullous	ADJ
dpc-4852	145	43	pemphigoid	pemphigoid	NOUN
dpc-4852	145	44	and	and	CCONJ
dpc-4852	145	45	diabetes	diabetes	NOUN
dpc-4852	145	46	mellitus	mellitus	NOUN
dpc-4852	145	47	treated	treat	VERB
dpc-4852	145	48	with	with	ADP
dpc-4852	145	49	d	d	NOUN
dpc-4852	145	50	-	-	ADJ
dpc-4852	145	51	pp4	pp4	VERB
dpc-4852	145	52	inhibitors	inhibitor	NOUN
dpc-4852	145	53	in	in	ADP
dpc-4852	145	54	comparison	comparison	NOUN
dpc-4852	145	55	with	with	ADP
dpc-4852	145	56	those	those	PRON
dpc-4852	145	57	treated	treat	VERB
dpc-4852	145	58	with	with	ADP
dpc-4852	145	59	different	different	ADJ
dpc-4852	145	60	agents	agent	NOUN
dpc-4852	145	61	.	.	PUNCT
dpc-4852	146	1	0	0	NUM
dpc-4852	146	2	5	5	NUM
dpc-4852	146	3	10	10	NUM
dpc-4852	146	4	15	15	NUM
dpc-4852	146	5	20	20	NUM
dpc-4852	146	6	25	25	NUM
dpc-4852	146	7	30	30	NUM
dpc-4852	146	8	death	death	NOUN
dpc-4852	146	9	iden	iden	PROPN
dpc-4852	146	10	�	�	PROPN
dpc-4852	146	11	fied	fie	VERB
dpc-4852	146	12	cause	cause	NOUN
dpc-4852	146	13	figure	figure	NOUN
dpc-4852	146	14	5	5	NUM
dpc-4852	146	15	.	.	PUNCT
dpc-4852	147	1	the	the	DET
dpc-4852	147	2	number	number	NOUN
dpc-4852	147	3	of	of	ADP
dpc-4852	147	4	deaths	death	NOUN
dpc-4852	147	5	after	after	ADP
dpc-4852	147	6	a	a	DET
dpc-4852	147	7	12	12	NUM
dpc-4852	147	8	-	-	PUNCT
dpc-4852	147	9	month	month	NOUN
dpc-4852	147	10	period	period	NOUN
dpc-4852	147	11	of	of	ADP
dpc-4852	147	12	follow	follow	NOUN
dpc-4852	147	13	-	-	PUNCT
dpc-4852	147	14	up	up	NOUN
dpc-4852	147	15	.	.	PUNCT
dpc-4852	147	16	0	0	NUM
dpc-4852	147	17	2	2	NUM
dpc-4852	147	18	4	4	NUM
dpc-4852	147	19	6	6	NUM
dpc-4852	147	20	8	8	NUM
dpc-4852	147	21	10	10	NUM
dpc-4852	147	22	12	12	NUM
dpc-4852	147	23	cvs	cvs	NOUN
dpc-4852	147	24	stroke	stroke	NOUN
dpc-4852	147	25	sepsis	sepsis	NOUN
dpc-4852	147	26	figure	figure	NOUN
dpc-4852	147	27	6	6	NUM
dpc-4852	147	28	.	.	NUM
dpc-4852	147	29	identified	identify	VERB
dpc-4852	147	30	causes	cause	NOUN
dpc-4852	147	31	of	of	ADP
dpc-4852	147	32	death	death	NOUN
dpc-4852	147	33	after	after	ADP
dpc-4852	147	34	a	a	DET
dpc-4852	147	35	12	12	NUM
dpc-4852	147	36	-	-	PUNCT
dpc-4852	147	37	month	month	NOUN
dpc-4852	147	38	period	period	NOUN
dpc-4852	147	39	.	.	PUNCT
dpc-4852	148	1	abbreviations	abbreviation	NOUN
dpc-4852	148	2	:	:	PUNCT
dpc-4852	148	3	cvs	cvs	NOUN
dpc-4852	148	4	:	:	PUNCT
dpc-4852	148	5	cardiovascular	cardiovascular	ADJ
dpc-4852	148	6	diseases	disease	NOUN
dpc-4852	148	7	.	.	PUNCT
dpc-4852	149	1	52	52	NUM
dpc-4852	149	2	11	11	NUM
dpc-4852	149	3	3	3	NUM
dpc-4852	149	4	2	2	NUM
dpc-4852	149	5	0	0	NUM
dpc-4852	149	6	10	10	NUM
dpc-4852	149	7	20	20	NUM
dpc-4852	149	8	30	30	NUM
dpc-4852	149	9	40	40	NUM
dpc-4852	149	10	50	50	NUM
dpc-4852	149	11	60	60	NUM
dpc-4852	149	12	vildaglip	vildaglip	NOUN
dpc-4852	149	13	�	�	NOUN
dpc-4852	149	14	n	n	NUM
dpc-4852	149	15	linaglip	linaglip	PROPN
dpc-4852	149	16	�	�	PROPN
dpc-4852	149	17	n	n	PART
dpc-4852	149	18	sitaglip	sitaglip	NOUN
dpc-4852	149	19	�	�	PROPN
dpc-4852	149	20	n	n	PART
dpc-4852	149	21	aloglip	aloglip	NOUN
dpc-4852	149	22	�	�	NOUN
dpc-4852	149	23	n	n	PRON
dpc-4852	149	24	figure	figure	NOUN
dpc-4852	149	25	4	4	NUM
dpc-4852	149	26	.	.	PUNCT
dpc-4852	149	27	comparison	comparison	NOUN
dpc-4852	149	28	of	of	ADP
dpc-4852	149	29	dpp-4	dpp-4	NOUN
dpc-4852	149	30	agents	agent	NOUN
dpc-4852	149	31	.	.	PUNCT
dpc-4852	150	1	cardiovascular	cardiovascular	ADJ
dpc-4852	150	2	disease	disease	NOUN
dpc-4852	150	3	(	(	PUNCT
dpc-4852	150	4	observed	observe	VERB
dpc-4852	150	5	in	in	ADP
dpc-4852	150	6	10	10	NUM
dpc-4852	150	7	patients	patient	NOUN
dpc-4852	150	8	,	,	PUNCT
dpc-4852	150	9	including	include	VERB
dpc-4852	150	10	eight	eight	NUM
dpc-4852	150	11	heavy	heavy	ADJ
dpc-4852	150	12	smokers	smoker	NOUN
dpc-4852	150	13	)	)	PUNCT
dpc-4852	150	14	,	,	PUNCT
dpc-4852	150	15	stroke	stroke	NOUN
dpc-4852	150	16	(	(	PUNCT
dpc-4852	150	17	two	two	NUM
dpc-4852	150	18	individuals	individual	NOUN
dpc-4852	150	19	)	)	PUNCT
dpc-4852	150	20	,	,	PUNCT
dpc-4852	150	21	and	and	CCONJ
dpc-4852	150	22	sepsis	sepsis	NOUN
dpc-4852	150	23	(	(	PUNCT
dpc-4852	150	24	seven	seven	NUM
dpc-4852	150	25	cases	case	NOUN
dpc-4852	150	26	,	,	PUNCT
dpc-4852	150	27	5	5	NUM
dpc-4852	150	28	of	of	ADP
dpc-4852	150	29	which	which	PRON
dpc-4852	150	30	caused	cause	VERB
dpc-4852	150	31	by	by	ADP
dpc-4852	150	32	pneumonia	pneumonia	NOUN
dpc-4852	150	33	)	)	PUNCT
dpc-4852	150	34	(	(	PUNCT
dpc-4852	150	35	figure	figure	NOUN
dpc-4852	150	36	6	6	NUM
dpc-4852	150	37	)	)	PUNCT
dpc-4852	150	38	.	.	PUNCT
dpc-4852	151	1	discussion	discussion	NOUN
dpc-4852	151	2	and	and	CCONJ
dpc-4852	151	3	conclusions	conclusion	NOUN
dpc-4852	151	4	bp	bp	PROPN
dpc-4852	151	5	accounts	account	VERB
dpc-4852	151	6	for	for	ADP
dpc-4852	151	7	70	70	NUM
dpc-4852	151	8	%	%	NOUN
dpc-4852	151	9	of	of	ADP
dpc-4852	151	10	subepidermal	subepidermal	NOUN
dpc-4852	151	11	blistering	blister	VERB
dpc-4852	151	12	diseases	disease	NOUN
dpc-4852	151	13	,	,	PUNCT
dpc-4852	151	14	predominantly	predominantly	ADV
dpc-4852	151	15	affecting	affect	VERB
dpc-4852	151	16	the	the	DET
dpc-4852	151	17	elderly	elderly	ADJ
dpc-4852	151	18	[	[	X
dpc-4852	151	19	10	10	NUM
dpc-4852	151	20	]	]	PUNCT
dpc-4852	151	21	.	.	PUNCT
dpc-4852	152	1	its	its	PRON
dpc-4852	152	2	annual	annual	ADJ
dpc-4852	152	3	incidence	incidence	NOUN
dpc-4852	152	4	6	6	NUM
dpc-4852	152	5	original	original	ADJ
dpc-4852	152	6	article	article	NOUN
dpc-4852	152	7	|	|	ADV
dpc-4852	152	8	dermatol	dermatol	ADJ
dpc-4852	152	9	pract	pract	NOUN
dpc-4852	152	10	concept	concept	NOUN
dpc-4852	152	11	.	.	PUNCT
dpc-4852	153	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	153	2	numerous	numerous	ADJ
dpc-4852	153	3	lesions	lesion	NOUN
dpc-4852	153	4	at	at	ADP
dpc-4852	153	5	disease	disease	NOUN
dpc-4852	153	6	onset	onset	NOUN
dpc-4852	153	7	have	have	VERB
dpc-4852	153	8	a	a	DET
dpc-4852	153	9	significant	significant	ADJ
dpc-4852	153	10	risk	risk	NOUN
dpc-4852	153	11	of	of	ADP
dpc-4852	153	12	relapse	relapse	NOUN
dpc-4852	153	13	[	[	X
dpc-4852	153	14	50	50	NUM
dpc-4852	153	15	,	,	PUNCT
dpc-4852	153	16	51	51	NUM
dpc-4852	153	17	]	]	PUNCT
dpc-4852	153	18	.	.	PUNCT
dpc-4852	154	1	by	by	ADP
dpc-4852	154	2	using	use	VERB
dpc-4852	154	3	the	the	DET
dpc-4852	154	4	bpdai	bpdai	NOUN
dpc-4852	154	5	score	score	NOUN
dpc-4852	154	6	for	for	ADP
dpc-4852	154	7	the	the	DET
dpc-4852	154	8	assessment	assessment	NOUN
dpc-4852	154	9	of	of	ADP
dpc-4852	154	10	disease	disease	NOUN
dpc-4852	154	11	severity	severity	NOUN
dpc-4852	154	12	,	,	PUNCT
dpc-4852	154	13	more	more	ADV
dpc-4852	154	14	precise	precise	ADJ
dpc-4852	154	15	conclusions	conclusion	NOUN
dpc-4852	154	16	may	may	AUX
dpc-4852	154	17	be	be	AUX
dpc-4852	154	18	reached	reach	VERB
dpc-4852	154	19	during	during	ADP
dpc-4852	154	20	baseline	baseline	NOUN
dpc-4852	154	21	and	and	CCONJ
dpc-4852	154	22	follow	follow	VERB
dpc-4852	154	23	-	-	PUNCT
dpc-4852	154	24	up	up	NOUN
dpc-4852	154	25	visits	visit	NOUN
dpc-4852	154	26	[	[	X
dpc-4852	154	27	45	45	NUM
dpc-4852	154	28	]	]	PUNCT
dpc-4852	154	29	.	.	PUNCT
dpc-4852	155	1	this	this	DET
dpc-4852	155	2	observational	observational	ADJ
dpc-4852	155	3	study	study	NOUN
dpc-4852	155	4	plays	play	VERB
dpc-4852	155	5	a	a	DET
dpc-4852	155	6	significant	significant	ADJ
dpc-4852	155	7	role	role	NOUN
dpc-4852	155	8	in	in	ADP
dpc-4852	155	9	identifying	identify	VERB
dpc-4852	155	10	new	new	ADJ
dpc-4852	155	11	areas	area	NOUN
dpc-4852	155	12	of	of	ADP
dpc-4852	155	13	investigation	investigation	NOUN
dpc-4852	155	14	that	that	PRON
dpc-4852	155	15	may	may	AUX
dpc-4852	155	16	require	require	VERB
dpc-4852	155	17	further	further	ADJ
dpc-4852	155	18	validation	validation	NOUN
dpc-4852	155	19	through	through	ADP
dpc-4852	155	20	fundamental	fundamental	ADJ
dpc-4852	155	21	or	or	CCONJ
dpc-4852	155	22	experimental	experimental	ADJ
dpc-4852	155	23	research	research	NOUN
dpc-4852	155	24	.	.	PUNCT
dpc-4852	156	1	nevertheless	nevertheless	ADV
dpc-4852	156	2	,	,	PUNCT
dpc-4852	156	3	it	it	PRON
dpc-4852	156	4	is	be	AUX
dpc-4852	156	5	crucial	crucial	ADJ
dpc-4852	156	6	to	to	PART
dpc-4852	156	7	acknowledge	acknowledge	VERB
dpc-4852	156	8	the	the	DET
dpc-4852	156	9	limitations	limitation	NOUN
dpc-4852	156	10	that	that	PRON
dpc-4852	156	11	can	can	AUX
dpc-4852	156	12	arise	arise	VERB
dpc-4852	156	13	in	in	ADP
dpc-4852	156	14	such	such	ADJ
dpc-4852	156	15	studies	study	NOUN
dpc-4852	156	16	,	,	PUNCT
dpc-4852	156	17	due	due	ADP
dpc-4852	156	18	to	to	ADP
dpc-4852	156	19	factors	factor	NOUN
dpc-4852	156	20	like	like	ADP
dpc-4852	156	21	small	small	ADJ
dpc-4852	156	22	sample	sample	NOUN
dpc-4852	156	23	sizes	size	NOUN
dpc-4852	156	24	,	,	PUNCT
dpc-4852	156	25	residual	residual	ADJ
dpc-4852	156	26	confounding	confounding	NOUN
dpc-4852	156	27	,	,	PUNCT
dpc-4852	156	28	multiple	multiple	ADJ
dpc-4852	156	29	comparisons	comparison	NOUN
dpc-4852	156	30	,	,	PUNCT
dpc-4852	156	31	or	or	CCONJ
dpc-4852	156	32	subgroup	subgroup	NOUN
dpc-4852	156	33	analyses	analysis	NOUN
dpc-4852	156	34	conducted	conduct	VERB
dpc-4852	156	35	without	without	ADP
dpc-4852	156	36	prespecified	prespecifie	VERB
dpc-4852	156	37	hypotheses	hypothesis	NOUN
dpc-4852	156	38	or	or	CCONJ
dpc-4852	156	39	sufficient	sufficient	ADJ
dpc-4852	156	40	statistical	statistical	ADJ
dpc-4852	156	41	power	power	NOUN
dpc-4852	156	42	[	[	X
dpc-4852	156	43	31	31	NUM
dpc-4852	156	44	]	]	PUNCT
dpc-4852	156	45	.	.	PUNCT
dpc-4852	157	1	the	the	DET
dpc-4852	157	2	findings	finding	NOUN
dpc-4852	157	3	of	of	ADP
dpc-4852	157	4	this	this	DET
dpc-4852	157	5	study	study	NOUN
dpc-4852	157	6	confirm	confirm	VERB
dpc-4852	157	7	the	the	DET
dpc-4852	157	8	higher	high	ADJ
dpc-4852	157	9	incidence	incidence	NOUN
dpc-4852	157	10	rates	rate	NOUN
dpc-4852	157	11	of	of	ADP
dpc-4852	157	12	bp	bp	PROPN
dpc-4852	157	13	in	in	ADP
dpc-4852	157	14	elderly	elderly	ADJ
dpc-4852	157	15	patients	patient	NOUN
dpc-4852	157	16	and	and	CCONJ
dpc-4852	157	17	dpp-4	dpp-4	ADV
dpc-4852	157	18	inhibitor	inhibitor	NOUN
dpc-4852	157	19	users	user	NOUN
dpc-4852	157	20	,	,	PUNCT
dpc-4852	157	21	reflecting	reflect	VERB
dpc-4852	157	22	trends	trend	NOUN
dpc-4852	157	23	observed	observe	VERB
dpc-4852	157	24	globally	globally	ADV
dpc-4852	157	25	.	.	PUNCT
dpc-4852	158	1	systemic	systemic	ADJ
dpc-4852	158	2	corticosteroids	corticosteroid	NOUN
dpc-4852	158	3	remain	remain	VERB
dpc-4852	158	4	the	the	DET
dpc-4852	158	5	primary	primary	ADJ
dpc-4852	158	6	therapeutic	therapeutic	ADJ
dpc-4852	158	7	strategy	strategy	NOUN
dpc-4852	158	8	at	at	ADP
dpc-4852	158	9	our	our	PRON
dpc-4852	158	10	center	center	NOUN
dpc-4852	158	11	.	.	PUNCT
dpc-4852	159	1	however	however	ADV
dpc-4852	159	2	,	,	PUNCT
dpc-4852	159	3	the	the	DET
dpc-4852	159	4	observed	observed	ADJ
dpc-4852	159	5	relapse	relapse	NOUN
dpc-4852	159	6	rates	rate	NOUN
dpc-4852	159	7	highlight	highlight	VERB
dpc-4852	159	8	the	the	DET
dpc-4852	159	9	chronic	chronic	ADJ
dpc-4852	159	10	nature	nature	NOUN
dpc-4852	159	11	of	of	ADP
dpc-4852	159	12	bp	bp	PROPN
dpc-4852	159	13	,	,	PUNCT
dpc-4852	159	14	while	while	SCONJ
dpc-4852	159	15	its	its	PRON
dpc-4852	159	16	associated	associated	ADJ
dpc-4852	159	17	mortality	mortality	NOUN
dpc-4852	159	18	underscores	underscore	VERB
dpc-4852	159	19	the	the	DET
dpc-4852	159	20	urgent	urgent	ADJ
dpc-4852	159	21	need	need	NOUN
dpc-4852	159	22	for	for	ADP
dpc-4852	159	23	optimized	optimize	VERB
dpc-4852	159	24	management	management	NOUN
dpc-4852	159	25	.	.	PUNCT
dpc-4852	160	1	continuous	continuous	ADJ
dpc-4852	160	2	monitoring	monitoring	NOUN
dpc-4852	160	3	of	of	ADP
dpc-4852	160	4	bp	bp	PROPN
dpc-4852	160	5	epidemiology	epidemiology	NOUN
dpc-4852	160	6	and	and	CCONJ
dpc-4852	160	7	further	further	ADJ
dpc-4852	160	8	research	research	NOUN
dpc-4852	160	9	into	into	ADP
dpc-4852	160	10	preventive	preventive	ADJ
dpc-4852	160	11	and	and	CCONJ
dpc-4852	160	12	management	management	NOUN
dpc-4852	160	13	strategies	strategy	NOUN
dpc-4852	160	14	are	be	AUX
dpc-4852	160	15	crucial	crucial	ADJ
dpc-4852	160	16	to	to	PART
dpc-4852	160	17	mitigate	mitigate	VERB
dpc-4852	160	18	the	the	DET
dpc-4852	160	19	disease	disease	NOUN
dpc-4852	160	20	burden	burden	VERB
dpc-4852	160	21	worldwide	worldwide	ADV
dpc-4852	160	22	.	.	PUNCT
dpc-4852	161	1	references	reference	NOUN
dpc-4852	161	2	1	1	NUM
dpc-4852	161	3	.	.	PUNCT
dpc-4852	161	4	cardones	cardones	PROPN
dpc-4852	161	5	arg	arg	PROPN
dpc-4852	161	6	,	,	PUNCT
dpc-4852	161	7	hall	hall	NOUN
dpc-4852	161	8	rp	rp	NOUN
dpc-4852	161	9	.	.	PUNCT
dpc-4852	162	1	bullous	bullous	ADJ
dpc-4852	162	2	diseases	disease	NOUN
dpc-4852	162	3	of	of	ADP
dpc-4852	162	4	the	the	DET
dpc-4852	162	5	skin	skin	NOUN
dpc-4852	162	6	and	and	CCONJ
dpc-4852	162	7	mucous	mucous	ADJ
dpc-4852	162	8	membranes	membrane	NOUN
dpc-4852	162	9	.	.	PUNCT
dpc-4852	163	1	in	in	ADP
dpc-4852	163	2	:	:	PUNCT
dpc-4852	163	3	rich	rich	PROPN
dpc-4852	163	4	rr	rr	PROPN
dpc-4852	163	5	,	,	PUNCT
dpc-4852	163	6	fleisher	fleisher	PROPN
dpc-4852	163	7	ta	ta	PROPN
dpc-4852	163	8	,	,	PUNCT
dpc-4852	163	9	shearer	shearer	PROPN
dpc-4852	163	10	wt	wt	PROPN
dpc-4852	163	11	,	,	PUNCT
dpc-4852	163	12	schroeder	schroeder	PROPN
dpc-4852	163	13	hw	hw	PROPN
dpc-4852	163	14	,	,	PUNCT
dpc-4852	163	15	frew	frew	PROPN
dpc-4852	163	16	aj	aj	PROPN
dpc-4852	163	17	,	,	PUNCT
dpc-4852	163	18	weyand	weyand	NOUN
dpc-4852	163	19	cm	cm	PROPN
dpc-4852	163	20	,	,	PUNCT
dpc-4852	163	21	eds	ed	NOUN
dpc-4852	163	22	.	.	PUNCT
dpc-4852	163	23	clinical	clinical	ADJ
dpc-4852	163	24	immunology	immunology	NOUN
dpc-4852	163	25	.	.	PUNCT
dpc-4852	164	1	5th	5th	ADJ
dpc-4852	164	2	ed	ed	NOUN
dpc-4852	164	3	.	.	PUNCT
dpc-4852	165	1	elsevier	elsevier	NOUN
dpc-4852	165	2	;	;	PUNCT
dpc-4852	165	3	2019:857	2019:857	NUM
dpc-4852	165	4	-	-	PUNCT
dpc-4852	165	5	870.e1	870.e1	NUM
dpc-4852	165	6	.	.	PUNCT
dpc-4852	166	1	2	2	X
dpc-4852	166	2	.	.	X
dpc-4852	166	3	miyamoto	miyamoto	PROPN
dpc-4852	166	4	d	d	PROPN
dpc-4852	166	5	,	,	PUNCT
dpc-4852	166	6	santi	santi	PROPN
dpc-4852	166	7	cg	cg	PROPN
dpc-4852	166	8	,	,	PUNCT
dpc-4852	166	9	aoki	aoki	PROPN
dpc-4852	166	10	v	v	PROPN
dpc-4852	166	11	,	,	PUNCT
dpc-4852	166	12	et.al	et.al	VERB
dpc-4852	166	13	bullous	bullous	ADJ
dpc-4852	166	14	pemphigoid	pemphigoid	NOUN
dpc-4852	166	15	.	.	PUNCT
dpc-4852	167	1	an	an	DET
dpc-4852	167	2	bras	bras	NOUN
dpc-4852	167	3	dermatol	dermatol	NOUN
dpc-4852	167	4	.	.	PUNCT
dpc-4852	168	1	2019;94(2):133	2019;94(2):133	PROPN
dpc-4852	168	2	-	-	SYM
dpc-4852	168	3	146	146	NUM
dpc-4852	168	4	.	.	PUNCT
dpc-4852	169	1	doi:10.1590	doi:10.1590	ADV
dpc-4852	169	2	/	/	SYM
dpc-4852	169	3	abd18064841.20199007	abd18064841.20199007	ADJ
dpc-4852	169	4	.	.	PUNCT
dpc-4852	170	1	pmid	pmid	NOUN
dpc-4852	170	2	:	:	PUNCT
dpc-4852	170	3	31090818	31090818	NUM
dpc-4852	170	4	3	3	NUM
dpc-4852	170	5	.	.	PUNCT
dpc-4852	170	6	genovese	genovese	NOUN
dpc-4852	170	7	g	g	PROPN
dpc-4852	170	8	,	,	PUNCT
dpc-4852	170	9	di	di	NOUN
dpc-4852	170	10	zenzo	zenzo	NOUN
dpc-4852	170	11	g	g	NOUN
dpc-4852	170	12	,	,	PUNCT
dpc-4852	170	13	cozzani	cozzani	NOUN
dpc-4852	170	14	e	e	NOUN
dpc-4852	170	15	,	,	PUNCT
dpc-4852	170	16	et.al	et.al	PROPN
dpc-4852	170	17	.	.	PUNCT
dpc-4852	171	1	new	new	ADJ
dpc-4852	171	2	insights	insight	NOUN
dpc-4852	171	3	into	into	ADP
dpc-4852	171	4	the	the	DET
dpc-4852	171	5	pathogenesis	pathogenesis	NOUN
dpc-4852	171	6	of	of	ADP
dpc-4852	171	7	bullous	bullous	ADJ
dpc-4852	171	8	pemphigoid	pemphigoid	NOUN
dpc-4852	171	9	:	:	PUNCT
dpc-4852	171	10	2019	2019	NUM
dpc-4852	171	11	update	update	NOUN
dpc-4852	171	12	.	.	PUNCT
dpc-4852	172	1	front	front	ADJ
dpc-4852	172	2	immunol	immunol	NOUN
dpc-4852	172	3	.	.	PUNCT
dpc-4852	173	1	2019;10:1506	2019;10:1506	X
dpc-4852	173	2	.	.	PUNCT
dpc-4852	173	3	published	publish	VERB
dpc-4852	173	4	2019	2019	NUM
dpc-4852	173	5	jul	jul	PROPN
dpc-4852	173	6	2	2	NUM
dpc-4852	173	7	.	.	PUNCT
dpc-4852	173	8	doi:10.3389	doi:10.3389	PROPN
dpc-4852	173	9	/fimmu.2019.01506	/fimmu.2019.01506	PUNCT
dpc-4852	174	1	pmid	pmid	NOUN
dpc-4852	174	2	:	:	PUNCT
dpc-4852	174	3	31312206	31312206	NUM
dpc-4852	174	4	4	4	NUM
dpc-4852	174	5	.	.	PUNCT
dpc-4852	174	6	lu	lu	PROPN
dpc-4852	174	7	l	l	PROPN
dpc-4852	174	8	,	,	PUNCT
dpc-4852	174	9	chen	chen	PROPN
dpc-4852	174	10	l	l	PROPN
dpc-4852	174	11	,	,	PUNCT
dpc-4852	174	12	xu	xu	PROPN
dpc-4852	175	1	y	y	PROPN
dpc-4852	175	2	,	,	PUNCT
dpc-4852	175	3	et.al	et.al	PROPN
dpc-4852	175	4	.	.	PUNCT
dpc-4852	176	1	global	global	ADJ
dpc-4852	176	2	incidence	incidence	NOUN
dpc-4852	176	3	and	and	CCONJ
dpc-4852	176	4	prevalence	prevalence	NOUN
dpc-4852	176	5	of	of	ADP
dpc-4852	176	6	bullous	bullous	ADJ
dpc-4852	176	7	pemphigoid	pemphigoid	NOUN
dpc-4852	176	8	:	:	PUNCT
dpc-4852	176	9	a	a	DET
dpc-4852	176	10	systematic	systematic	ADJ
dpc-4852	176	11	review	review	NOUN
dpc-4852	176	12	and	and	CCONJ
dpc-4852	176	13	meta	meta	ADJ
dpc-4852	176	14	-	-	PUNCT
dpc-4852	176	15	analysis	analysis	NOUN
dpc-4852	176	16	.	.	PUNCT
dpc-4852	177	1	j	j	PROPN
dpc-4852	177	2	cosmet	cosmet	PROPN
dpc-4852	177	3	dermatol	dermatol	NOUN
dpc-4852	177	4	.	.	PUNCT
dpc-4852	178	1	2022;21(10):4818	2022;21(10):4818	NUM
dpc-4852	178	2	-	-	SYM
dpc-4852	178	3	4835	4835	NUM
dpc-4852	178	4	.	.	PUNCT
dpc-4852	179	1	doi	doi	NOUN
dpc-4852	179	2	:	:	PUNCT
dpc-4852	179	3	10.1111	10.1111	NUM
dpc-4852	179	4	/jocd.14797	/jocd.14797	PUNCT
dpc-4852	180	1	pmid	pmid	NOUN
dpc-4852	180	2	:	:	PUNCT
dpc-4852	180	3	35080093	35080093	NUM
dpc-4852	180	4	5	5	NUM
dpc-4852	180	5	.	.	PUNCT
dpc-4852	181	1	kridin	kridin	VERB
dpc-4852	181	2	k	k	PROPN
dpc-4852	181	3	,	,	PUNCT
dpc-4852	181	4	ludwig	ludwig	PROPN
dpc-4852	181	5	rj	rj	PROPN
dpc-4852	181	6	.	.	PUNCT
dpc-4852	182	1	the	the	DET
dpc-4852	182	2	growing	grow	VERB
dpc-4852	182	3	incidence	incidence	NOUN
dpc-4852	182	4	of	of	ADP
dpc-4852	182	5	bullous	bullous	ADJ
dpc-4852	182	6	pemphigoid	pemphigoid	NOUN
dpc-4852	182	7	:	:	PUNCT
dpc-4852	182	8	overview	overview	NOUN
dpc-4852	182	9	and	and	CCONJ
dpc-4852	182	10	potential	potential	ADJ
dpc-4852	182	11	explanations	explanation	NOUN
dpc-4852	182	12	.	.	PUNCT
dpc-4852	183	1	front	front	ADJ
dpc-4852	183	2	med	med	PROPN
dpc-4852	183	3	(	(	PUNCT
dpc-4852	183	4	lausanne	lausanne	PROPN
dpc-4852	183	5	)	)	PUNCT
dpc-4852	183	6	.	.	PUNCT
dpc-4852	184	1	2018	2018	NUM
dpc-4852	184	2	;	;	PUNCT
dpc-4852	184	3	5:220	5:220	X
dpc-4852	184	4	.	.	X
dpc-4852	184	5	doi:10.3389	doi:10.3389	PROPN
dpc-4852	184	6	/	/	SYM
dpc-4852	184	7	fmed.2018.00220	fmed.2018.00220	PROPN
dpc-4852	184	8	.	.	PUNCT
dpc-4852	185	1	pmid	pmid	NOUN
dpc-4852	185	2	:	:	PUNCT
dpc-4852	185	3	30177969	30177969	NUM
dpc-4852	185	4	6	6	NUM
dpc-4852	185	5	.	.	PUNCT
dpc-4852	186	1	persson	persson	NOUN
dpc-4852	186	2	msm	msm	NOUN
dpc-4852	186	3	,	,	PUNCT
dpc-4852	186	4	harman	harman	PROPN
dpc-4852	186	5	ke	ke	PROPN
dpc-4852	186	6	,	,	PUNCT
dpc-4852	186	7	vinogradova	vinogradova	PROPN
dpc-4852	186	8	y	y	PROPN
dpc-4852	186	9	,	,	PUNCT
dpc-4852	186	10	et	et	PROPN
dpc-4852	186	11	al	al	PROPN
dpc-4852	186	12	.	.	PROPN
dpc-4852	186	13	incidence	incidence	PROPN
dpc-4852	186	14	,	,	PUNCT
dpc-4852	186	15	prevalence	prevalence	NOUN
dpc-4852	186	16	and	and	CCONJ
dpc-4852	186	17	mortality	mortality	NOUN
dpc-4852	186	18	of	of	ADP
dpc-4852	186	19	bullous	bullous	ADJ
dpc-4852	186	20	pemphigoid	pemphigoid	NOUN
dpc-4852	186	21	in	in	ADP
dpc-4852	186	22	england	england	PROPN
dpc-4852	186	23	1998–2017	1998–2017	NUM
dpc-4852	186	24	:	:	PUNCT
dpc-4852	186	25	a	a	DET
dpc-4852	186	26	population	population	NOUN
dpc-4852	186	27	-	-	PUNCT
dpc-4852	186	28	based	base	VERB
dpc-4852	186	29	cohort	cohort	NOUN
dpc-4852	186	30	study	study	NOUN
dpc-4852	186	31	.	.	PUNCT
dpc-4852	187	1	br	br	PROPN
dpc-4852	187	2	j	j	PROPN
dpc-4852	187	3	dermatol	dermatol	NOUN
dpc-4852	187	4	.	.	PUNCT
dpc-4852	188	1	2021;184(1):68	2021;184(1):68	NUM
dpc-4852	188	2	-	-	SYM
dpc-4852	188	3	77	77	NUM
dpc-4852	188	4	.	.	PUNCT
dpc-4852	189	1	doi:10.1111	doi:10.1111	ADJ
dpc-4852	189	2	/	/	SYM
dpc-4852	189	3	bjd.19022	bjd.19022	NOUN
dpc-4852	189	4	.	.	PUNCT
dpc-4852	190	1	pmid	pmid	NOUN
dpc-4852	190	2	:	:	PUNCT
dpc-4852	190	3	32147814	32147814	NUM
dpc-4852	190	4	7	7	NUM
dpc-4852	190	5	.	.	PUNCT
dpc-4852	191	1	verheyden	verheyden	PROPN
dpc-4852	191	2	mj	mj	PROPN
dpc-4852	191	3	,	,	PUNCT
dpc-4852	191	4	bilgic	bilgic	ADV
dpc-4852	191	5	a	a	PRON
dpc-4852	191	6	,	,	PUNCT
dpc-4852	191	7	murrell	murrell	PROPN
dpc-4852	191	8	df	df	PROPN
dpc-4852	191	9	.	.	PUNCT
dpc-4852	192	1	a	a	DET
dpc-4852	192	2	systematic	systematic	ADJ
dpc-4852	192	3	review	review	NOUN
dpc-4852	192	4	of	of	ADP
dpc-4852	192	5	drug	drug	NOUN
dpc-4852	192	6	-	-	PUNCT
dpc-4852	192	7	induced	induce	VERB
dpc-4852	192	8	pemphigoid	pemphigoid	NOUN
dpc-4852	192	9	.	.	PUNCT
dpc-4852	193	1	acta	acta	PROPN
dpc-4852	193	2	derm	derm	PROPN
dpc-4852	193	3	venereol	venereol	NOUN
dpc-4852	193	4	.	.	PUNCT
dpc-4852	194	1	2020;100(15):adv00224	2020;100(15):adv00224	X
dpc-4852	194	2	.	.	PUNCT
dpc-4852	194	3	published	publish	VERB
dpc-4852	194	4	2020	2020	NUM
dpc-4852	194	5	aug	aug	PROPN
dpc-4852	194	6	17	17	NUM
dpc-4852	194	7	.	.	PUNCT
dpc-4852	195	1	doi	doi	NOUN
dpc-4852	195	2	:	:	PUNCT
dpc-4852	195	3	10.2340	10.2340	NUM
dpc-4852	195	4	/00015555	/00015555	SYM
dpc-4852	195	5	-	-	SYM
dpc-4852	195	6	3457	3457	NUM
dpc-4852	195	7	pmid	pmid	NOUN
dpc-4852	195	8	:	:	PUNCT
dpc-4852	195	9	32176310	32176310	NUM
dpc-4852	195	10	8	8	NUM
dpc-4852	195	11	.	.	PUNCT
dpc-4852	196	1	persson	persson	NOUN
dpc-4852	196	2	msm	msm	NOUN
dpc-4852	196	3	,	,	PUNCT
dpc-4852	196	4	begum	begum	PROPN
dpc-4852	196	5	n	n	CCONJ
dpc-4852	196	6	,	,	PUNCT
dpc-4852	196	7	grainge	grainge	PROPN
dpc-4852	196	8	mj	mj	PROPN
dpc-4852	196	9	,	,	PUNCT
dpc-4852	196	10	et	et	PROPN
dpc-4852	196	11	al	al	PROPN
dpc-4852	196	12	.	.	PUNCT
dpc-4852	197	1	the	the	DET
dpc-4852	197	2	global	global	ADJ
dpc-4852	197	3	incidence	incidence	NOUN
dpc-4852	197	4	of	of	ADP
dpc-4852	197	5	bullous	bullous	ADJ
dpc-4852	197	6	pemphigoid	pemphigoid	NOUN
dpc-4852	197	7	:	:	PUNCT
dpc-4852	197	8	a	a	DET
dpc-4852	197	9	systematic	systematic	ADJ
dpc-4852	197	10	review	review	NOUN
dpc-4852	197	11	and	and	CCONJ
dpc-4852	197	12	meta	meta	ADJ
dpc-4852	197	13	-	-	PUNCT
dpc-4852	197	14	analysis	analysis	NOUN
dpc-4852	197	15	.	.	PUNCT
dpc-4852	198	1	br	br	PROPN
dpc-4852	198	2	j	j	PROPN
dpc-4852	198	3	dermatol	dermatol	NOUN
dpc-4852	198	4	.	.	PUNCT
dpc-4852	199	1	2022;186(3):414	2022;186(3):414	NUM
dpc-4852	199	2	-	-	SYM
dpc-4852	199	3	425	425	NUM
dpc-4852	199	4	.	.	PUNCT
dpc-4852	200	1	doi:10.1111	doi:10.1111	ADJ
dpc-4852	200	2	/	/	SYM
dpc-4852	200	3	bjd.20743	bjd.20743	PROPN
dpc-4852	200	4	.	.	PUNCT
dpc-4852	201	1	pmid	pmid	NOUN
dpc-4852	201	2	:	:	PUNCT
dpc-4852	201	3	34480482	34480482	NUM
dpc-4852	201	4	medication	medication	NOUN
dpc-4852	201	5	,	,	PUNCT
dpc-4852	201	6	especially	especially	ADV
dpc-4852	201	7	vildagliptin	vildagliptin	NOUN
dpc-4852	201	8	and	and	CCONJ
dpc-4852	201	9	,	,	PUNCT
dpc-4852	201	10	to	to	ADP
dpc-4852	201	11	a	a	DET
dpc-4852	201	12	lesser	less	ADJ
dpc-4852	201	13	extent	extent	NOUN
dpc-4852	201	14	,	,	PUNCT
dpc-4852	201	15	linagliptin	linagliptin	ADJ
dpc-4852	201	16	,	,	PUNCT
dpc-4852	201	17	relates	relate	VERB
dpc-4852	201	18	to	to	ADP
dpc-4852	201	19	an	an	DET
dpc-4852	201	20	increased	increase	VERB
dpc-4852	201	21	risk	risk	NOUN
dpc-4852	201	22	of	of	ADP
dpc-4852	201	23	bp	bp	PROPN
dpc-4852	201	24	,	,	PUNCT
dpc-4852	201	25	independently	independently	ADV
dpc-4852	201	26	of	of	ADP
dpc-4852	201	27	the	the	DET
dpc-4852	201	28	metformin	metformin	NOUN
dpc-4852	201	29	intake	intake	NOUN
dpc-4852	201	30	[	[	X
dpc-4852	201	31	42	42	NUM
dpc-4852	201	32	]	]	PUNCT
dpc-4852	201	33	.	.	PUNCT
dpc-4852	202	1	although	although	SCONJ
dpc-4852	202	2	dpp-4	dpp-4	ADV
dpc-4852	202	3	is	be	AUX
dpc-4852	202	4	a	a	DET
dpc-4852	202	5	plasminogen	plasminogen	NOUN
dpc-4852	202	6	receptor	receptor	NOUN
dpc-4852	202	7	expressed	express	VERB
dpc-4852	202	8	in	in	ADP
dpc-4852	202	9	various	various	ADJ
dpc-4852	202	10	tissues	tissue	NOUN
dpc-4852	202	11	,	,	PUNCT
dpc-4852	202	12	including	include	VERB
dpc-4852	202	13	the	the	DET
dpc-4852	202	14	skin	skin	NOUN
dpc-4852	202	15	,	,	PUNCT
dpc-4852	202	16	the	the	DET
dpc-4852	202	17	exact	exact	ADJ
dpc-4852	202	18	mechanism	mechanism	NOUN
dpc-4852	202	19	underlying	underlie	VERB
dpc-4852	202	20	bp	bp	PROPN
dpc-4852	202	21	development	development	NOUN
dpc-4852	202	22	remains	remain	VERB
dpc-4852	202	23	unclear	unclear	ADJ
dpc-4852	202	24	.	.	PUNCT
dpc-4852	203	1	it	it	PRON
dpc-4852	203	2	is	be	AUX
dpc-4852	203	3	proposed	propose	VERB
dpc-4852	203	4	that	that	SCONJ
dpc-4852	203	5	ddp-4	ddp-4	PUNCT
dpc-4852	203	6	inhibitors	inhibitor	NOUN
dpc-4852	203	7	hinder	hinder	VERB
dpc-4852	203	8	the	the	DET
dpc-4852	203	9	plasmin	plasmin	ADJ
dpc-4852	203	10	formation	formation	NOUN
dpc-4852	203	11	,	,	PUNCT
dpc-4852	203	12	which	which	PRON
dpc-4852	203	13	may	may	AUX
dpc-4852	203	14	be	be	AUX
dpc-4852	203	15	responsible	responsible	ADJ
dpc-4852	203	16	for	for	ADP
dpc-4852	203	17	the	the	DET
dpc-4852	203	18	unsuitable	unsuitable	ADJ
dpc-4852	203	19	cleavage	cleavage	NOUN
dpc-4852	203	20	of	of	ADP
dpc-4852	203	21	bp180	bp180	PROPN
dpc-4852	203	22	.	.	PUNCT
dpc-4852	204	1	various	various	ADJ
dpc-4852	204	2	cell	cell	NOUN
dpc-4852	204	3	types	type	NOUN
dpc-4852	204	4	within	within	ADP
dpc-4852	204	5	the	the	DET
dpc-4852	204	6	epidermis	epidermis	NOUN
dpc-4852	204	7	and	and	CCONJ
dpc-4852	204	8	the	the	DET
dpc-4852	204	9	dermis	dermis	NOUN
dpc-4852	204	10	,	,	PUNCT
dpc-4852	204	11	including	include	VERB
dpc-4852	204	12	keratinocytes	keratinocyte	NOUN
dpc-4852	204	13	and	and	CCONJ
dpc-4852	204	14	t	t	PROPN
dpc-4852	204	15	-	-	PUNCT
dpc-4852	204	16	cells	cell	NOUN
dpc-4852	204	17	,	,	PUNCT
dpc-4852	204	18	express	express	VERB
dpc-4852	204	19	dpp-4	dpp-4	NOUN
dpc-4852	204	20	.	.	PUNCT
dpc-4852	205	1	its	its	PRON
dpc-4852	205	2	suppression	suppression	NOUN
dpc-4852	205	3	induces	induce	VERB
dpc-4852	205	4	proinflammatory	proinflammatory	ADJ
dpc-4852	205	5	cytokines	cytokine	NOUN
dpc-4852	205	6	,	,	PUNCT
dpc-4852	205	7	such	such	ADJ
dpc-4852	205	8	as	as	ADP
dpc-4852	205	9	eotaxin	eotaxin	PROPN
dpc-4852	205	10	(	(	PUNCT
dpc-4852	205	11	ccl11	ccl11	PROPN
dpc-4852	205	12	chemokine	chemokine	ADJ
dpc-4852	205	13	)	)	PUNCT
dpc-4852	205	14	,	,	PUNCT
dpc-4852	205	15	and	and	CCONJ
dpc-4852	205	16	leads	lead	VERB
dpc-4852	205	17	to	to	ADP
dpc-4852	205	18	cutaneous	cutaneous	ADJ
dpc-4852	205	19	eosinophil	eosinophil	ADJ
dpc-4852	205	20	activation	activation	NOUN
dpc-4852	205	21	and	and	CCONJ
dpc-4852	205	22	blister	blister	NOUN
dpc-4852	205	23	formation[43	formation[43	NOUN
dpc-4852	205	24	]	]	PUNCT
dpc-4852	205	25	.	.	PUNCT
dpc-4852	206	1	other	other	ADJ
dpc-4852	206	2	mechanisms	mechanism	NOUN
dpc-4852	206	3	that	that	PRON
dpc-4852	206	4	have	have	AUX
dpc-4852	206	5	been	be	AUX
dpc-4852	206	6	proposed	propose	VERB
dpc-4852	206	7	for	for	ADP
dpc-4852	206	8	gliptin	gliptin	PROPN
dpc-4852	206	9	’s	’s	PART
dpc-4852	206	10	mechanism	mechanism	NOUN
dpc-4852	206	11	of	of	ADP
dpc-4852	206	12	action	action	NOUN
dpc-4852	206	13	include	include	VERB
dpc-4852	206	14	the	the	DET
dpc-4852	206	15	modification	modification	NOUN
dpc-4852	206	16	of	of	ADP
dpc-4852	206	17	the	the	DET
dpc-4852	206	18	immune	immune	ADJ
dpc-4852	206	19	response	response	NOUN
dpc-4852	206	20	,	,	PUNCT
dpc-4852	206	21	the	the	DET
dpc-4852	206	22	alteration	alteration	NOUN
dpc-4852	206	23	of	of	ADP
dpc-4852	206	24	the	the	DET
dpc-4852	206	25	antigenic	antigenic	ADJ
dpc-4852	206	26	properties	property	NOUN
dpc-4852	206	27	of	of	ADP
dpc-4852	206	28	the	the	DET
dpc-4852	206	29	epidermal	epidermal	ADJ
dpc-4852	206	30	basement	basement	NOUN
dpc-4852	206	31	membrane	membrane	NOUN
dpc-4852	206	32	zone	zone	NOUN
dpc-4852	206	33	,	,	PUNCT
dpc-4852	206	34	and	and	CCONJ
dpc-4852	206	35	the	the	DET
dpc-4852	206	36	modification	modification	NOUN
dpc-4852	206	37	of	of	ADP
dpc-4852	206	38	the	the	DET
dpc-4852	206	39	activity	activity	NOUN
dpc-4852	206	40	of	of	ADP
dpc-4852	206	41	proteases	protease	NOUN
dpc-4852	206	42	,	,	PUNCT
dpc-4852	206	43	resulting	result	VERB
dpc-4852	206	44	in	in	ADP
dpc-4852	206	45	abnormal	abnormal	ADJ
dpc-4852	206	46	processing	processing	NOUN
dpc-4852	206	47	and/or	and/or	CCONJ
dpc-4852	206	48	destruction	destruction	NOUN
dpc-4852	206	49	of	of	ADP
dpc-4852	206	50	bp180	bp180	ADJ
dpc-4852	206	51	antigen	antigen	NOUN
dpc-4852	207	1	[	[	X
dpc-4852	207	2	44	44	NUM
dpc-4852	207	3	]	]	PUNCT
dpc-4852	207	4	.	.	PUNCT
dpc-4852	208	1	at	at	ADP
dpc-4852	208	2	the	the	DET
dpc-4852	208	3	referral	referral	ADJ
dpc-4852	208	4	center	center	NOUN
dpc-4852	208	5	of	of	ADP
dpc-4852	208	6	autoimmune	autoimmune	ADJ
dpc-4852	208	7	bullous	bullous	ADJ
dpc-4852	208	8	diseases	disease	NOUN
dpc-4852	208	9	of	of	ADP
dpc-4852	208	10	our	our	PRON
dpc-4852	208	11	hospital	hospital	NOUN
dpc-4852	208	12	,	,	PUNCT
dpc-4852	208	13	the	the	DET
dpc-4852	208	14	primary	primary	ADJ
dpc-4852	208	15	treatment	treatment	NOUN
dpc-4852	208	16	strategy	strategy	NOUN
dpc-4852	208	17	is	be	AUX
dpc-4852	208	18	systemic	systemic	ADJ
dpc-4852	208	19	steroid	steroid	NOUN
dpc-4852	208	20	monotherapy	monotherapy	NOUN
dpc-4852	208	21	(	(	PUNCT
dpc-4852	208	22	78.7	78.7	NUM
dpc-4852	208	23	%	%	NOUN
dpc-4852	208	24	of	of	ADP
dpc-4852	208	25	patients	patient	NOUN
dpc-4852	208	26	)	)	PUNCT
dpc-4852	208	27	,	,	PUNCT
dpc-4852	208	28	consistent	consistent	ADJ
dpc-4852	208	29	with	with	ADP
dpc-4852	208	30	european	european	PROPN
dpc-4852	208	31	academy	academy	PROPN
dpc-4852	208	32	of	of	ADP
dpc-4852	208	33	dermatology	dermatology	NOUN
dpc-4852	208	34	and	and	CCONJ
dpc-4852	208	35	venereology	venereology	NOUN
dpc-4852	208	36	(	(	PUNCT
dpc-4852	208	37	eadv	eadv	ADJ
dpc-4852	208	38	)	)	PUNCT
dpc-4852	208	39	guidelines	guideline	NOUN
dpc-4852	208	40	[	[	X
dpc-4852	208	41	45	45	NUM
dpc-4852	208	42	]	]	PUNCT
dpc-4852	208	43	.	.	PUNCT
dpc-4852	209	1	the	the	DET
dpc-4852	209	2	average	average	ADJ
dpc-4852	209	3	time	time	NOUN
dpc-4852	209	4	to	to	PART
dpc-4852	209	5	initiate	initiate	VERB
dpc-4852	209	6	steroid	steroid	NOUN
dpc-4852	209	7	tapering	tapering	NOUN
dpc-4852	209	8	was	be	AUX
dpc-4852	209	9	23	23	NUM
dpc-4852	209	10	days	day	NOUN
dpc-4852	209	11	,	,	PUNCT
dpc-4852	209	12	with	with	ADP
dpc-4852	209	13	a	a	DET
dpc-4852	209	14	total	total	ADJ
dpc-4852	209	15	treatment	treatment	NOUN
dpc-4852	209	16	duration	duration	NOUN
dpc-4852	209	17	of	of	ADP
dpc-4852	209	18	16	16	NUM
dpc-4852	209	19	months	month	NOUN
dpc-4852	209	20	.	.	PUNCT
dpc-4852	210	1	adjuvant	adjuvant	ADJ
dpc-4852	210	2	immunosuppressive	immunosuppressive	ADJ
dpc-4852	210	3	agents	agent	NOUN
dpc-4852	210	4	were	be	AUX
dpc-4852	210	5	avoided	avoid	VERB
dpc-4852	210	6	due	due	ADP
dpc-4852	210	7	to	to	ADP
dpc-4852	210	8	their	their	PRON
dpc-4852	210	9	potential	potential	ADJ
dpc-4852	210	10	severe	severe	ADJ
dpc-4852	210	11	side	side	NOUN
dpc-4852	210	12	effects	effect	NOUN
dpc-4852	210	13	and	and	CCONJ
dpc-4852	210	14	limited	limited	ADJ
dpc-4852	210	15	benefits	benefit	NOUN
dpc-4852	210	16	.	.	PUNCT
dpc-4852	211	1	significantly	significantly	ADV
dpc-4852	211	2	,	,	PUNCT
dpc-4852	211	3	the	the	DET
dpc-4852	211	4	study	study	NOUN
dpc-4852	211	5	revealed	reveal	VERB
dpc-4852	211	6	a	a	DET
dpc-4852	211	7	13.8	13.8	NUM
dpc-4852	211	8	%	%	NOUN
dpc-4852	211	9	mortality	mortality	NOUN
dpc-4852	211	10	rate	rate	NOUN
dpc-4852	211	11	over	over	ADP
dpc-4852	211	12	the	the	DET
dpc-4852	211	13	1	1	NUM
dpc-4852	211	14	-	-	PUNCT
dpc-4852	211	15	year	year	NOUN
dpc-4852	211	16	follow	follow	NOUN
dpc-4852	211	17	-	-	PUNCT
dpc-4852	211	18	up	up	NOUN
dpc-4852	211	19	period	period	NOUN
dpc-4852	211	20	,	,	PUNCT
dpc-4852	211	21	with	with	ADP
dpc-4852	211	22	cardiovascular	cardiovascular	ADJ
dpc-4852	211	23	disease	disease	NOUN
dpc-4852	211	24	,	,	PUNCT
dpc-4852	211	25	sepsis	sepsis	NOUN
dpc-4852	211	26	,	,	PUNCT
dpc-4852	211	27	and	and	CCONJ
dpc-4852	211	28	stroke	stroke	NOUN
dpc-4852	211	29	identified	identify	VERB
dpc-4852	211	30	as	as	ADP
dpc-4852	211	31	the	the	DET
dpc-4852	211	32	primary	primary	ADJ
dpc-4852	211	33	causes	cause	NOUN
dpc-4852	211	34	.	.	PUNCT
dpc-4852	212	1	it	it	PRON
dpc-4852	212	2	is	be	AUX
dpc-4852	212	3	noteworthy	noteworthy	ADJ
dpc-4852	212	4	that	that	SCONJ
dpc-4852	212	5	the	the	DET
dpc-4852	212	6	prevalence	prevalence	NOUN
dpc-4852	212	7	of	of	ADP
dpc-4852	212	8	sepsis	sepsis	NOUN
dpc-4852	212	9	as	as	ADP
dpc-4852	212	10	a	a	DET
dpc-4852	212	11	cause	cause	NOUN
dpc-4852	212	12	of	of	ADP
dpc-4852	212	13	death	death	NOUN
dpc-4852	212	14	may	may	AUX
dpc-4852	212	15	have	have	AUX
dpc-4852	212	16	been	be	AUX
dpc-4852	212	17	influenced	influence	VERB
dpc-4852	212	18	by	by	ADP
dpc-4852	212	19	the	the	DET
dpc-4852	212	20	recent	recent	ADJ
dpc-4852	212	21	covid-19	covid-19	PROPN
dpc-4852	212	22	pandemic	pandemic	NOUN
dpc-4852	212	23	.	.	PUNCT
dpc-4852	213	1	overall	overall	ADJ
dpc-4852	213	2	,	,	PUNCT
dpc-4852	213	3	disease	disease	NOUN
dpc-4852	213	4	control	control	NOUN
dpc-4852	213	5	corresponds	correspond	VERB
dpc-4852	213	6	either	either	CCONJ
dpc-4852	213	7	to	to	ADP
dpc-4852	213	8	no	no	DET
dpc-4852	213	9	new	new	ADJ
dpc-4852	213	10	lesion	lesion	NOUN
dpc-4852	213	11	occurrence	occurrence	NOUN
dpc-4852	213	12	or	or	CCONJ
dpc-4852	213	13	pruritus	pruritus	PROPN
dpc-4852	213	14	or	or	CCONJ
dpc-4852	213	15	established	establish	VERB
dpc-4852	213	16	bp	bp	PROPN
dpc-4852	213	17	lesions	lesion	NOUN
dpc-4852	213	18	under	under	ADP
dpc-4852	213	19	the	the	DET
dpc-4852	213	20	healing	healing	NOUN
dpc-4852	213	21	process	process	NOUN
dpc-4852	213	22	[	[	X
dpc-4852	213	23	46	46	NUM
dpc-4852	213	24	]	]	PUNCT
dpc-4852	213	25	.	.	PUNCT
dpc-4852	214	1	the	the	DET
dpc-4852	214	2	average	average	ADJ
dpc-4852	214	3	time	time	NOUN
dpc-4852	214	4	to	to	PART
dpc-4852	214	5	start	start	VERB
dpc-4852	214	6	tapering	taper	VERB
dpc-4852	214	7	(	(	PUNCT
dpc-4852	214	8	disease	disease	NOUN
dpc-4852	214	9	control	control	NOUN
dpc-4852	214	10	)	)	PUNCT
dpc-4852	214	11	in	in	ADP
dpc-4852	214	12	our	our	PRON
dpc-4852	214	13	study	study	NOUN
dpc-4852	214	14	was	be	AUX
dpc-4852	214	15	on	on	ADP
dpc-4852	214	16	day	day	NOUN
dpc-4852	214	17	23	23	NUM
dpc-4852	214	18	.	.	PUNCT
dpc-4852	215	1	the	the	DET
dpc-4852	215	2	mean	mean	ADJ
dpc-4852	215	3	duration	duration	NOUN
dpc-4852	215	4	of	of	ADP
dpc-4852	215	5	maintenance	maintenance	NOUN
dpc-4852	215	6	therapy	therapy	NOUN
dpc-4852	215	7	(	(	PUNCT
dpc-4852	215	8	minimal	minimal	ADJ
dpc-4852	215	9	0.1	0.1	NUM
dpc-4852	215	10	mg	mg	PROPN
dpc-4852	215	11	/	/	SYM
dpc-4852	215	12	kg	kg	NOUN
dpc-4852	215	13	per	per	ADP
dpc-4852	215	14	day	day	NOUN
dpc-4852	215	15	)	)	PUNCT
dpc-4852	215	16	was	be	AUX
dpc-4852	215	17	one	one	NUM
dpc-4852	215	18	year	year	NOUN
dpc-4852	215	19	and	and	CCONJ
dpc-4852	215	20	two	two	NUM
dpc-4852	215	21	months	month	NOUN
dpc-4852	215	22	(	(	PUNCT
dpc-4852	215	23	13.8	13.8	NUM
dpc-4852	215	24	months	month	NOUN
dpc-4852	215	25	)	)	PUNCT
dpc-4852	215	26	.	.	PUNCT
dpc-4852	216	1	overall	overall	ADV
dpc-4852	216	2	,	,	PUNCT
dpc-4852	216	3	the	the	DET
dpc-4852	216	4	average	average	ADJ
dpc-4852	216	5	total	total	ADJ
dpc-4852	216	6	treatment	treatment	NOUN
dpc-4852	216	7	duration	duration	NOUN
dpc-4852	216	8	,	,	PUNCT
dpc-4852	216	9	including	include	VERB
dpc-4852	216	10	the	the	DET
dpc-4852	216	11	consolidation	consolidation	NOUN
dpc-4852	216	12	phase	phase	NOUN
dpc-4852	216	13	and	and	CCONJ
dpc-4852	216	14	maintenance	maintenance	NOUN
dpc-4852	216	15	treatment	treatment	NOUN
dpc-4852	216	16	,	,	PUNCT
dpc-4852	216	17	was	be	AUX
dpc-4852	216	18	sixteen	sixteen	NUM
dpc-4852	216	19	months	month	NOUN
dpc-4852	216	20	.	.	PUNCT
dpc-4852	217	1	this	this	DET
dpc-4852	217	2	total	total	ADJ
dpc-4852	217	3	treatment	treatment	NOUN
dpc-4852	217	4	duration	duration	NOUN
dpc-4852	217	5	was	be	AUX
dpc-4852	217	6	longer	long	ADJ
dpc-4852	217	7	than	than	ADP
dpc-4852	217	8	that	that	PRON
dpc-4852	217	9	proposed	propose	VERB
dpc-4852	217	10	by	by	ADP
dpc-4852	217	11	experts	expert	NOUN
dpc-4852	217	12	(	(	PUNCT
dpc-4852	217	13	9	9	NUM
dpc-4852	217	14	-	-	SYM
dpc-4852	217	15	12	12	NUM
dpc-4852	217	16	months	month	NOUN
dpc-4852	217	17	)	)	PUNCT
dpc-4852	218	1	[	[	X
dpc-4852	218	2	45	45	NUM
dpc-4852	218	3	]	]	PUNCT
dpc-4852	218	4	.	.	PUNCT
dpc-4852	219	1	additionally	additionally	ADV
dpc-4852	219	2	,	,	PUNCT
dpc-4852	219	3	the	the	DET
dpc-4852	219	4	relapse	relapse	NOUN
dpc-4852	219	5	rate	rate	NOUN
dpc-4852	219	6	(	(	PUNCT
dpc-4852	219	7	36	36	NUM
dpc-4852	219	8	%	%	NOUN
dpc-4852	219	9	)	)	PUNCT
dpc-4852	219	10	found	find	VERB
dpc-4852	219	11	in	in	ADP
dpc-4852	219	12	the	the	DET
dpc-4852	219	13	study	study	NOUN
dpc-4852	219	14	aligns	align	VERB
dpc-4852	219	15	well	well	ADV
dpc-4852	219	16	with	with	ADP
dpc-4852	219	17	data	datum	NOUN
dpc-4852	219	18	from	from	ADP
dpc-4852	219	19	the	the	DET
dpc-4852	219	20	current	current	ADJ
dpc-4852	219	21	literature	literature	NOUN
dpc-4852	219	22	,	,	PUNCT
dpc-4852	219	23	which	which	PRON
dpc-4852	219	24	demonstrates	demonstrate	VERB
dpc-4852	219	25	a	a	DET
dpc-4852	219	26	range	range	NOUN
dpc-4852	219	27	of	of	ADP
dpc-4852	219	28	relapse	relapse	NOUN
dpc-4852	219	29	rates	rate	NOUN
dpc-4852	219	30	from	from	ADP
dpc-4852	219	31	27.87	27.87	NUM
dpc-4852	219	32	%	%	NOUN
dpc-4852	219	33	to	to	ADP
dpc-4852	219	34	53	53	NUM
dpc-4852	219	35	%	%	NOUN
dpc-4852	219	36	.	.	PUNCT
dpc-4852	220	1	interestingly	interestingly	ADV
dpc-4852	220	2	,	,	PUNCT
dpc-4852	220	3	most	most	ADJ
dpc-4852	220	4	relapses	relapse	NOUN
dpc-4852	220	5	tended	tend	VERB
dpc-4852	220	6	to	to	PART
dpc-4852	220	7	occur	occur	VERB
dpc-4852	220	8	early	early	ADV
dpc-4852	220	9	,	,	PUNCT
dpc-4852	220	10	within	within	ADP
dpc-4852	220	11	six	six	NUM
dpc-4852	220	12	months	month	NOUN
dpc-4852	220	13	during	during	ADP
dpc-4852	220	14	the	the	DET
dpc-4852	220	15	remission	remission	NOUN
dpc-4852	220	16	[	[	X
dpc-4852	220	17	47	47	NUM
dpc-4852	220	18	,	,	PUNCT
dpc-4852	220	19	48	48	NUM
dpc-4852	220	20	]	]	PUNCT
dpc-4852	220	21	.	.	PUNCT
dpc-4852	221	1	a	a	DET
dpc-4852	221	2	relapse	relapse	NOUN
dpc-4852	221	3	of	of	ADP
dpc-4852	221	4	bp	bp	PROPN
dpc-4852	221	5	is	be	AUX
dpc-4852	221	6	defined	define	VERB
dpc-4852	221	7	as	as	ADP
dpc-4852	221	8	the	the	DET
dpc-4852	221	9	appearance	appearance	NOUN
dpc-4852	221	10	of	of	ADP
dpc-4852	221	11	at	at	ADV
dpc-4852	221	12	least	least	ADV
dpc-4852	221	13	three	three	NUM
dpc-4852	221	14	new	new	ADJ
dpc-4852	221	15	lesions	lesion	NOUN
dpc-4852	221	16	within	within	ADP
dpc-4852	221	17	one	one	NUM
dpc-4852	221	18	month	month	NOUN
dpc-4852	221	19	or	or	CCONJ
dpc-4852	221	20	one	one	NUM
dpc-4852	221	21	large	large	ADJ
dpc-4852	221	22	(	(	PUNCT
dpc-4852	221	23	diameter	diameter	NOUN
dpc-4852	221	24	larger	large	ADJ
dpc-4852	221	25	than	than	ADP
dpc-4852	221	26	10	10	NUM
dpc-4852	221	27	cm	cm	NOUN
dpc-4852	221	28	)	)	PUNCT
dpc-4852	221	29	lesion	lesion	NOUN
dpc-4852	221	30	that	that	PRON
dpc-4852	221	31	does	do	AUX
dpc-4852	221	32	not	not	PART
dpc-4852	221	33	heal	heal	VERB
dpc-4852	221	34	in	in	ADP
dpc-4852	221	35	one	one	NUM
dpc-4852	221	36	week	week	NOUN
dpc-4852	221	37	,	,	PUNCT
dpc-4852	221	38	or	or	CCONJ
dpc-4852	221	39	the	the	DET
dpc-4852	221	40	extension	extension	NOUN
dpc-4852	221	41	of	of	ADP
dpc-4852	221	42	original	original	ADJ
dpc-4852	221	43	exanthem	exanthem	NOUN
dpc-4852	221	44	or	or	CCONJ
dpc-4852	221	45	daily	daily	ADJ
dpc-4852	221	46	pruritus	pruritus	NOUN
dpc-4852	221	47	in	in	ADP
dpc-4852	221	48	patients	patient	NOUN
dpc-4852	221	49	in	in	ADP
dpc-4852	221	50	remission	remission	NOUN
dpc-4852	221	51	[	[	X
dpc-4852	221	52	49	49	NUM
dpc-4852	221	53	]	]	PUNCT
dpc-4852	221	54	.	.	PUNCT
dpc-4852	222	1	questions	question	NOUN
dpc-4852	222	2	that	that	PRON
dpc-4852	222	3	emerge	emerge	VERB
dpc-4852	222	4	are	be	AUX
dpc-4852	222	5	how	how	SCONJ
dpc-4852	222	6	to	to	PART
dpc-4852	222	7	identify	identify	VERB
dpc-4852	222	8	patients	patient	NOUN
dpc-4852	222	9	at	at	ADP
dpc-4852	222	10	a	a	DET
dpc-4852	222	11	higher	high	ADJ
dpc-4852	222	12	risk	risk	NOUN
dpc-4852	222	13	of	of	ADP
dpc-4852	222	14	relapse	relapse	NOUN
dpc-4852	222	15	and	and	CCONJ
dpc-4852	222	16	what	what	PRON
dpc-4852	222	17	the	the	DET
dpc-4852	222	18	optimal	optimal	ADJ
dpc-4852	222	19	therapeutic	therapeutic	ADJ
dpc-4852	222	20	option	option	NOUN
dpc-4852	222	21	for	for	ADP
dpc-4852	222	22	the	the	DET
dpc-4852	222	23	management	management	NOUN
dpc-4852	222	24	of	of	ADP
dpc-4852	222	25	a	a	DET
dpc-4852	222	26	relapse	relapse	NOUN
dpc-4852	222	27	is	be	AUX
dpc-4852	222	28	.	.	PUNCT
dpc-4852	223	1	several	several	ADJ
dpc-4852	223	2	studies	study	NOUN
dpc-4852	223	3	have	have	AUX
dpc-4852	223	4	shown	show	VERB
dpc-4852	223	5	that	that	SCONJ
dpc-4852	223	6	patients	patient	NOUN
dpc-4852	223	7	with	with	ADP
dpc-4852	223	8	original	original	ADJ
dpc-4852	223	9	article	article	NOUN
dpc-4852	223	10	|	|	ADV
dpc-4852	223	11	dermatol	dermatol	ADJ
dpc-4852	223	12	pract	pract	NOUN
dpc-4852	223	13	concept	concept	NOUN
dpc-4852	223	14	.	.	PUNCT
dpc-4852	224	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	224	2	7	7	NUM
dpc-4852	224	3	23	23	NUM
dpc-4852	224	4	.	.	PUNCT
dpc-4852	225	1	fairley	fairley	PROPN
dpc-4852	225	2	ja	ja	PROPN
dpc-4852	225	3	,	,	PUNCT
dpc-4852	225	4	burnett	burnett	PROPN
dpc-4852	225	5	ct	ct	PROPN
dpc-4852	225	6	,	,	PUNCT
dpc-4852	225	7	fu	fu	PROPN
dpc-4852	225	8	cl	cl	NOUN
dpc-4852	225	9	,	,	PUNCT
dpc-4852	225	10	et	et	PROPN
dpc-4852	225	11	al	al	PROPN
dpc-4852	225	12	.	.	PUNCT
dpc-4852	226	1	a	a	DET
dpc-4852	226	2	pathogenic	pathogenic	ADJ
dpc-4852	226	3	role	role	NOUN
dpc-4852	226	4	for	for	ADP
dpc-4852	226	5	ige	ige	PROPN
dpc-4852	226	6	in	in	ADP
dpc-4852	226	7	autoimmunity	autoimmunity	NOUN
dpc-4852	226	8	:	:	PUNCT
dpc-4852	226	9	bullous	bullous	ADJ
dpc-4852	226	10	pemphigoid	pemphigoid	PROPN
dpc-4852	226	11	ige	ige	PROPN
dpc-4852	226	12	reproduces	reproduce	VERB
dpc-4852	226	13	the	the	DET
dpc-4852	226	14	early	early	ADJ
dpc-4852	226	15	phase	phase	NOUN
dpc-4852	226	16	of	of	ADP
dpc-4852	226	17	lesion	lesion	NOUN
dpc-4852	226	18	development	development	NOUN
dpc-4852	226	19	in	in	ADP
dpc-4852	226	20	human	human	ADJ
dpc-4852	226	21	skin	skin	NOUN
dpc-4852	226	22	grafted	graft	VERB
dpc-4852	226	23	to	to	ADP
dpc-4852	226	24	nu	nu	PROPN
dpc-4852	226	25	/	/	SYM
dpc-4852	226	26	nu	nu	NOUN
dpc-4852	226	27	mice	mouse	NOUN
dpc-4852	226	28	.	.	PUNCT
dpc-4852	227	1	j	j	PROPN
dpc-4852	227	2	invest	invest	VERB
dpc-4852	227	3	dermatol	dermatol	NOUN
dpc-4852	227	4	.	.	PUNCT
dpc-4852	228	1	2007;127(11):2605	2007;127(11):2605	NUM
dpc-4852	228	2	-	-	SYM
dpc-4852	228	3	2611	2611	NUM
dpc-4852	228	4	.	.	PUNCT
dpc-4852	229	1	doi	doi	NOUN
dpc-4852	229	2	:	:	PUNCT
dpc-4852	229	3	10.1038	10.1038	NUM
dpc-4852	229	4	/sj.jid.5700958	/sj.jid.5700958	PUNCT
dpc-4852	229	5	.	.	PUNCT
dpc-4852	230	1	pmid	pmid	NOUN
dpc-4852	230	2	:	:	PUNCT
dpc-4852	230	3	17611576	17611576	NUM
dpc-4852	230	4	24	24	NUM
dpc-4852	230	5	.	.	PUNCT
dpc-4852	231	1	borradori	borradori	PROPN
dpc-4852	231	2	l	l	PROPN
dpc-4852	231	3	,	,	PUNCT
dpc-4852	231	4	van	van	PROPN
dpc-4852	231	5	beek	beek	PROPN
dpc-4852	231	6	n	n	CCONJ
dpc-4852	231	7	,	,	PUNCT
dpc-4852	231	8	feliciani	feliciani	PROPN
dpc-4852	231	9	c	c	X
dpc-4852	231	10	,	,	PUNCT
dpc-4852	231	11	et	et	PROPN
dpc-4852	231	12	al	al	PROPN
dpc-4852	231	13	.	.	PROPN
dpc-4852	231	14	updated	update	VERB
dpc-4852	231	15	s2	s2	PROPN
dpc-4852	231	16	k	k	PROPN
dpc-4852	231	17	guidelines	guideline	NOUN
dpc-4852	231	18	for	for	ADP
dpc-4852	231	19	the	the	DET
dpc-4852	231	20	management	management	NOUN
dpc-4852	231	21	of	of	ADP
dpc-4852	231	22	bullous	bullous	ADJ
dpc-4852	231	23	pemphigoid	pemphigoid	NOUN
dpc-4852	231	24	initiated	initiate	VERB
dpc-4852	231	25	by	by	ADP
dpc-4852	231	26	the	the	DET
dpc-4852	231	27	european	european	PROPN
dpc-4852	231	28	academy	academy	PROPN
dpc-4852	231	29	of	of	ADP
dpc-4852	231	30	dermatology	dermatology	NOUN
dpc-4852	231	31	and	and	CCONJ
dpc-4852	231	32	venereology	venereology	NOUN
dpc-4852	231	33	(	(	PUNCT
dpc-4852	231	34	eadv	eadv	ADJ
dpc-4852	231	35	)	)	PUNCT
dpc-4852	231	36	.	.	PUNCT
dpc-4852	232	1	j	j	PROPN
dpc-4852	232	2	eur	eur	PROPN
dpc-4852	232	3	acad	acad	PROPN
dpc-4852	232	4	dermatol	dermatol	NOUN
dpc-4852	232	5	venereol	venereol	NOUN
dpc-4852	232	6	.	.	PUNCT
dpc-4852	233	1	2022;36(10):1689	2022;36(10):1689	X
dpc-4852	233	2	-	-	SYM
dpc-4852	233	3	1704	1704	NUM
dpc-4852	233	4	.	.	PUNCT
dpc-4852	234	1	doi	doi	NOUN
dpc-4852	234	2	:	:	PUNCT
dpc-4852	234	3	10.1111	10.1111	NUM
dpc-4852	234	4	/	/	SYM
dpc-4852	234	5	jdv.18220	jdv.18220	NOUN
dpc-4852	234	6	.	.	PUNCT
dpc-4852	235	1	pmid	pmid	NOUN
dpc-4852	235	2	:	:	PUNCT
dpc-4852	235	3	35766904	35766904	NUM
dpc-4852	235	4	25	25	NUM
dpc-4852	235	5	.	.	PUNCT
dpc-4852	236	1	lamberts	lamberts	PROPN
dpc-4852	236	2	a	a	PRON
dpc-4852	236	3	,	,	PUNCT
dpc-4852	236	4	meijer	meijer	PROPN
dpc-4852	236	5	jm	jm	PROPN
dpc-4852	236	6	,	,	PUNCT
dpc-4852	236	7	jonkman	jonkman	NOUN
dpc-4852	236	8	mf	mf	NOUN
dpc-4852	236	9	.	.	PROPN
dpc-4852	236	10	nonbullous	nonbullous	ADJ
dpc-4852	236	11	pemphigoid	pemphigoid	ADV
dpc-4852	236	12	:	:	PUNCT
dpc-4852	236	13	a	a	DET
dpc-4852	236	14	systematic	systematic	ADJ
dpc-4852	236	15	review	review	NOUN
dpc-4852	236	16	.	.	PUNCT
dpc-4852	237	1	j	j	PROPN
dpc-4852	237	2	am	be	AUX
dpc-4852	237	3	acad	acad	ADJ
dpc-4852	237	4	dermatol	dermatol	NOUN
dpc-4852	237	5	.	.	PUNCT
dpc-4852	238	1	2018;78(5):989	2018;78(5):989	PROPN
dpc-4852	238	2	-	-	PUNCT
dpc-4852	238	3	995	995	NUM
dpc-4852	238	4	.	.	PUNCT
dpc-4852	239	1	e2	e2	PROPN
dpc-4852	239	2	.	.	PUNCT
dpc-4852	239	3	doi:10.1016	doi:10.1016	PROPN
dpc-4852	239	4	/	/	SYM
dpc-4852	239	5	j.jaad.2017.10.035	j.jaad.2017.10.035	PROPN
dpc-4852	239	6	pmid	pmid	PROPN
dpc-4852	239	7	:	:	PUNCT
dpc-4852	239	8	29102490	29102490	NUM
dpc-4852	239	9	26	26	NUM
dpc-4852	239	10	.	.	PUNCT
dpc-4852	240	1	joly	joly	PROPN
dpc-4852	240	2	p	p	PROPN
dpc-4852	240	3	,	,	PUNCT
dpc-4852	240	4	tedbirt	tedbirt	PROPN
dpc-4852	240	5	b.	b.	PROPN
dpc-4852	240	6	topical	topical	ADJ
dpc-4852	240	7	corticosteroids	corticosteroid	NOUN
dpc-4852	240	8	in	in	ADP
dpc-4852	240	9	bullous	bullous	ADJ
dpc-4852	240	10	pemphigoid	pemphigoid	NOUN
dpc-4852	240	11	:	:	PUNCT
dpc-4852	240	12	what	what	PRON
dpc-4852	240	13	we	we	PRON
dpc-4852	240	14	have	have	AUX
dpc-4852	240	15	learned	learn	VERB
dpc-4852	240	16	after	after	ADP
dpc-4852	240	17	two	two	NUM
dpc-4852	240	18	decades	decade	NOUN
dpc-4852	240	19	.	.	PUNCT
dpc-4852	241	1	ann	ann	PROPN
dpc-4852	241	2	dermatol	dermatol	NOUN
dpc-4852	241	3	venereol	venereol	NOUN
dpc-4852	241	4	.	.	PUNCT
dpc-4852	242	1	2022;149(2):79	2022;149(2):79	NUM
dpc-4852	242	2	-	-	SYM
dpc-4852	242	3	80	80	NUM
dpc-4852	242	4	.	.	PUNCT
dpc-4852	243	1	doi	doi	NOUN
dpc-4852	243	2	:	:	PUNCT
dpc-4852	243	3	10.1016	10.1016	NUM
dpc-4852	243	4	/	/	SYM
dpc-4852	243	5	j.annder.2022.01.009	j.annder.2022.01.009	PROPN
dpc-4852	243	6	.	.	PUNCT
dpc-4852	244	1	pmid	pmid	NOUN
dpc-4852	244	2	:	:	PUNCT
dpc-4852	244	3	35282895	35282895	NUM
dpc-4852	244	4	.	.	PUNCT
dpc-4852	245	1	27	27	NUM
dpc-4852	245	2	.	.	X
dpc-4852	246	1	bağcı	bağcı	PROPN
dpc-4852	246	2	is	be	AUX
dpc-4852	246	3	,	,	PUNCT
dpc-4852	246	4	horváth	horváth	ADV
dpc-4852	246	5	on	on	ADP
dpc-4852	246	6	,	,	PUNCT
dpc-4852	246	7	ruzicka	ruzicka	PROPN
dpc-4852	246	8	t	t	PROPN
dpc-4852	246	9	,	,	PUNCT
dpc-4852	246	10	et.al	et.al	VERB
dpc-4852	246	11	bullous	bullous	ADJ
dpc-4852	246	12	pemphigoid	pemphigoid	NOUN
dpc-4852	246	13	.	.	PUNCT
dpc-4852	247	1	autoimmun	autoimmun	PROPN
dpc-4852	247	2	rev	rev	PROPN
dpc-4852	247	3	.	.	PROPN
dpc-4852	247	4	2017;16(5):445	2017;16(5):445	PROPN
dpc-4852	247	5	-	-	PUNCT
dpc-4852	247	6	455	455	NUM
dpc-4852	247	7	.	.	PUNCT
dpc-4852	248	1	doi	doi	NOUN
dpc-4852	248	2	:	:	PUNCT
dpc-4852	248	3	10.1016	10.1016	NUM
dpc-4852	248	4	/	/	SYM
dpc-4852	248	5	j.autrev	j.autrev	PROPN
dpc-4852	248	6	.2017.03.010	.2017.03.010	PROPN
dpc-4852	248	7	.	.	PUNCT
dpc-4852	249	1	pmid	pmid	NOUN
dpc-4852	249	2	:	:	PUNCT
dpc-4852	249	3	28286109	28286109	NUM
dpc-4852	249	4	.	.	PUNCT
dpc-4852	250	1	28	28	NUM
dpc-4852	250	2	.	.	PUNCT
dpc-4852	251	1	oren	oren	NOUN
dpc-4852	251	2	-	-	PUNCT
dpc-4852	251	3	shabtai	shabtai	PROPN
dpc-4852	251	4	m	m	PROPN
dpc-4852	251	5	,	,	PUNCT
dpc-4852	251	6	mimouni	mimouni	PROPN
dpc-4852	251	7	d	d	PROPN
dpc-4852	251	8	,	,	PUNCT
dpc-4852	251	9	nosrati	nosrati	PROPN
dpc-4852	251	10	a	a	X
dpc-4852	251	11	,	,	PUNCT
dpc-4852	251	12	et	et	PROPN
dpc-4852	251	13	al	al	PROPN
dpc-4852	251	14	.	.	PUNCT
dpc-4852	251	15	biological	biological	ADJ
dpc-4852	251	16	treatment	treatment	NOUN
dpc-4852	251	17	for	for	ADP
dpc-4852	251	18	bullous	bullous	ADJ
dpc-4852	251	19	pemphigoid	pemphigoid	NOUN
dpc-4852	251	20	.	.	PUNCT
dpc-4852	252	1	front	front	ADJ
dpc-4852	252	2	immunol	immunol	NOUN
dpc-4852	252	3	.	.	PUNCT
dpc-4852	253	1	2023;14:1157250	2023;14:1157250	NUM
dpc-4852	253	2	.	.	PUNCT
dpc-4852	254	1	published	publish	VERB
dpc-4852	254	2	2023	2023	NUM
dpc-4852	254	3	apr	apr	NOUN
dpc-4852	254	4	27	27	NUM
dpc-4852	254	5	.	.	PUNCT
dpc-4852	255	1	doi	doi	NOUN
dpc-4852	255	2	:	:	PUNCT
dpc-4852	255	3	10.3389	10.3389	NUM
dpc-4852	255	4	/	/	SYM
dpc-4852	255	5	fimmu.2023.1157250	fimmu.2023.1157250	PROPN
dpc-4852	255	6	.	.	PUNCT
dpc-4852	256	1	pmid	pmid	NOUN
dpc-4852	256	2	:	:	PUNCT
dpc-4852	256	3	37180101	37180101	NUM
dpc-4852	256	4	.	.	PUNCT
dpc-4852	257	1	29	29	NUM
dpc-4852	257	2	.	.	PUNCT
dpc-4852	258	1	liu	liu	PROPN
dpc-4852	258	2	z	z	PROPN
dpc-4852	258	3	,	,	PUNCT
dpc-4852	258	4	diaz	diaz	PROPN
dpc-4852	258	5	la	la	PROPN
dpc-4852	258	6	,	,	PUNCT
dpc-4852	258	7	troy	troy	PROPN
dpc-4852	258	8	jl	jl	PROPN
dpc-4852	258	9	,	,	PUNCT
dpc-4852	258	10	et	et	PROPN
dpc-4852	258	11	al	al	PROPN
dpc-4852	258	12	.	.	PUNCT
dpc-4852	259	1	a	a	DET
dpc-4852	259	2	passive	passive	ADJ
dpc-4852	259	3	transfer	transfer	NOUN
dpc-4852	259	4	model	model	NOUN
dpc-4852	259	5	of	of	ADP
dpc-4852	259	6	the	the	DET
dpc-4852	259	7	organ	organ	NOUN
dpc-4852	259	8	-	-	PUNCT
dpc-4852	259	9	specific	specific	ADJ
dpc-4852	259	10	autoimmune	autoimmune	ADJ
dpc-4852	259	11	disease	disease	NOUN
dpc-4852	259	12	,	,	PUNCT
dpc-4852	259	13	bullous	bullous	ADJ
dpc-4852	259	14	pemphigoid	pemphigoid	NOUN
dpc-4852	259	15	,	,	PUNCT
dpc-4852	259	16	using	use	VERB
dpc-4852	259	17	antibodies	antibody	NOUN
dpc-4852	259	18	generated	generate	VERB
dpc-4852	259	19	against	against	ADP
dpc-4852	259	20	the	the	DET
dpc-4852	259	21	hemidesmosomal	hemidesmosomal	PROPN
dpc-4852	259	22	antigen	antigen	PROPN
dpc-4852	259	23	,	,	PUNCT
dpc-4852	259	24	bp180	bp180	PROPN
dpc-4852	259	25	.	.	PUNCT
dpc-4852	260	1	j	j	PROPN
dpc-4852	260	2	clin	clin	PROPN
dpc-4852	260	3	invest	invest	PROPN
dpc-4852	260	4	.	.	PUNCT
dpc-4852	261	1	1993;92(5):2480	1993;92(5):2480	NUM
dpc-4852	261	2	-	-	SYM
dpc-4852	261	3	2488	2488	NUM
dpc-4852	261	4	.	.	PUNCT
dpc-4852	262	1	doi	doi	NOUN
dpc-4852	262	2	:	:	PUNCT
dpc-4852	262	3	  	  	SPACE
dpc-4852	262	4	10.1172	10.1172	NUM
dpc-4852	262	5	/jci116856	/jci116856	PUNCT
dpc-4852	262	6	.	.	PUNCT
dpc-4852	263	1	pmcid	pmcid	NOUN
dpc-4852	263	2	:	:	PUNCT
dpc-4852	263	3	 	 	SPACE
dpc-4852	263	4	pmc288433	pmc288433	NOUN
dpc-4852	263	5	.	.	PUNCT
dpc-4852	264	1	30	30	NUM
dpc-4852	264	2	.	.	PUNCT
dpc-4852	265	1	phachu	phachu	PROPN
dpc-4852	265	2	d	d	PROPN
dpc-4852	265	3	,	,	PUNCT
dpc-4852	265	4	elali	elali	PROPN
dpc-4852	265	5	i	i	PROPN
dpc-4852	265	6	,	,	PUNCT
dpc-4852	265	7	garay	garay	NOUN
dpc-4852	265	8	b	b	PROPN
dpc-4852	265	9	,	,	PUNCT
dpc-4852	265	10	et.al	et.al	VERB
dpc-4852	265	11	therapeutic	therapeutic	ADJ
dpc-4852	265	12	plasma	plasma	NOUN
dpc-4852	265	13	exchange	exchange	NOUN
dpc-4852	265	14	as	as	ADP
dpc-4852	265	15	adjunct	adjunct	ADJ
dpc-4852	265	16	therapy	therapy	NOUN
dpc-4852	265	17	for	for	ADP
dpc-4852	265	18	bullous	bullous	ADJ
dpc-4852	265	19	pemphigoid	pemphigoid	NOUN
dpc-4852	265	20	.	.	PUNCT
dpc-4852	266	1	j	j	PROPN
dpc-4852	266	2	clin	clin	PROPN
dpc-4852	266	3	apher	apher	ADV
dpc-4852	266	4	.	.	PUNCT
dpc-4852	267	1	2022;37(6):594	2022;37(6):594	NUM
dpc-4852	267	2	-	-	PUNCT
dpc-4852	267	3	596	596	NUM
dpc-4852	267	4	.	.	PUNCT
dpc-4852	268	1	doi	doi	NOUN
dpc-4852	268	2	:	:	PUNCT
dpc-4852	268	3	10.1002	10.1002	NUM
dpc-4852	268	4	/	/	SYM
dpc-4852	268	5	jca.22017	jca.22017	PROPN
dpc-4852	268	6	.	.	PUNCT
dpc-4852	269	1	pmid	pmid	NOUN
dpc-4852	269	2	:	:	PUNCT
dpc-4852	269	3	3614	3614	NUM
dpc-4852	269	4	8920	8920	NUM
dpc-4852	269	5	.	.	PUNCT
dpc-4852	270	1	31	31	NUM
dpc-4852	270	2	.	.	PUNCT
dpc-4852	271	1	skrivankova	skrivankova	PROPN
dpc-4852	271	2	vw	vw	PROPN
dpc-4852	271	3	,	,	PUNCT
dpc-4852	271	4	richmond	richmond	PROPN
dpc-4852	271	5	rc	rc	PROPN
dpc-4852	271	6	,	,	PUNCT
dpc-4852	271	7	woolf	woolf	PROPN
dpc-4852	271	8	bar	bar	PROPN
dpc-4852	271	9	,	,	PUNCT
dpc-4852	271	10	et	et	PROPN
dpc-4852	271	11	al	al	PROPN
dpc-4852	271	12	.	.	PUNCT
dpc-4852	272	1	strengthening	strengthen	VERB
dpc-4852	272	2	the	the	DET
dpc-4852	272	3	reporting	reporting	NOUN
dpc-4852	272	4	of	of	ADP
dpc-4852	272	5	observational	observational	ADJ
dpc-4852	272	6	studies	study	NOUN
dpc-4852	272	7	in	in	ADP
dpc-4852	272	8	epidemiology	epidemiology	NOUN
dpc-4852	272	9	using	use	VERB
dpc-4852	272	10	mendelian	mendelian	ADJ
dpc-4852	272	11	randomization	randomization	NOUN
dpc-4852	272	12	:	:	PUNCT
dpc-4852	272	13	the	the	DET
dpc-4852	272	14	strobe	strobe	PROPN
dpc-4852	272	15	-	-	PUNCT
dpc-4852	272	16	mr	mr	PROPN
dpc-4852	272	17	statement	statement	NOUN
dpc-4852	272	18	.	.	PUNCT
dpc-4852	273	1	jama	jama	PROPN
dpc-4852	273	2	.	.	PUNCT
dpc-4852	274	1	2021;326(16):1614	2021;326(16):1614	NUM
dpc-4852	274	2	-	-	SYM
dpc-4852	274	3	1621	1621	NUM
dpc-4852	274	4	.	.	PUNCT
dpc-4852	275	1	doi:10.1001	doi:10.1001	PROPN
dpc-4852	275	2	/	/	SYM
dpc-4852	275	3	jama.2021.18236	jama.2021.18236	PROPN
dpc-4852	275	4	.	.	PUNCT
dpc-4852	276	1	pmid	pmid	NOUN
dpc-4852	276	2	:	:	PUNCT
dpc-4852	276	3	34698778	34698778	NUM
dpc-4852	276	4	.	.	PUNCT
dpc-4852	277	1	32	32	NUM
dpc-4852	277	2	.	.	PUNCT
dpc-4852	278	1	masmoudi	masmoudi	PROPN
dpc-4852	278	2	w	w	PROPN
dpc-4852	278	3	,	,	PUNCT
dpc-4852	278	4	vaillant	vaillant	PROPN
dpc-4852	278	5	m	m	PROPN
dpc-4852	278	6	,	,	PUNCT
dpc-4852	278	7	vassileva	vassileva	PROPN
dpc-4852	278	8	s	s	PROPN
dpc-4852	278	9	,	,	PUNCT
dpc-4852	278	10	et	et	PROPN
dpc-4852	278	11	al	al	PROPN
dpc-4852	278	12	.	.	PUNCT
dpc-4852	278	13	international	international	ADJ
dpc-4852	278	14	validation	validation	NOUN
dpc-4852	278	15	of	of	ADP
dpc-4852	278	16	the	the	DET
dpc-4852	278	17	bullous	bullous	ADJ
dpc-4852	278	18	pemphigoid	pemphigoid	PROPN
dpc-4852	278	19	disease	disease	PROPN
dpc-4852	278	20	area	area	NOUN
dpc-4852	278	21	index	index	NOUN
dpc-4852	278	22	severity	severity	NOUN
dpc-4852	278	23	score	score	NOUN
dpc-4852	278	24	and	and	CCONJ
dpc-4852	278	25	calculation	calculation	NOUN
dpc-4852	278	26	of	of	ADP
dpc-4852	278	27	cut	cut	NOUN
dpc-4852	278	28	-	-	PUNCT
dpc-4852	278	29	off	off	ADP
dpc-4852	278	30	values	value	NOUN
dpc-4852	278	31	for	for	ADP
dpc-4852	278	32	defining	define	VERB
dpc-4852	278	33	mild	mild	ADJ
dpc-4852	278	34	,	,	PUNCT
dpc-4852	278	35	moderate	moderate	ADJ
dpc-4852	278	36	and	and	CCONJ
dpc-4852	278	37	severe	severe	ADJ
dpc-4852	278	38	types	type	NOUN
dpc-4852	278	39	of	of	ADP
dpc-4852	278	40	bullous	bullous	ADJ
dpc-4852	278	41	pemphigoid	pemphigoid	NOUN
dpc-4852	278	42	.	.	PUNCT
dpc-4852	279	1	br	br	PROPN
dpc-4852	279	2	j	j	PROPN
dpc-4852	279	3	dermatol	dermatol	NOUN
dpc-4852	279	4	.	.	PUNCT
dpc-4852	280	1	2021;184(6	2021;184(6	NUM
dpc-4852	280	2	):	):	PUNCT
dpc-4852	280	3	1106	1106	NUM
dpc-4852	280	4	-	-	SYM
dpc-4852	280	5	1112	1112	NUM
dpc-4852	280	6	.	.	PUNCT
dpc-4852	281	1	doi:10.1111	doi:10.1111	ADJ
dpc-4852	281	2	/	/	SYM
dpc-4852	281	3	bjd.19611	bjd.19611	PROPN
dpc-4852	281	4	.	.	PUNCT
dpc-4852	282	1	pmid	pmid	NOUN
dpc-4852	282	2	:	:	PUNCT
dpc-4852	282	3	33067805	33067805	NUM
dpc-4852	282	4	.	.	PUNCT
dpc-4852	283	1	33	33	NUM
dpc-4852	283	2	.	.	PUNCT
dpc-4852	284	1	chou	chou	PROPN
dpc-4852	284	2	py	py	PROPN
dpc-4852	284	3	,	,	PUNCT
dpc-4852	284	4	yu	yu	PROPN
dpc-4852	284	5	cl	cl	PROPN
dpc-4852	284	6	,	,	PUNCT
dpc-4852	284	7	wen	wen	PROPN
dpc-4852	284	8	cn	cn	PROPN
dpc-4852	284	9	,	,	PUNCT
dpc-4852	284	10	et.al	et.al	PROPN
dpc-4852	284	11	.	.	PUNCT
dpc-4852	285	1	bullous	bullous	ADJ
dpc-4852	285	2	pemphigoid	pemphigoid	ADJ
dpc-4852	285	3	severity	severity	NOUN
dpc-4852	285	4	and	and	CCONJ
dpc-4852	285	5	levels	level	NOUN
dpc-4852	285	6	of	of	ADP
dpc-4852	285	7	antibodies	antibody	NOUN
dpc-4852	285	8	to	to	ADP
dpc-4852	285	9	bp180	bp180	PROPN
dpc-4852	285	10	and	and	CCONJ
dpc-4852	285	11	bp230	bp230	PRON
dpc-4852	285	12	:	:	PUNCT
dpc-4852	285	13	a	a	DET
dpc-4852	285	14	systematic	systematic	ADJ
dpc-4852	285	15	review	review	NOUN
dpc-4852	285	16	and	and	CCONJ
dpc-4852	285	17	meta	meta	ADJ
dpc-4852	285	18	-	-	PUNCT
dpc-4852	285	19	analysis	analysis	NOUN
dpc-4852	285	20	.	.	PUNCT
dpc-4852	286	1	jama	jama	PROPN
dpc-4852	286	2	dermatol	dermatol	NOUN
dpc-4852	286	3	.	.	PUNCT
dpc-4852	287	1	2024;160(11):1192	2024;160(11):1192	NUM
dpc-4852	287	2	-	-	SYM
dpc-4852	287	3	1200	1200	NUM
dpc-4852	287	4	.	.	PUNCT
dpc-4852	288	1	doi:10.1001	doi:10.1001	PROPN
dpc-4852	288	2	/	/	SYM
dpc-4852	288	3	jamadermatol.2024.3425	jamadermatol.2024.3425	PROPN
dpc-4852	288	4	.	.	PUNCT
dpc-4852	289	1	pmid	pmid	NOUN
dpc-4852	289	2	:	:	PUNCT
dpc-4852	289	3	39356527	39356527	NUM
dpc-4852	289	4	.	.	PUNCT
dpc-4852	290	1	34	34	NUM
dpc-4852	290	2	.	.	PUNCT
dpc-4852	291	1	zhao	zhao	PROPN
dpc-4852	291	2	cy	cy	PROPN
dpc-4852	291	3	,	,	PUNCT
dpc-4852	291	4	murrell	murrell	PROPN
dpc-4852	291	5	df	df	PROPN
dpc-4852	291	6	.	.	PUNCT
dpc-4852	292	1	outcome	outcome	NOUN
dpc-4852	292	2	measures	measure	NOUN
dpc-4852	292	3	for	for	ADP
dpc-4852	292	4	autoimmune	autoimmune	ADJ
dpc-4852	292	5	blistering	blister	VERB
dpc-4852	292	6	diseases	disease	NOUN
dpc-4852	292	7	.	.	PUNCT
dpc-4852	293	1	j	j	PROPN
dpc-4852	293	2	dermatol	dermatol	NOUN
dpc-4852	293	3	.	.	PUNCT
dpc-4852	294	1	2015;42(1):31	2015;42(1):31	NUM
dpc-4852	294	2	-	-	SYM
dpc-4852	294	3	36	36	NUM
dpc-4852	294	4	.	.	PUNCT
dpc-4852	295	1	doi:10.1111/1346	doi:10.1111/1346	ADJ
dpc-4852	295	2	-8138.12711	-8138.12711	NOUN
dpc-4852	295	3	.	.	PUNCT
dpc-4852	295	4	pmid	pmid	NOUN
dpc-4852	295	5	:	:	PUNCT
dpc-4852	295	6	25558950	25558950	NUM
dpc-4852	295	7	.	.	PUNCT
dpc-4852	296	1	35	35	NUM
dpc-4852	296	2	.	.	PUNCT
dpc-4852	297	1	nishie	nishie	PROPN
dpc-4852	297	2	w	w	PROPN
dpc-4852	297	3	,	,	PUNCT
dpc-4852	297	4	sawamura	sawamura	NOUN
dpc-4852	297	5	d	d	PROPN
dpc-4852	297	6	,	,	PUNCT
dpc-4852	297	7	goto	goto	NOUN
dpc-4852	297	8	m	m	PROPN
dpc-4852	297	9	,	,	PUNCT
dpc-4852	297	10	et	et	PROPN
dpc-4852	297	11	al	al	PROPN
dpc-4852	297	12	.	.	PROPN
dpc-4852	297	13	humanization	humanization	NOUN
dpc-4852	297	14	of	of	ADP
dpc-4852	297	15	autoantigen	autoantigen	PROPN
dpc-4852	297	16	.	.	PUNCT
dpc-4852	298	1	nat	nat	PROPN
dpc-4852	298	2	med	med	PROPN
dpc-4852	298	3	.	.	PUNCT
dpc-4852	299	1	2007;13(3):378	2007;13(3):378	NUM
dpc-4852	299	2	-	-	SYM
dpc-4852	299	3	383	383	NUM
dpc-4852	299	4	.	.	PUNCT
dpc-4852	300	1	doi	doi	NOUN
dpc-4852	300	2	:	:	PUNCT
dpc-4852	300	3	10.1038	10.1038	NUM
dpc-4852	300	4	/	/	SYM
dpc-4852	300	5	nm1496	nm1496	PROPN
dpc-4852	300	6	.	.	PUNCT
dpc-4852	301	1	pmid	pmid	NOUN
dpc-4852	301	2	:	:	PUNCT
dpc-4852	301	3	 	 	SPACE
dpc-4852	301	4	17322897	17322897	NUM
dpc-4852	301	5	.	.	PUNCT
dpc-4852	302	1	36	36	NUM
dpc-4852	302	2	.	.	PUNCT
dpc-4852	303	1	rosi	rosi	PROPN
dpc-4852	303	2	-	-	PUNCT
dpc-4852	303	3	schumacher	schumacher	PROPN
dpc-4852	303	4	m	m	PROPN
dpc-4852	303	5	,	,	PUNCT
dpc-4852	303	6	baker	baker	PROPN
dpc-4852	303	7	j	j	PROPN
dpc-4852	303	8	,	,	PUNCT
dpc-4852	303	9	waris	waris	PROPN
dpc-4852	303	10	j	j	PROPN
dpc-4852	303	11	,	,	PUNCT
dpc-4852	303	12	et.al	et.al	PROPN
dpc-4852	303	13	.	.	PUNCT
dpc-4852	304	1	worldwide	worldwide	ADJ
dpc-4852	304	2	epidemiologic	epidemiologic	ADJ
dpc-4852	304	3	factors	factor	NOUN
dpc-4852	304	4	in	in	ADP
dpc-4852	304	5	pemphigus	pemphigus	ADJ
dpc-4852	304	6	vulgaris	vulgaris	NOUN
dpc-4852	304	7	and	and	CCONJ
dpc-4852	304	8	bullous	bullous	ADJ
dpc-4852	304	9	pemphigoid	pemphigoid	NOUN
dpc-4852	304	10	.	.	PUNCT
dpc-4852	305	1	front	front	ADJ
dpc-4852	305	2	immunol	immunol	NOUN
dpc-4852	305	3	.	.	PUNCT
dpc-4852	306	1	2023	2023	NUM
dpc-4852	306	2	;	;	PUNCT
dpc-4852	306	3	14:1159351	14:1159351	X
dpc-4852	306	4	.	.	PUNCT
dpc-4852	306	5	published	publish	VERB
dpc-4852	306	6	2023	2023	NUM
dpc-4852	306	7	apr	apr	NOUN
dpc-4852	306	8	25	25	NUM
dpc-4852	306	9	.	.	PUNCT
dpc-4852	306	10	doi:10.3389	doi:10.3389	PROPN
dpc-4852	306	11	/	/	SYM
dpc-4852	306	12	fimmu.2023.1159351	fimmu.2023.1159351	NOUN
dpc-4852	306	13	.	.	PUNCT
dpc-4852	307	1	pmid	pmid	NOUN
dpc-4852	307	2	:	:	PUNCT
dpc-4852	307	3	37180132	37180132	NUM
dpc-4852	307	4	.	.	PUNCT
dpc-4852	308	1	37	37	NUM
dpc-4852	308	2	.	.	PUNCT
dpc-4852	308	3	khandpur	khandpur	PROPN
dpc-4852	308	4	s	s	PROPN
dpc-4852	308	5	,	,	PUNCT
dpc-4852	308	6	verma	verma	PROPN
dpc-4852	308	7	p.	p.	PROPN
dpc-4852	308	8	bullous	bullous	ADJ
dpc-4852	308	9	pemphigoid	pemphigoid	ADJ
dpc-4852	308	10	.	.	PUNCT
dpc-4852	309	1	indian	indian	PROPN
dpc-4852	309	2	j	j	PROPN
dpc-4852	309	3	dermatol	dermatol	PROPN
dpc-4852	309	4	venereol	venereol	ADJ
dpc-4852	309	5	leprol	leprol	NOUN
dpc-4852	309	6	.	.	PUNCT
dpc-4852	310	1	2011;77(4):450	2011;77(4):450	NUM
dpc-4852	310	2	-	-	SYM
dpc-4852	310	3	455	455	NUM
dpc-4852	310	4	.	.	PUNCT
dpc-4852	311	1	doi:10.4103/03786323.82398	doi:10.4103/03786323.82398	PROPN
dpc-4852	311	2	.	.	PUNCT
dpc-4852	312	1	pmid	pmid	NOUN
dpc-4852	312	2	:	:	PUNCT
dpc-4852	312	3	21727692	21727692	NUM
dpc-4852	312	4	.	.	PUNCT
dpc-4852	313	1	9	9	X
dpc-4852	313	2	.	.	X
dpc-4852	313	3	joly	joly	PROPN
dpc-4852	313	4	p	p	PROPN
dpc-4852	313	5	,	,	PUNCT
dpc-4852	313	6	benichou	benichou	PROPN
dpc-4852	313	7	j	j	PROPN
dpc-4852	313	8	,	,	PUNCT
dpc-4852	313	9	lok	lok	PROPN
dpc-4852	313	10	c	c	PROPN
dpc-4852	313	11	,	,	PUNCT
dpc-4852	313	12	et	et	PROPN
dpc-4852	313	13	al	al	PROPN
dpc-4852	313	14	.	.	PROPN
dpc-4852	313	15	prediction	prediction	NOUN
dpc-4852	313	16	of	of	ADP
dpc-4852	313	17	survival	survival	NOUN
dpc-4852	313	18	for	for	ADP
dpc-4852	313	19	patients	patient	NOUN
dpc-4852	313	20	with	with	ADP
dpc-4852	313	21	bullous	bullous	ADJ
dpc-4852	313	22	pemphigoid	pemphigoid	NOUN
dpc-4852	313	23	:	:	PUNCT
dpc-4852	313	24	a	a	DET
dpc-4852	313	25	prospective	prospective	ADJ
dpc-4852	313	26	study	study	NOUN
dpc-4852	313	27	.	.	PUNCT
dpc-4852	314	1	arch	arch	ADJ
dpc-4852	314	2	dermatol	dermatol	NOUN
dpc-4852	314	3	.	.	PUNCT
dpc-4852	315	1	2005;141(6):691	2005;141(6):691	NUM
dpc-4852	315	2	-	-	SYM
dpc-4852	315	3	698	698	NUM
dpc-4852	315	4	.	.	PUNCT
dpc-4852	316	1	doi:10.1001	doi:10.1001	PROPN
dpc-4852	316	2	/	/	SYM
dpc-4852	316	3	archderm.141.6.691	archderm.141.6.691	PROPN
dpc-4852	316	4	.	.	PUNCT
dpc-4852	317	1	pmid	pmid	NOUN
dpc-4852	317	2	:	:	PUNCT
dpc-4852	317	3	15967914	15967914	NUM
dpc-4852	317	4	10	10	NUM
dpc-4852	317	5	.	.	PUNCT
dpc-4852	318	1	hesari	hesari	PROPN
dpc-4852	318	2	r	r	NOUN
dpc-4852	318	3	,	,	PUNCT
dpc-4852	318	4	thibaut	thibaut	PROPN
dpc-4852	318	5	d	d	PROPN
dpc-4852	318	6	,	,	PUNCT
dpc-4852	318	7	schur	schur	PROPN
dpc-4852	318	8	n	n	CCONJ
dpc-4852	318	9	,	,	PUNCT
dpc-4852	318	10	et.al	et.al	PROPN
dpc-4852	318	11	.	.	PUNCT
dpc-4852	319	1	bullous	bullous	ADJ
dpc-4852	319	2	pemphigoid	pemphigoid	NOUN
dpc-4852	319	3	and	and	CCONJ
dpc-4852	319	4	human	human	ADJ
dpc-4852	319	5	leukocyte	leukocyte	NOUN
dpc-4852	319	6	antigen	antigen	NOUN
dpc-4852	319	7	(	(	PUNCT
dpc-4852	319	8	hla)-dqa1	hla)-dqa1	PROPN
dpc-4852	319	9	:	:	PUNCT
dpc-4852	319	10	a	a	DET
dpc-4852	319	11	systematic	systematic	ADJ
dpc-4852	319	12	review	review	NOUN
dpc-4852	319	13	.	.	PUNCT
dpc-4852	320	1	cureus	cureus	NOUN
dpc-4852	320	2	.	.	PUNCT
dpc-4852	321	1	2023;15(6):e39923	2023;15(6):e39923	X
dpc-4852	321	2	.	.	NUM
dpc-4852	321	3	published	publish	VERB
dpc-4852	321	4	2023	2023	NUM
dpc-4852	321	5	jun	jun	PROPN
dpc-4852	321	6	3	3	NUM
dpc-4852	321	7	.	.	PUNCT
dpc-4852	321	8	doi	doi	NOUN
dpc-4852	321	9	:	:	PUNCT
dpc-4852	321	10	10.7759	10.7759	NUM
dpc-4852	321	11	/	/	SYM
dpc-4852	321	12	cureus.39923	cureus.39923	PROPN
dpc-4852	321	13	.	.	PUNCT
dpc-4852	322	1	pmid	pmid	PROPN
dpc-4852	322	2	:	:	PUNCT
dpc-4852	322	3	37416040	37416040	NUM
dpc-4852	322	4	11	11	NUM
dpc-4852	322	5	.	.	PUNCT
dpc-4852	323	1	zhang	zhang	PROPN
dpc-4852	323	2	j	j	PROPN
dpc-4852	323	3	,	,	PUNCT
dpc-4852	323	4	wang	wang	PROPN
dpc-4852	323	5	g.	g.	PROPN
dpc-4852	323	6	genetic	genetic	ADJ
dpc-4852	323	7	predisposition	predisposition	NOUN
dpc-4852	323	8	to	to	ADP
dpc-4852	323	9	bullous	bullous	ADJ
dpc-4852	323	10	pemphigoid	pemphigoid	NOUN
dpc-4852	323	11	.	.	PUNCT
dpc-4852	324	1	j	j	PROPN
dpc-4852	324	2	dermatol	dermatol	NOUN
dpc-4852	324	3	sci	sci	PROPN
dpc-4852	324	4	.	.	PUNCT
dpc-4852	325	1	2020;100(2):86	2020;100(2):86	PROPN
dpc-4852	325	2	-	-	PUNCT
dpc-4852	325	3	91	91	NUM
dpc-4852	325	4	.	.	PUNCT
dpc-4852	326	1	doi	doi	NOUN
dpc-4852	326	2	:	:	PUNCT
dpc-4852	326	3	10.1016	10.1016	NUM
dpc-4852	326	4	/	/	SYM
dpc-4852	326	5	j.jdermsci	j.jdermsci	X
dpc-4852	326	6	.2020.05.010	.2020.05.010	PROPN
dpc-4852	326	7	.	.	PUNCT
dpc-4852	327	1	pmid	pmid	NOUN
dpc-4852	327	2	:	:	PUNCT
dpc-4852	327	3	33129650	33129650	NUM
dpc-4852	327	4	12	12	NUM
dpc-4852	327	5	.	.	PUNCT
dpc-4852	328	1	amber	amber	PROPN
dpc-4852	328	2	kt	kt	PROPN
dpc-4852	328	3	,	,	PUNCT
dpc-4852	328	4	murrell	murrell	PROPN
dpc-4852	328	5	df	df	PROPN
dpc-4852	328	6	,	,	PUNCT
dpc-4852	328	7	schmidt	schmidt	PROPN
dpc-4852	328	8	e	e	PROPN
dpc-4852	328	9	,	,	PUNCT
dpc-4852	328	10	et.al	et.al	VERB
dpc-4852	328	11	autoimmune	autoimmune	ADJ
dpc-4852	328	12	subepidermal	subepidermal	NOUN
dpc-4852	328	13	bullous	bullous	ADJ
dpc-4852	328	14	diseases	disease	NOUN
dpc-4852	328	15	of	of	ADP
dpc-4852	328	16	the	the	DET
dpc-4852	328	17	skin	skin	NOUN
dpc-4852	328	18	and	and	CCONJ
dpc-4852	328	19	mucosae	mucosa	NOUN
dpc-4852	328	20	:	:	PUNCT
dpc-4852	328	21	clinical	clinical	ADJ
dpc-4852	328	22	features	feature	NOUN
dpc-4852	328	23	,	,	PUNCT
dpc-4852	328	24	diagnosis	diagnosis	NOUN
dpc-4852	328	25	,	,	PUNCT
dpc-4852	328	26	and	and	CCONJ
dpc-4852	328	27	management	management	NOUN
dpc-4852	328	28	.	.	PUNCT
dpc-4852	329	1	clin	clin	PROPN
dpc-4852	329	2	rev	rev	PROPN
dpc-4852	329	3	allergy	allergy	PROPN
dpc-4852	329	4	immunol	immunol	PROPN
dpc-4852	329	5	.	.	PUNCT
dpc-4852	330	1	2018;54(1	2018;54(1	NUM
dpc-4852	330	2	):	):	PUNCT
dpc-4852	330	3	26	26	NUM
dpc-4852	330	4	-	-	SYM
dpc-4852	330	5	51	51	NUM
dpc-4852	330	6	.	.	PUNCT
dpc-4852	331	1	doi	doi	NOUN
dpc-4852	331	2	:	:	PUNCT
dpc-4852	331	3	10.1007	10.1007	NUM
dpc-4852	331	4	/	/	SYM
dpc-4852	331	5	s12016	s12016	PROPN
dpc-4852	331	6	-	-	PUNCT
dpc-4852	331	7	017	017	NUM
dpc-4852	331	8	-	-	PUNCT
dpc-4852	331	9	8633	8633	NUM
dpc-4852	331	10	-	-	SYM
dpc-4852	331	11	4	4	NUM
dpc-4852	331	12	.	.	PUNCT
dpc-4852	332	1	pmid	pmid	NOUN
dpc-4852	332	2	:	:	PUNCT
dpc-4852	332	3	28779299	28779299	NUM
dpc-4852	332	4	13	13	NUM
dpc-4852	332	5	.	.	PUNCT
dpc-4852	333	1	ruggiero	ruggiero	PROPN
dpc-4852	333	2	a	a	DET
dpc-4852	333	3	,	,	PUNCT
dpc-4852	333	4	megna	megna	PROPN
dpc-4852	333	5	m	m	PROPN
dpc-4852	333	6	,	,	PUNCT
dpc-4852	333	7	villani	villani	PROPN
dpc-4852	333	8	a	a	DET
dpc-4852	333	9	,	,	PUNCT
dpc-4852	333	10	et.al	et.al	ADJ
dpc-4852	333	11	strategies	strategy	NOUN
dpc-4852	333	12	to	to	PART
dpc-4852	333	13	improve	improve	VERB
dpc-4852	333	14	outcomes	outcome	NOUN
dpc-4852	333	15	of	of	ADP
dpc-4852	333	16	bullous	bullous	ADJ
dpc-4852	333	17	pemphigoid	pemphigoid	NOUN
dpc-4852	333	18	:	:	PUNCT
dpc-4852	333	19	a	a	DET
dpc-4852	333	20	comprehensive	comprehensive	ADJ
dpc-4852	333	21	review	review	NOUN
dpc-4852	333	22	of	of	ADP
dpc-4852	333	23	clinical	clinical	ADJ
dpc-4852	333	24	presentations	presentation	NOUN
dpc-4852	333	25	,	,	PUNCT
dpc-4852	333	26	diagnosis	diagnosis	NOUN
dpc-4852	333	27	,	,	PUNCT
dpc-4852	333	28	and	and	CCONJ
dpc-4852	333	29	patients	patient	NOUN
dpc-4852	333	30	’	'	PUNCT
dpc-4852	333	31	assessment	assessment	NOUN
dpc-4852	333	32	.	.	PUNCT
dpc-4852	334	1	clin	clin	PROPN
dpc-4852	334	2	cosmet	cosmet	PROPN
dpc-4852	334	3	investig	investig	NOUN
dpc-4852	334	4	dermatol	dermatol	NOUN
dpc-4852	334	5	.	.	PUNCT
dpc-4852	335	1	2022	2022	NUM
dpc-4852	335	2	;	;	PUNCT
dpc-4852	335	3	15:661	15:661	NUM
dpc-4852	335	4	-	-	PUNCT
dpc-4852	335	5	673	673	NUM
dpc-4852	335	6	.	.	PUNCT
dpc-4852	336	1	published	publish	VERB
dpc-4852	336	2	2022	2022	NUM
dpc-4852	336	3	apr	apr	NOUN
dpc-4852	336	4	14	14	NUM
dpc-4852	336	5	.	.	PUNCT
dpc-4852	337	1	doi	doi	NOUN
dpc-4852	337	2	:	:	PUNCT
dpc-4852	337	3	10.2147	10.2147	NUM
dpc-4852	337	4	/	/	SYM
dpc-4852	337	5	ccid.s267573	ccid.s267573	NOUN
dpc-4852	337	6	pmid	pmid	NOUN
dpc-4852	337	7	:	:	PUNCT
dpc-4852	337	8	35444441	35444441	NUM
dpc-4852	337	9	14	14	NUM
dpc-4852	337	10	.	.	PUNCT
dpc-4852	338	1	liu	liu	PROPN
dpc-4852	338	2	z	z	PROPN
dpc-4852	338	3	,	,	PUNCT
dpc-4852	338	4	diaz	diaz	PROPN
dpc-4852	338	5	la	la	PROPN
dpc-4852	338	6	,	,	PUNCT
dpc-4852	338	7	giudice	giudice	PROPN
dpc-4852	338	8	gj	gj	PROPN
dpc-4852	338	9	.	.	PUNCT
dpc-4852	338	10	autoimmune	autoimmune	ADJ
dpc-4852	338	11	response	response	NOUN
dpc-4852	338	12	against	against	ADP
dpc-4852	338	13	the	the	DET
dpc-4852	338	14	bullous	bullous	ADJ
dpc-4852	338	15	pemphigoid	pemphigoid	NOUN
dpc-4852	338	16	180	180	NUM
dpc-4852	338	17	autoantigen	autoantigen	PROPN
dpc-4852	338	18	.	.	PUNCT
dpc-4852	339	1	dermatology	dermatology	NOUN
dpc-4852	339	2	.	.	PUNCT
dpc-4852	340	1	1994;189(suppl	1994;189(suppl	NUM
dpc-4852	340	2	1):34	1):34	NUM
dpc-4852	340	3	-	-	SYM
dpc-4852	340	4	37	37	NUM
dpc-4852	340	5	.	.	PUNCT
dpc-4852	341	1	doi:10.1159/000246925	doi:10.1159/000246925	NOUN
dpc-4852	341	2	.	.	PUNCT
dpc-4852	342	1	pmid	pmid	NOUN
dpc-4852	342	2	:	:	PUNCT
dpc-4852	342	3	7519485	7519485	NUM
dpc-4852	342	4	15	15	NUM
dpc-4852	342	5	.	.	PUNCT
dpc-4852	343	1	meyer	meyer	PROPN
dpc-4852	343	2	lj	lj	PROPN
dpc-4852	343	3	,	,	PUNCT
dpc-4852	343	4	taylor	taylor	PROPN
dpc-4852	343	5	tb	tb	PROPN
dpc-4852	343	6	,	,	PUNCT
dpc-4852	343	7	kadunce	kadunce	NOUN
dpc-4852	343	8	dp	dp	PROPN
dpc-4852	343	9	,	,	PUNCT
dpc-4852	343	10	zone	zone	NOUN
dpc-4852	343	11	jj	jj	PROPN
dpc-4852	343	12	.	.	PROPN
dpc-4852	343	13	two	two	NUM
dpc-4852	343	14	groups	group	NOUN
dpc-4852	343	15	of	of	ADP
dpc-4852	343	16	bullous	bullous	ADJ
dpc-4852	343	17	pemphigoid	pemphigoid	ADJ
dpc-4852	343	18	antigens	antigen	NOUN
dpc-4852	343	19	are	be	AUX
dpc-4852	343	20	identified	identify	VERB
dpc-4852	343	21	by	by	ADP
dpc-4852	343	22	affinity	affinity	NOUN
dpc-4852	343	23	purified	purify	VERB
dpc-4852	343	24	antibodies	antibodie	VERB
dpc-4852	343	25	.	.	PUNCT
dpc-4852	344	1	j	j	PROPN
dpc-4852	344	2	invest	invest	VERB
dpc-4852	344	3	dermatol	dermatol	NOUN
dpc-4852	344	4	.	.	PUNCT
dpc-4852	345	1	1990;94(5):611	1990;94(5):611	NUM
dpc-4852	345	2	-	-	PUNCT
dpc-4852	345	3	616	616	NUM
dpc-4852	345	4	.	.	PUNCT
dpc-4852	346	1	doi	doi	NOUN
dpc-4852	346	2	:	:	PUNCT
dpc-4852	346	3	10.1111/1523	10.1111/1523	NUM
dpc-4852	346	4	-	-	NOUN
dpc-4852	346	5	1747.ep12876194	1747.ep12876194	NOUN
dpc-4852	346	6	.	.	PUNCT
dpc-4852	347	1	pmid	pmid	NOUN
dpc-4852	347	2	:	:	PUNCT
dpc-4852	347	3	2182719	2182719	NUM
dpc-4852	347	4	16	16	NUM
dpc-4852	347	5	.	.	PUNCT
dpc-4852	348	1	holtsche	holtsche	PROPN
dpc-4852	348	2	mm	mm	PROPN
dpc-4852	348	3	,	,	PUNCT
dpc-4852	348	4	van	van	PROPN
dpc-4852	348	5	beek	beek	PROPN
dpc-4852	348	6	n	n	CCONJ
dpc-4852	348	7	,	,	PUNCT
dpc-4852	348	8	künstner	künstner	NOUN
dpc-4852	348	9	a	a	NOUN
dpc-4852	348	10	,	,	PUNCT
dpc-4852	348	11	busch	busch	PROPN
dpc-4852	348	12	h	h	PROPN
dpc-4852	348	13	,	,	PUNCT
dpc-4852	348	14	zillikens	zillikens	PROPN
dpc-4852	348	15	d	d	PROPN
dpc-4852	348	16	,	,	PUNCT
dpc-4852	348	17	schmidt	schmidt	PROPN
dpc-4852	348	18	e.	e.	PROPN
dpc-4852	348	19	diagnostic	diagnostic	PROPN
dpc-4852	348	20	value	value	NOUN
dpc-4852	348	21	and	and	CCONJ
dpc-4852	348	22	practicability	practicability	NOUN
dpc-4852	348	23	of	of	ADP
dpc-4852	348	24	serration	serration	NOUN
dpc-4852	348	25	pattern	pattern	NOUN
dpc-4852	348	26	analysis	analysis	NOUN
dpc-4852	348	27	by	by	ADP
dpc-4852	348	28	direct	direct	ADJ
dpc-4852	348	29	immunofluorescence	immunofluorescence	NOUN
dpc-4852	348	30	microscopy	microscopy	NOUN
dpc-4852	348	31	in	in	ADP
dpc-4852	348	32	pemphigoid	pemphigoid	ADJ
dpc-4852	348	33	diseases	disease	NOUN
dpc-4852	348	34	.	.	PUNCT
dpc-4852	349	1	acta	acta	PROPN
dpc-4852	349	2	derm	derm	PROPN
dpc-4852	349	3	venereol	venereol	NOUN
dpc-4852	349	4	.	.	PUNCT
dpc-4852	350	1	2021;101(3):adv00410	2021;101(3):adv00410	X
dpc-4852	350	2	.	.	PUNCT
dpc-4852	351	1	doi:10.2340/00015555	doi:10.2340/00015555	NOUN
dpc-4852	351	2	-	-	SYM
dpc-4852	351	3	3748	3748	NUM
dpc-4852	351	4	.	.	PUNCT
dpc-4852	352	1	pmid	pmid	NOUN
dpc-4852	352	2	:	:	PUNCT
dpc-4852	352	3	33491096	33491096	NUM
dpc-4852	352	4	17	17	NUM
dpc-4852	352	5	.	.	PUNCT
dpc-4852	353	1	de	de	PROPN
dpc-4852	353	2	a	a	X
dpc-4852	353	3	,	,	PUNCT
dpc-4852	353	4	rao	rao	NOUN
dpc-4852	353	5	r	r	NOUN
dpc-4852	353	6	,	,	PUNCT
dpc-4852	353	7	balachandran	balachandran	PROPN
dpc-4852	353	8	c.	c.	PROPN
dpc-4852	353	9	salt	salt	PROPN
dpc-4852	353	10	split	split	NOUN
dpc-4852	353	11	technique	technique	NOUN
dpc-4852	353	12	:	:	PUNCT
dpc-4852	353	13	a	a	DET
dpc-4852	353	14	useful	useful	ADJ
dpc-4852	353	15	tool	tool	NOUN
dpc-4852	353	16	in	in	ADP
dpc-4852	353	17	the	the	DET
dpc-4852	353	18	diagnosis	diagnosis	NOUN
dpc-4852	353	19	of	of	ADP
dpc-4852	353	20	subepidermal	subepidermal	ADJ
dpc-4852	353	21	bullous	bullous	ADJ
dpc-4852	353	22	disorders	disorder	NOUN
dpc-4852	353	23	.	.	PUNCT
dpc-4852	354	1	indian	indian	PROPN
dpc-4852	354	2	j	j	PROPN
dpc-4852	354	3	dermatol	dermatol	NOUN
dpc-4852	354	4	.	.	PUNCT
dpc-4852	355	1	2010;55(4):334	2010;55(4):334	NUM
dpc-4852	355	2	-	-	PUNCT
dpc-4852	355	3	336	336	NUM
dpc-4852	355	4	.	.	PUNCT
dpc-4852	356	1	doi:10.4103/0019	doi:10.4103/0019	X
dpc-4852	356	2	-	-	PUNCT
dpc-4852	356	3	5154.74534	5154.74534	NUM
dpc-4852	356	4	.	.	PUNCT
dpc-4852	357	1	pmid	pmid	NOUN
dpc-4852	357	2	:	:	PUNCT
dpc-4852	357	3	21430884	21430884	NUM
dpc-4852	357	4	18	18	NUM
dpc-4852	357	5	.	.	PUNCT
dpc-4852	358	1	wojtczak	wojtczak	PROPN
dpc-4852	358	2	m	m	PROPN
dpc-4852	358	3	,	,	PUNCT
dpc-4852	358	4	nolbrzak	nolbrzak	PROPN
dpc-4852	358	5	a	a	PRON
dpc-4852	358	6	,	,	PUNCT
dpc-4852	358	7	woźniacka	woźniacka	PROPN
dpc-4852	358	8	a	a	PRON
dpc-4852	358	9	,	,	PUNCT
dpc-4852	359	1	żebrowska	żebrowska	ADJ
dpc-4852	359	2	a.	a.	NOUN
dpc-4852	359	3	can	can	AUX
dpc-4852	359	4	methotrexate	methotrexate	VERB
dpc-4852	359	5	be	be	AUX
dpc-4852	359	6	employed	employ	VERB
dpc-4852	359	7	as	as	ADP
dpc-4852	359	8	monotherapy	monotherapy	NOUN
dpc-4852	359	9	for	for	ADP
dpc-4852	359	10	bullous	bullous	ADJ
dpc-4852	359	11	pemphigoid	pemphigoid	NOUN
dpc-4852	359	12	?	?	PUNCT
dpc-4852	360	1	analysis	analysis	NOUN
dpc-4852	360	2	of	of	ADP
dpc-4852	360	3	efficiency	efficiency	NOUN
dpc-4852	360	4	and	and	CCONJ
dpc-4852	360	5	tolerance	tolerance	NOUN
dpc-4852	360	6	of	of	ADP
dpc-4852	360	7	methotrexate	methotrexate	ADJ
dpc-4852	360	8	treatment	treatment	NOUN
dpc-4852	360	9	in	in	ADP
dpc-4852	360	10	patients	patient	NOUN
dpc-4852	360	11	with	with	ADP
dpc-4852	360	12	bullous	bullous	ADJ
dpc-4852	360	13	pemphigoid	pemphigoid	NOUN
dpc-4852	360	14	.	.	PUNCT
dpc-4852	361	1	j	j	PROPN
dpc-4852	361	2	clin	clin	PROPN
dpc-4852	361	3	med	med	PROPN
dpc-4852	361	4	.	.	PUNCT
dpc-4852	362	1	2023;12(4):1638	2023;12(4):1638	NUM
dpc-4852	362	2	.	.	PUNCT
dpc-4852	362	3	doi:10.3390	doi:10.3390	NOUN
dpc-4852	362	4	/	/	SYM
dpc-4852	362	5	jcm12041638	jcm12041638	PROPN
dpc-4852	362	6	.	.	PUNCT
dpc-4852	363	1	pmid	pmid	NOUN
dpc-4852	363	2	:	:	PUNCT
dpc-4852	363	3	36836172	36836172	NUM
dpc-4852	363	4	19	19	NUM
dpc-4852	363	5	.	.	PUNCT
dpc-4852	364	1	logan	logan	PROPN
dpc-4852	364	2	ra	ra	PROPN
dpc-4852	364	3	,	,	PUNCT
dpc-4852	364	4	bhogal	bhogal	ADJ
dpc-4852	364	5	b	b	NUM
dpc-4852	364	6	,	,	PUNCT
dpc-4852	364	7	das	das	PROPN
dpc-4852	364	8	ak	ak	PROPN
dpc-4852	364	9	,	,	PUNCT
dpc-4852	364	10	mckee	mckee	PROPN
dpc-4852	364	11	pm	pm	PROPN
dpc-4852	364	12	,	,	PUNCT
dpc-4852	364	13	black	black	ADJ
dpc-4852	364	14	mm	mm	NOUN
dpc-4852	364	15	.	.	PUNCT
dpc-4852	365	1	localization	localization	NOUN
dpc-4852	365	2	of	of	ADP
dpc-4852	365	3	bullous	bullous	ADJ
dpc-4852	365	4	pemphigoid	pemphigoid	ADJ
dpc-4852	365	5	antibody	antibody	NOUN
dpc-4852	365	6	—	—	PUNCT
dpc-4852	365	7	an	an	DET
dpc-4852	365	8	indirect	indirect	ADJ
dpc-4852	365	9	immunofluorescence	immunofluorescence	NOUN
dpc-4852	365	10	study	study	NOUN
dpc-4852	365	11	of	of	ADP
dpc-4852	365	12	228	228	NUM
dpc-4852	365	13	cases	case	NOUN
dpc-4852	365	14	using	use	VERB
dpc-4852	365	15	a	a	DET
dpc-4852	365	16	split	split	ADJ
dpc-4852	365	17	-	-	PUNCT
dpc-4852	365	18	skin	skin	NOUN
dpc-4852	365	19	technique	technique	NOUN
dpc-4852	365	20	.	.	PUNCT
dpc-4852	366	1	br	br	PROPN
dpc-4852	366	2	j	j	PROPN
dpc-4852	366	3	dermatol	dermatol	NOUN
dpc-4852	366	4	.	.	PUNCT
dpc-4852	367	1	1987;117(4):471	1987;117(4):471	NUM
dpc-4852	367	2	-	-	SYM
dpc-4852	367	3	478	478	NUM
dpc-4852	367	4	.	.	PUNCT
dpc-4852	368	1	doi:10.1111	doi:10.1111	ADJ
dpc-4852	368	2	/	/	SYM
dpc-4852	368	3	j.1365	j.1365	NOUN
dpc-4852	368	4	-	-	PUNCT
dpc-4852	368	5	2133	2133	NUM
dpc-4852	368	6	.	.	PUNCT
dpc-4852	369	1	1987.tb04927	1987.tb04927	X
dpc-4852	369	2	.	.	PUNCT
dpc-4852	370	1	pmid	pmid	NOUN
dpc-4852	370	2	:	:	PUNCT
dpc-4852	370	3	3314971	3314971	NUM
dpc-4852	370	4	20	20	NUM
dpc-4852	370	5	.	.	PUNCT
dpc-4852	371	1	kirschig	kirschig	PROPN
dpc-4852	371	2	g	g	NOUN
dpc-4852	371	3	,	,	PUNCT
dpc-4852	371	4	wojnarowska	wojnarowska	PROPN
dpc-4852	371	5	f	f	NUM
dpc-4852	371	6	,	,	PUNCT
dpc-4852	371	7	marsden	marsden	PROPN
dpc-4852	371	8	ra	ra	PROPN
dpc-4852	371	9	,	,	PUNCT
dpc-4852	371	10	et.al	et.al	PROPN
dpc-4852	371	11	.	.	PUNCT
dpc-4852	371	12	acquired	acquire	VERB
dpc-4852	371	13	bullous	bullous	ADJ
dpc-4852	371	14	diseases	disease	NOUN
dpc-4852	371	15	of	of	ADP
dpc-4852	371	16	childhood	childhood	NOUN
dpc-4852	371	17	:	:	PUNCT
dpc-4852	371	18	re	re	NOUN
dpc-4852	371	19	-	-	NOUN
dpc-4852	371	20	evaluation	evaluation	NOUN
dpc-4852	371	21	of	of	ADP
dpc-4852	371	22	diagnosis	diagnosis	NOUN
dpc-4852	371	23	by	by	ADP
dpc-4852	371	24	indirect	indirect	ADJ
dpc-4852	371	25	immunofluorescence	immunofluorescence	NOUN
dpc-4852	371	26	examination	examination	NOUN
dpc-4852	371	27	on	on	ADP
dpc-4852	371	28	1	1	NUM
dpc-4852	371	29	m	m	NOUN
dpc-4852	371	30	nacl	nacl	NOUN
dpc-4852	371	31	split	split	NOUN
dpc-4852	371	32	skin	skin	NOUN
dpc-4852	371	33	and	and	CCONJ
dpc-4852	371	34	immunoblotting	immunoblotting	NOUN
dpc-4852	371	35	.	.	PUNCT
dpc-4852	372	1	br	br	PROPN
dpc-4852	372	2	j	j	PROPN
dpc-4852	372	3	dermatol	dermatol	NOUN
dpc-4852	372	4	.	.	PUNCT
dpc-4852	373	1	1994;130(5):610	1994;130(5):610	NUM
dpc-4852	373	2	-	-	SYM
dpc-4852	373	3	616	616	NUM
dpc-4852	373	4	.	.	PUNCT
dpc-4852	374	1	doi:10.1111	doi:10.1111	ADJ
dpc-4852	374	2	/	/	SYM
dpc-4852	374	3	j.1365	j.1365	NOUN
dpc-4852	374	4	-	-	PUNCT
dpc-4852	374	5	2133.1994.tb13108.x	2133.1994.tb13108.x	NUM
dpc-4852	374	6	pmid	pmid	NOUN
dpc-4852	374	7	:	:	PUNCT
dpc-4852	374	8	8204469	8204469	NUM
dpc-4852	374	9	21	21	NUM
dpc-4852	374	10	.	.	PUNCT
dpc-4852	375	1	cao	cao	PROPN
dpc-4852	375	2	p	p	X
dpc-4852	375	3	,	,	PUNCT
dpc-4852	375	4	xu	xu	PROPN
dpc-4852	375	5	w	w	PROPN
dpc-4852	375	6	,	,	PUNCT
dpc-4852	375	7	zhang	zhang	PROPN
dpc-4852	375	8	l.	l.	PROPN
dpc-4852	375	9	rituximab	rituximab	PROPN
dpc-4852	375	10	,	,	PUNCT
dpc-4852	375	11	omalizumab	omalizumab	NOUN
dpc-4852	375	12	,	,	PUNCT
dpc-4852	375	13	and	and	CCONJ
dpc-4852	375	14	dupilumab	dupilumab	NOUN
dpc-4852	375	15	treatment	treatment	NOUN
dpc-4852	375	16	outcomes	outcome	NOUN
dpc-4852	375	17	in	in	ADP
dpc-4852	375	18	bullous	bullous	ADJ
dpc-4852	375	19	pemphigoid	pemphigoid	NOUN
dpc-4852	375	20	:	:	PUNCT
dpc-4852	375	21	a	a	DET
dpc-4852	375	22	systematic	systematic	ADJ
dpc-4852	375	23	review	review	NOUN
dpc-4852	375	24	.	.	PUNCT
dpc-4852	376	1	front	front	ADJ
dpc-4852	376	2	immunol	immunol	NOUN
dpc-4852	376	3	.	.	PUNCT
dpc-4852	377	1	2022;13:928621	2022;13:928621	NUM
dpc-4852	377	2	.	.	PROPN
dpc-4852	377	3	published	publish	VERB
dpc-4852	377	4	2022	2022	NUM
dpc-4852	377	5	jun	jun	PROPN
dpc-4852	377	6	13	13	NUM
dpc-4852	377	7	.	.	PUNCT
dpc-4852	378	1	doi	doi	NOUN
dpc-4852	378	2	:	:	PUNCT
dpc-4852	378	3	10.3389	10.3389	NUM
dpc-4852	378	4	/	/	SYM
dpc-4852	378	5	fimmu.2022.928621	fimmu.2022.928621	NOUN
dpc-4852	378	6	.	.	PUNCT
dpc-4852	379	1	pmid	pmid	NOUN
dpc-4852	379	2	:	:	PUNCT
dpc-4852	379	3	35769474	35769474	NUM
dpc-4852	379	4	22	22	NUM
dpc-4852	379	5	.	.	PUNCT
dpc-4852	380	1	kunadia	kunadia	VERB
dpc-4852	380	2	a	a	PROPN
dpc-4852	380	3	,	,	PUNCT
dpc-4852	380	4	sami	sami	PROPN
dpc-4852	380	5	n.	n.	PROPN
dpc-4852	380	6	combination	combination	NOUN
dpc-4852	380	7	therapy	therapy	NOUN
dpc-4852	380	8	of	of	ADP
dpc-4852	380	9	plasma	plasma	NOUN
dpc-4852	380	10	exchange	exchange	NOUN
dpc-4852	380	11	and	and	CCONJ
dpc-4852	380	12	rituximab	rituximab	NOUN
dpc-4852	380	13	to	to	PART
dpc-4852	380	14	treat	treat	VERB
dpc-4852	380	15	cicatricial	cicatricial	ADJ
dpc-4852	380	16	pemphigoid	pemphigoid	NOUN
dpc-4852	380	17	and	and	CCONJ
dpc-4852	380	18	bullous	bullous	ADJ
dpc-4852	380	19	pemphigoid	pemphigoid	NOUN
dpc-4852	380	20	.	.	PUNCT
dpc-4852	381	1	cureus	cureus	NOUN
dpc-4852	381	2	.	.	PUNCT
dpc-4852	382	1	2021;13(11):e19932	2021;13(11):e19932	NOUN
dpc-4852	382	2	.	.	PUNCT
dpc-4852	383	1	published	publish	VERB
dpc-4852	383	2	2021	2021	NUM
dpc-4852	383	3	nov	nov	PROPN
dpc-4852	383	4	27	27	NUM
dpc-4852	383	5	.	.	PUNCT
dpc-4852	384	1	doi	doi	NOUN
dpc-4852	384	2	:	:	PUNCT
dpc-4852	384	3	10.7759	10.7759	NUM
dpc-4852	384	4	/	/	SYM
dpc-4852	384	5	cureus.19932	cureus.19932	PROPN
dpc-4852	384	6	.	.	NOUN
dpc-4852	384	7	pmid	pmid	PROPN
dpc-4852	384	8	:	:	PUNCT
dpc-4852	384	9	34984113	34984113	NUM
dpc-4852	384	10	8	8	NUM
dpc-4852	384	11	original	original	ADJ
dpc-4852	384	12	article	article	NOUN
dpc-4852	384	13	|	|	ADV
dpc-4852	384	14	dermatol	dermatol	ADJ
dpc-4852	384	15	pract	pract	NOUN
dpc-4852	384	16	concept	concept	NOUN
dpc-4852	384	17	.	.	PUNCT
dpc-4852	385	1	2025;15(2):4852	2025;15(2):4852	NUM
dpc-4852	385	2	168(1):511	168(1):511	NOUN
dpc-4852	385	3	]	]	PUNCT
dpc-4852	385	4	.	.	PUNCT
dpc-4852	386	1	j	j	PROPN
dpc-4852	386	2	immunol	immunol	NOUN
dpc-4852	386	3	.	.	PUNCT
dpc-4852	387	1	2001;166(12):7571	2001;166(12):7571	NUM
dpc-4852	387	2	-	-	SYM
dpc-4852	387	3	7578	7578	NUM
dpc-4852	387	4	.	.	PUNCT
dpc-4852	388	1	doi:10.4049	doi:10.4049	PROPN
dpc-4852	388	2	/jimmunol.166.12.7571	/jimmunol.166.12.7571	PROPN
dpc-4852	388	3	.	.	PUNCT
dpc-4852	389	1	pmid	pmid	NOUN
dpc-4852	389	2	:	:	PUNCT
dpc-4852	389	3	11390513	11390513	NUM
dpc-4852	389	4	.	.	PUNCT
dpc-4852	390	1	45	45	NUM
dpc-4852	390	2	.	.	X
dpc-4852	390	3	dudeck	dudeck	PROPN
dpc-4852	390	4	a	a	PRON
dpc-4852	390	5	,	,	PUNCT
dpc-4852	390	6	dudeck	dudeck	PROPN
dpc-4852	390	7	j	j	PROPN
dpc-4852	390	8	,	,	PUNCT
dpc-4852	390	9	scholten	scholten	VERB
dpc-4852	390	10	j	j	PROPN
dpc-4852	390	11	,	,	PUNCT
dpc-4852	390	12	et	et	PROPN
dpc-4852	390	13	al	al	PROPN
dpc-4852	390	14	.	.	PUNCT
dpc-4852	391	1	mast	mast	PROPN
dpc-4852	391	2	cells	cell	NOUN
dpc-4852	391	3	are	be	AUX
dpc-4852	391	4	key	key	ADJ
dpc-4852	391	5	promoters	promoter	NOUN
dpc-4852	391	6	of	of	ADP
dpc-4852	391	7	contact	contact	NOUN
dpc-4852	391	8	allergy	allergy	NOUN
dpc-4852	391	9	that	that	PRON
dpc-4852	391	10	mediate	mediate	VERB
dpc-4852	391	11	the	the	DET
dpc-4852	391	12	adjuvant	adjuvant	ADJ
dpc-4852	391	13	effects	effect	NOUN
dpc-4852	391	14	of	of	ADP
dpc-4852	391	15	haptens	haptens	PROPN
dpc-4852	391	16	.	.	PUNCT
dpc-4852	392	1	immunity	immunity	NOUN
dpc-4852	392	2	.	.	PUNCT
dpc-4852	393	1	2011;34(6):973	2011;34(6):973	NUM
dpc-4852	393	2	-	-	SYM
dpc-4852	393	3	984	984	NUM
dpc-4852	393	4	doi	doi	NOUN
dpc-4852	393	5	:	:	PUNCT
dpc-4852	393	6	10.1016	10.1016	NUM
dpc-4852	393	7	/	/	SYM
dpc-4852	393	8	j.immuni	j.immuni	ADJ
dpc-4852	393	9	.2011.03.028	.2011.03.028	NOUN
dpc-4852	393	10	.	.	PUNCT
dpc-4852	394	1	pmid	pmid	NOUN
dpc-4852	394	2	:	:	PUNCT
dpc-4852	394	3	 	 	SPACE
dpc-4852	394	4	21703544	21703544	NUM
dpc-4852	394	5	.	.	PUNCT
dpc-4852	395	1	46	46	NUM
dpc-4852	395	2	.	.	PUNCT
dpc-4852	396	1	bakema	bakema	PROPN
dpc-4852	396	2	je	je	PROPN
dpc-4852	396	3	,	,	PUNCT
dpc-4852	396	4	van	van	PROPN
dpc-4852	396	5	egmond	egmond	PROPN
dpc-4852	396	6	m.	m.	NOUN
dpc-4852	396	7	the	the	DET
dpc-4852	396	8	human	human	ADJ
dpc-4852	396	9	immunoglobulin	immunoglobulin	PROPN
dpc-4852	396	10	a	a	DET
dpc-4852	396	11	fc	fc	PROPN
dpc-4852	396	12	receptor	receptor	NOUN
dpc-4852	396	13	fcαri	fcαri	PROPN
dpc-4852	396	14	:	:	PUNCT
dpc-4852	396	15	a	a	DET
dpc-4852	396	16	multifaceted	multifaceted	ADJ
dpc-4852	396	17	regulator	regulator	NOUN
dpc-4852	396	18	of	of	ADP
dpc-4852	396	19	mucosal	mucosal	ADJ
dpc-4852	396	20	immunity	immunity	NOUN
dpc-4852	396	21	.	.	PUNCT
dpc-4852	397	1	mucosal	mucosal	ADJ
dpc-4852	397	2	immunol	immunol	NOUN
dpc-4852	397	3	.	.	PUNCT
dpc-4852	398	1	2011;4(6):612	2011;4(6):612	X
dpc-4852	398	2	-	-	PUNCT
dpc-4852	398	3	624	624	NUM
dpc-4852	398	4	.	.	PUNCT
dpc-4852	399	1	doi:10.1038	doi:10.1038	PROPN
dpc-4852	399	2	/	/	SYM
dpc-4852	399	3	mi	mi	PROPN
dpc-4852	399	4	.2011.36	.2011.36	PROPN
dpc-4852	399	5	.	.	PUNCT
dpc-4852	400	1	pmid	pmid	NOUN
dpc-4852	400	2	:	:	PUNCT
dpc-4852	400	3	 	 	SPACE
dpc-4852	400	4	21937986	21937986	NUM
dpc-4852	400	5	.	.	PUNCT
dpc-4852	401	1	47	47	NUM
dpc-4852	401	2	.	.	PUNCT
dpc-4852	402	1	wang	wang	PROPN
dpc-4852	402	2	y	y	PROPN
dpc-4852	402	3	,	,	PUNCT
dpc-4852	402	4	mao	mao	X
dpc-4852	403	1	x	x	NOUN
dpc-4852	403	2	,	,	PUNCT
dpc-4852	403	3	wang	wang	PROPN
dpc-4852	403	4	y	y	PROPN
dpc-4852	403	5	,	,	PUNCT
dpc-4852	403	6	et	et	PROPN
dpc-4852	403	7	al	al	PROPN
dpc-4852	403	8	.	.	PUNCT
dpc-4852	403	9	relapse	relapse	NOUN
dpc-4852	403	10	of	of	ADP
dpc-4852	403	11	bullous	bullous	ADJ
dpc-4852	403	12	pemphigoid	pemphigoid	NOUN
dpc-4852	403	13	:	:	PUNCT
dpc-4852	403	14	an	an	DET
dpc-4852	403	15	update	update	NOUN
dpc-4852	403	16	on	on	ADP
dpc-4852	403	17	this	this	DET
dpc-4852	403	18	stubborn	stubborn	ADJ
dpc-4852	403	19	clinical	clinical	ADJ
dpc-4852	403	20	problem	problem	NOUN
dpc-4852	403	21	.	.	PUNCT
dpc-4852	404	1	ann	ann	PROPN
dpc-4852	404	2	med	med	PROPN
dpc-4852	404	3	.	.	PUNCT
dpc-4852	405	1	2018;50(3):234	2018;50(3):234	NUM
dpc-4852	405	2	-	-	PUNCT
dpc-4852	405	3	239	239	NUM
dpc-4852	405	4	.	.	PUNCT
dpc-4852	406	1	doi:10.1080/07853890.2018.1443346	doi:10.1080/07853890.2018.1443346	NOUN
dpc-4852	406	2	.	.	PUNCT
dpc-4852	407	1	pmid	pmid	NOUN
dpc-4852	407	2	:	:	PUNCT
dpc-4852	407	3	29457514	29457514	NUM
dpc-4852	407	4	48	48	NUM
dpc-4852	407	5	.	.	PUNCT
dpc-4852	408	1	liu	liu	PROPN
dpc-4852	408	2	y	y	PROPN
dpc-4852	408	3	,	,	PUNCT
dpc-4852	408	4	wang	wang	PROPN
dpc-4852	408	5	y	y	PROPN
dpc-4852	408	6	,	,	PUNCT
dpc-4852	408	7	zhang	zhang	PROPN
dpc-4852	408	8	j	j	PROPN
dpc-4852	408	9	,	,	PUNCT
dpc-4852	408	10	et	et	PROPN
dpc-4852	408	11	al	al	PROPN
dpc-4852	408	12	.	.	PUNCT
dpc-4852	409	1	risk	risk	NOUN
dpc-4852	409	2	factors	factor	NOUN
dpc-4852	409	3	predisposing	predispose	VERB
dpc-4852	409	4	relapse	relapse	NOUN
dpc-4852	409	5	of	of	ADP
dpc-4852	409	6	bullous	bullous	ADJ
dpc-4852	409	7	pemphigoid	pemphigoid	NOUN
dpc-4852	409	8	at	at	ADP
dpc-4852	409	9	initial	initial	ADJ
dpc-4852	409	10	diagnosis	diagnosis	NOUN
dpc-4852	409	11	:	:	PUNCT
dpc-4852	409	12	a	a	DET
dpc-4852	409	13	retrospective	retrospective	ADJ
dpc-4852	409	14	cohort	cohort	NOUN
dpc-4852	409	15	study	study	NOUN
dpc-4852	409	16	of	of	ADP
dpc-4852	409	17	205	205	NUM
dpc-4852	409	18	patients	patient	NOUN
dpc-4852	409	19	.	.	PUNCT
dpc-4852	410	1	int	int	NOUN
dpc-4852	410	2	immunopharmacology	immunopharmacology	NOUN
dpc-4852	410	3	.	.	PUNCT
dpc-4852	411	1	2023;125(pt	2023;125(pt	NUM
dpc-4852	411	2	a):111082	a):111082	PROPN
dpc-4852	411	3	.	.	PUNCT
dpc-4852	411	4	doi	doi	PROPN
dpc-4852	411	5	:	:	PUNCT
dpc-4852	411	6	10.1016	10.1016	NUM
dpc-4852	411	7	/	/	SYM
dpc-4852	411	8	j.intimp.2023.111082	j.intimp.2023.111082	NOUN
dpc-4852	411	9	.	.	PUNCT
dpc-4852	412	1	pmid	pmid	NOUN
dpc-4852	412	2	:	:	PUNCT
dpc-4852	412	3	37913571	37913571	NUM
dpc-4852	412	4	.	.	PUNCT
dpc-4852	413	1	49	49	NUM
dpc-4852	413	2	.	.	PUNCT
dpc-4852	414	1	giudice	giudice	PROPN
dpc-4852	414	2	gj	gj	PROPN
dpc-4852	414	3	,	,	PUNCT
dpc-4852	414	4	emery	emery	PROPN
dpc-4852	414	5	dj	dj	PROPN
dpc-4852	414	6	,	,	PUNCT
dpc-4852	414	7	diaz	diaz	PROPN
dpc-4852	414	8	la	la	PROPN
dpc-4852	414	9	.	.	PUNCT
dpc-4852	414	10	cloning	cloning	NOUN
dpc-4852	414	11	and	and	CCONJ
dpc-4852	414	12	primary	primary	ADJ
dpc-4852	414	13	structural	structural	ADJ
dpc-4852	414	14	analysis	analysis	NOUN
dpc-4852	414	15	of	of	ADP
dpc-4852	414	16	the	the	DET
dpc-4852	414	17	bullous	bullous	ADJ
dpc-4852	414	18	pemphigoid	pemphigoid	PROPN
dpc-4852	414	19	autoantigen	autoantigen	PROPN
dpc-4852	414	20	bp180	bp180	PROPN
dpc-4852	414	21	.	.	PUNCT
dpc-4852	415	1	j	j	PROPN
dpc-4852	415	2	invest	invest	VERB
dpc-4852	415	3	dermatol	dermatol	NOUN
dpc-4852	415	4	.	.	PUNCT
dpc-4852	416	1	1992;99(3):243	1992;99(3):243	NUM
dpc-4852	416	2	-	-	PUNCT
dpc-4852	416	3	250	250	NUM
dpc-4852	416	4	.	.	PUNCT
dpc-4852	416	5	doi:10.1111/1523	doi:10.1111/1523	NOUN
dpc-4852	416	6	-	-	PUNCT
dpc-4852	416	7	1747	1747	NUM
dpc-4852	416	8	.	.	PUNCT
dpc-4852	417	1	ep12616580	ep12616580	NOUN
dpc-4852	417	2	.	.	PUNCT
dpc-4852	418	1	pmid	pmid	NOUN
dpc-4852	418	2	:	:	PUNCT
dpc-4852	418	3	 	 	SPACE
dpc-4852	418	4	1324962	1324962	NUM
dpc-4852	418	5	.	.	PUNCT
dpc-4852	419	1	50	50	NUM
dpc-4852	419	2	.	.	PUNCT
dpc-4852	420	1	patsatsi	patsatsi	PROPN
dpc-4852	421	1	a	a	PRON
dpc-4852	421	2	,	,	PUNCT
dpc-4852	421	3	kyriakou	kyriakou	PROPN
dpc-4852	421	4	a	a	X
dpc-4852	421	5	,	,	PUNCT
dpc-4852	421	6	werth	werth	PROPN
dpc-4852	421	7	vp	vp	PROPN
dpc-4852	421	8	.	.	PUNCT
dpc-4852	421	9	bullous	bullous	ADJ
dpc-4852	421	10	pemphigoid	pemphigoid	NOUN
dpc-4852	421	11	in	in	ADP
dpc-4852	421	12	adolescence	adolescence	NOUN
dpc-4852	421	13	.	.	PUNCT
dpc-4852	422	1	pediatr	pediatr	ADJ
dpc-4852	422	2	dermatol	dermatol	NOUN
dpc-4852	422	3	.	.	PUNCT
dpc-4852	423	1	2019;36(2):184	2019;36(2):184	NUM
dpc-4852	423	2	-	-	SYM
dpc-4852	423	3	188	188	NUM
dpc-4852	423	4	.	.	PUNCT
dpc-4852	424	1	doi:10.1111	doi:10.1111	NOUN
dpc-4852	424	2	/pde.13717	/pde.13717	PROPN
dpc-4852	424	3	.	.	PUNCT
dpc-4852	425	1	pmid	pmid	NOUN
dpc-4852	425	2	:	:	PUNCT
dpc-4852	425	3	30569520	30569520	NUM
dpc-4852	425	4	.	.	PUNCT
dpc-4852	426	1	51	51	NUM
dpc-4852	426	2	.	.	PUNCT
dpc-4852	427	1	lee	lee	PROPN
dpc-4852	427	2	jh	jh	PROPN
dpc-4852	427	3	,	,	PUNCT
dpc-4852	427	4	kim	kim	PROPN
dpc-4852	427	5	th	th	PROPN
dpc-4852	427	6	,	,	PUNCT
dpc-4852	427	7	park	park	PROPN
dpc-4852	427	8	sh	sh	PROPN
dpc-4852	427	9	,	,	PUNCT
dpc-4852	427	10	et.al	et.al	PROPN
dpc-4852	427	11	.	.	PUNCT
dpc-4852	428	1	prognostic	prognostic	ADJ
dpc-4852	428	2	clinical	clinical	ADJ
dpc-4852	428	3	factors	factor	NOUN
dpc-4852	428	4	associated	associate	VERB
dpc-4852	428	5	with	with	ADP
dpc-4852	428	6	remission	remission	NOUN
dpc-4852	428	7	and	and	CCONJ
dpc-4852	428	8	relapse	relapse	NOUN
dpc-4852	428	9	in	in	ADP
dpc-4852	428	10	bullous	bullous	ADJ
dpc-4852	428	11	pemphigoid	pemphigoid	NOUN
dpc-4852	428	12	.	.	PUNCT
dpc-4852	429	1	j	j	PROPN
dpc-4852	429	2	eur	eur	PROPN
dpc-4852	429	3	acad	acad	PROPN
dpc-4852	429	4	dermatol	dermatol	NOUN
dpc-4852	429	5	venereol	venereol	NOUN
dpc-4852	429	6	.	.	PUNCT
dpc-4852	430	1	2017;31(1):81	2017;31(1):81	NUM
dpc-4852	430	2	-	-	SYM
dpc-4852	430	3	84	84	NUM
dpc-4852	430	4	.	.	PUNCT
dpc-4852	431	1	doi:10.1111	doi:10.1111	PROPN
dpc-4852	431	2	/jdv.13839	/jdv.13839	PROPN
dpc-4852	431	3	.	.	PUNCT
dpc-4852	432	1	pmid	pmid	NOUN
dpc-4852	432	2	:	:	PUNCT
dpc-4852	432	3	27422758	27422758	NUM
dpc-4852	432	4	.	.	PUNCT
dpc-4852	433	1	38	38	NUM
dpc-4852	433	2	.	.	PUNCT
dpc-4852	434	1	moro	moro	PROPN
dpc-4852	434	2	f	f	PROPN
dpc-4852	434	3	,	,	PUNCT
dpc-4852	434	4	fania	fania	PROPN
dpc-4852	434	5	l	l	PROPN
dpc-4852	434	6	,	,	PUNCT
dpc-4852	434	7	sinagra	sinagra	VERB
dpc-4852	434	8	jlm	jlm	PROPN
dpc-4852	434	9	,	,	PUNCT
dpc-4852	434	10	et.al	et.al	PROPN
dpc-4852	434	11	.	.	PUNCT
dpc-4852	435	1	bullous	bullous	ADJ
dpc-4852	435	2	pemphigoid	pemphigoid	NOUN
dpc-4852	435	3	:	:	PUNCT
dpc-4852	435	4	trigger	trigger	NOUN
dpc-4852	435	5	and	and	CCONJ
dpc-4852	435	6	predisposing	predispose	VERB
dpc-4852	435	7	factors	factor	NOUN
dpc-4852	435	8	.	.	PUNCT
dpc-4852	436	1	biomolecules	biomolecule	NOUN
dpc-4852	436	2	.	.	PUNCT
dpc-4852	437	1	2020;10(10):1432	2020;10(10):1432	X
dpc-4852	437	2	.	.	PUNCT
dpc-4852	437	3	published	publish	VERB
dpc-4852	437	4	2020	2020	NUM
dpc-4852	437	5	oct	oct	PROPN
dpc-4852	437	6	10	10	NUM
dpc-4852	437	7	.	.	PUNCT
dpc-4852	438	1	doi:10.3390	doi:10.3390	NOUN
dpc-4852	438	2	/	/	SYM
dpc-4852	438	3	biom10101432	biom10101432	PROPN
dpc-4852	438	4	.	.	PUNCT
dpc-4852	439	1	pmid	pmid	NOUN
dpc-4852	439	2	:	:	PUNCT
dpc-4852	439	3	33050407	33050407	NUM
dpc-4852	439	4	39	39	NUM
dpc-4852	439	5	.	.	PUNCT
dpc-4852	440	1	bech	bech	PROPN
dpc-4852	440	2	r	r	PROPN
dpc-4852	440	3	,	,	PUNCT
dpc-4852	440	4	kibsgaard	kibsgaard	ADJ
dpc-4852	440	5	l	l	NOUN
dpc-4852	440	6	,	,	PUNCT
dpc-4852	440	7	vestergaard	vestergaard	PROPN
dpc-4852	440	8	c.	c.	NOUN
dpc-4852	440	9	comorbidities	comorbiditie	NOUN
dpc-4852	440	10	and	and	CCONJ
dpc-4852	440	11	treatment	treatment	NOUN
dpc-4852	440	12	strategies	strategy	NOUN
dpc-4852	440	13	in	in	ADP
dpc-4852	440	14	bullous	bullous	ADJ
dpc-4852	440	15	pemphigoid	pemphigoid	NOUN
dpc-4852	440	16	:	:	PUNCT
dpc-4852	440	17	an	an	DET
dpc-4852	440	18	appraisal	appraisal	NOUN
dpc-4852	440	19	of	of	ADP
dpc-4852	440	20	the	the	DET
dpc-4852	440	21	existing	exist	VERB
dpc-4852	440	22	litterature	litterature	NOUN
dpc-4852	440	23	.	.	PUNCT
dpc-4852	441	1	front	front	ADJ
dpc-4852	441	2	med	med	PROPN
dpc-4852	441	3	(	(	PUNCT
dpc-4852	441	4	lausanne	lausanne	PROPN
dpc-4852	441	5	)	)	PUNCT
dpc-4852	441	6	.	.	PUNCT
dpc-4852	442	1	2018	2018	NUM
dpc-4852	442	2	;	;	PUNCT
dpc-4852	442	3	5:238	5:238	NUM
dpc-4852	442	4	.	.	PUNCT
dpc-4852	442	5	published	publish	VERB
dpc-4852	442	6	2018	2018	NUM
dpc-4852	442	7	sep	sep	PROPN
dpc-4852	442	8	4	4	NUM
dpc-4852	442	9	.	.	PUNCT
dpc-4852	442	10	doi:10.3389	doi:10.3389	PROPN
dpc-4852	442	11	/	/	SYM
dpc-4852	442	12	fmed.2018.00238	fmed.2018.00238	PROPN
dpc-4852	442	13	.	.	PUNCT
dpc-4852	443	1	pmid	pmid	NOUN
dpc-4852	443	2	:	:	PUNCT
dpc-4852	443	3	302	302	NUM
dpc-4852	443	4	34116	34116	NUM
dpc-4852	443	5	.	.	PUNCT
dpc-4852	444	1	40	40	NUM
dpc-4852	444	2	.	.	PUNCT
dpc-4852	445	1	kılıç	kılıç	PROPN
dpc-4852	445	2	sayar	sayar	PROPN
dpc-4852	445	3	s	s	PROPN
dpc-4852	445	4	,	,	PUNCT
dpc-4852	445	5	sun	sun	NOUN
dpc-4852	445	6	gp	gp	NOUN
dpc-4852	445	7	,	,	PUNCT
dpc-4852	445	8	küçükoğlu	küçükoğlu	PROPN
dpc-4852	445	9	r.	r.	PROPN
dpc-4852	445	10	comorbidities	comorbiditie	NOUN
dpc-4852	445	11	of	of	ADP
dpc-4852	445	12	bullous	bullous	ADJ
dpc-4852	445	13	pemphigoid	pemphigoid	NOUN
dpc-4852	445	14	:	:	PUNCT
dpc-4852	445	15	a	a	DET
dpc-4852	445	16	single	single	ADJ
dpc-4852	445	17	-	-	PUNCT
dpc-4852	445	18	center	center	NOUN
dpc-4852	445	19	retrospective	retrospective	ADJ
dpc-4852	445	20	case	case	NOUN
dpc-4852	445	21	-	-	PUNCT
dpc-4852	445	22	control	control	NOUN
dpc-4852	445	23	study	study	NOUN
dpc-4852	445	24	from	from	ADP
dpc-4852	445	25	turkey	turkey	PROPN
dpc-4852	445	26	.	.	PUNCT
dpc-4852	446	1	dermatol	dermatol	NOUN
dpc-4852	446	2	ther	ther	ADV
dpc-4852	446	3	.	.	PUNCT
dpc-4852	447	1	2021;34(5):e15031	2021;34(5):e15031	X
dpc-4852	447	2	.	.	PUNCT
dpc-4852	448	1	doi:10.1111/	doi:10.1111/	PROPN
dpc-4852	448	2	dth.15031	dth.15031	PROPN
dpc-4852	448	3	.	.	PUNCT
dpc-4852	449	1	pmid	pmid	NOUN
dpc-4852	449	2	:	:	PUNCT
dpc-4852	449	3	34137146	34137146	NUM
dpc-4852	449	4	.	.	PUNCT
dpc-4852	450	1	41	41	NUM
dpc-4852	450	2	.	.	PUNCT
dpc-4852	451	1	bernard	bernard	PROPN
dpc-4852	451	2	p	p	PROPN
dpc-4852	451	3	,	,	PUNCT
dpc-4852	451	4	antonicelli	antonicelli	PROPN
dpc-4852	451	5	f.	f.	PROPN
dpc-4852	451	6	bullous	bullous	ADJ
dpc-4852	451	7	pemphigoid	pemphigoid	ADV
dpc-4852	451	8	:	:	PUNCT
dpc-4852	451	9	a	a	DET
dpc-4852	451	10	review	review	NOUN
dpc-4852	451	11	of	of	ADP
dpc-4852	451	12	its	its	PRON
dpc-4852	451	13	diagnosis	diagnosis	NOUN
dpc-4852	451	14	,	,	PUNCT
dpc-4852	451	15	associations	association	NOUN
dpc-4852	451	16	and	and	CCONJ
dpc-4852	451	17	treatment	treatment	NOUN
dpc-4852	451	18	.	.	PUNCT
dpc-4852	452	1	am	be	AUX
dpc-4852	452	2	j	j	PROPN
dpc-4852	452	3	clin	clin	PROPN
dpc-4852	452	4	dermatol	dermatol	NOUN
dpc-4852	452	5	.	.	PUNCT
dpc-4852	453	1	2017;18(4):513	2017;18(4):513	NUM
dpc-4852	453	2	-	-	PUNCT
dpc-4852	453	3	528	528	NUM
dpc-4852	453	4	.	.	PUNCT
dpc-4852	453	5	doi:10.1007	doi:10.1007	VERB
dpc-4852	453	6	/	/	SYM
dpc-4852	453	7	s40257	s40257	NOUN
dpc-4852	453	8	-	-	PUNCT
dpc-4852	453	9	017	017	NUM
dpc-4852	453	10	-	-	PUNCT
dpc-4852	453	11	0264	0264	NUM
dpc-4852	453	12	-	-	PUNCT
dpc-4852	453	13	2	2	NUM
dpc-4852	453	14	.	.	PUNCT
dpc-4852	453	15	pmid	pmid	NOUN
dpc-4852	453	16	:	:	PUNCT
dpc-4852	453	17	28247089	28247089	NUM
dpc-4852	453	18	.	.	PUNCT
dpc-4852	454	1	42	42	NUM
dpc-4852	454	2	.	.	PUNCT
dpc-4852	455	1	charitaki	charitaki	PROPN
dpc-4852	455	2	e	e	PROPN
dpc-4852	455	3	,	,	PUNCT
dpc-4852	455	4	damianakis	damianakis	PROPN
dpc-4852	455	5	n	n	CCONJ
dpc-4852	455	6	,	,	PUNCT
dpc-4852	455	7	garbidaki	garbidaki	PROPN
dpc-4852	455	8	a	a	X
dpc-4852	455	9	,	,	PUNCT
dpc-4852	455	10	et	et	PROPN
dpc-4852	455	11	al	al	PROPN
dpc-4852	455	12	.	.	PROPN
dpc-4852	456	1	dpp4	dpp4	PROPN
dpc-4852	456	2	inhibitor	inhibitor	PROPN
dpc-4852	456	3	induced	induce	VERB
dpc-4852	456	4	bullous	bullous	ADJ
dpc-4852	456	5	pemphigoid	pemphigoid	NOUN
dpc-4852	456	6	in	in	ADP
dpc-4852	456	7	patients	patient	NOUN
dpc-4852	456	8	with	with	ADP
dpc-4852	456	9	diabetes	diabetes	NOUN
dpc-4852	456	10	and	and	CCONJ
dpc-4852	456	11	chronic	chronic	ADJ
dpc-4852	456	12	kidney	kidney	NOUN
dpc-4852	456	13	disease	disease	NOUN
dpc-4852	456	14	:	:	PUNCT
dpc-4852	456	15	clinical	clinical	ADJ
dpc-4852	456	16	case	case	NOUN
dpc-4852	456	17	series	series	NOUN
dpc-4852	456	18	.	.	PUNCT
dpc-4852	457	1	nephron	nephron	NOUN
dpc-4852	457	2	.	.	PUNCT
dpc-4852	458	1	2023;147(2	2023;147(2	NUM
dpc-4852	458	2	):	):	PUNCT
dpc-4852	458	3	97	97	NUM
dpc-4852	458	4	-	-	SYM
dpc-4852	458	5	102	102	NUM
dpc-4852	458	6	.	.	PUNCT
dpc-4852	459	1	doi:10.1159/000525520	doi:10.1159/000525520	PROPN
dpc-4852	459	2	.	.	PUNCT
dpc-4852	460	1	pmid	pmid	NOUN
dpc-4852	460	2	:	:	PUNCT
dpc-4852	460	3	35850099	35850099	NUM
dpc-4852	460	4	.	.	PUNCT
dpc-4852	461	1	43	43	NUM
dpc-4852	461	2	.	.	PUNCT
dpc-4852	462	1	kridin	kridin	VERB
dpc-4852	462	2	k	k	PROPN
dpc-4852	462	3	,	,	PUNCT
dpc-4852	462	4	bergman	bergman	PROPN
dpc-4852	462	5	r.	r.	PROPN
dpc-4852	462	6	association	association	PROPN
dpc-4852	462	7	of	of	ADP
dpc-4852	462	8	bullous	bullous	ADJ
dpc-4852	462	9	pemphigoid	pemphigoid	NOUN
dpc-4852	462	10	with	with	ADP
dpc-4852	462	11	dipeptidyl	dipeptidyl	NOUN
dpc-4852	462	12	-	-	PUNCT
dpc-4852	462	13	peptidase	peptidase	NOUN
dpc-4852	462	14	4	4	NUM
dpc-4852	462	15	inhibitors	inhibitor	NOUN
dpc-4852	462	16	in	in	ADP
dpc-4852	462	17	patients	patient	NOUN
dpc-4852	462	18	with	with	ADP
dpc-4852	462	19	diabetes	diabetes	NOUN
dpc-4852	462	20	:	:	PUNCT
dpc-4852	462	21	estimating	estimate	VERB
dpc-4852	462	22	the	the	DET
dpc-4852	462	23	risk	risk	NOUN
dpc-4852	462	24	of	of	ADP
dpc-4852	462	25	the	the	DET
dpc-4852	462	26	new	new	ADJ
dpc-4852	462	27	agents	agent	NOUN
dpc-4852	462	28	and	and	CCONJ
dpc-4852	462	29	characterizing	characterize	VERB
dpc-4852	462	30	the	the	DET
dpc-4852	462	31	patients	patient	NOUN
dpc-4852	462	32	.	.	PUNCT
dpc-4852	463	1	jama	jama	PROPN
dpc-4852	463	2	dermatol	dermatol	NOUN
dpc-4852	463	3	.	.	PUNCT
dpc-4852	464	1	2018;154(10):1152	2018;154(10):1152	NUM
dpc-4852	464	2	-	-	SYM
dpc-4852	464	3	1158	1158	NUM
dpc-4852	464	4	.	.	PUNCT
dpc-4852	465	1	doi:10.1001	doi:10.1001	PROPN
dpc-4852	465	2	/	/	SYM
dpc-4852	465	3	jamadermatol.2018.2352	jamadermatol.2018.2352	PROPN
dpc-4852	465	4	.	.	PUNCT
dpc-4852	466	1	pmid	pmid	NOUN
dpc-4852	466	2	:	:	PUNCT
dpc-4852	466	3	30090931	30090931	NUM
dpc-4852	466	4	.	.	PUNCT
dpc-4852	467	1	44	44	NUM
dpc-4852	467	2	.	.	PUNCT
dpc-4852	468	1	salcedo	salcedo	PROPN
dpc-4852	468	2	r	r	PROPN
dpc-4852	468	3	,	,	PUNCT
dpc-4852	468	4	young	young	ADJ
dpc-4852	468	5	ha	ha	INTJ
dpc-4852	468	6	,	,	PUNCT
dpc-4852	468	7	ponce	ponce	PROPN
dpc-4852	468	8	ml	ml	PROPN
dpc-4852	468	9	,	,	PUNCT
dpc-4852	468	10	et	et	PROPN
dpc-4852	468	11	al	al	PROPN
dpc-4852	468	12	.	.	PUNCT
dpc-4852	469	1	eotaxin	eotaxin	PROPN
dpc-4852	469	2	(	(	PUNCT
dpc-4852	469	3	ccl11	ccl11	NOUN
dpc-4852	469	4	)	)	PUNCT
dpc-4852	469	5	induces	induce	VERB
dpc-4852	469	6	in	in	ADP
dpc-4852	469	7	vivo	vivo	ADJ
dpc-4852	469	8	angiogenic	angiogenic	ADJ
dpc-4852	469	9	responses	response	NOUN
dpc-4852	469	10	by	by	ADP
dpc-4852	469	11	human	human	ADJ
dpc-4852	469	12	ccr3	ccr3	PROPN
dpc-4852	469	13	+	+	CCONJ
dpc-4852	469	14	endothelial	endothelial	ADJ
dpc-4852	469	15	cells	cell	NOUN
dpc-4852	469	16	[	[	X
dpc-4852	469	17	published	publish	VERB
dpc-4852	469	18	correction	correction	NOUN
dpc-4852	469	19	appears	appear	VERB
dpc-4852	469	20	in	in	ADP
dpc-4852	469	21	j	j	PROPN
dpc-4852	469	22	immunol	immunol	PROPN
dpc-4852	469	23	2002	2002	NUM
dpc-4852	469	24	jan	jan	PROPN
dpc-4852	469	25	1	1	NUM
dpc-4852	469	26	;	;	PUNCT